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Summary
Summary
IgA nephropathy is the most common form of glomerulonephritis and is the 
underlying cause of renal failure in up to 10% of patients in dialysis and renal 
transplantation programmes. The condition has a variable natural history, leading over 
a period of several years to end stage renal failure in approximately one third of those 
affected. The pathogenesis of IgA nephropathy, and the factors determining 
susceptibility and disease progression are incompletely understood, but abnormalities 
have been described in both the systemic and mucosal limbs of the immune system. 
Although circulating levels of IgA may be increased in patients, and the IgA is 
abnormally glycosylated, the characteristic diagnostic feature is the presence of IgA- 
containing immune complexes in the glomerular mesangium. However, the 
mechanism by which these complexes are deposited in the mesangium, and the nature 
of their pathophysiological role, is unknown. Human mesangial cells (HMCs) 
cultured in vitro can bind monomeric and polymeric IgA in a dose-dependent, 
specifically inhibitable manner but do not express classical IgA receptors such as the 
Fc alpha receptor (FcaRI), the polymeric immunoglobulin receptor or the 
asialoglycoprotein receptor. This evidence has led several authors to suggest that 
HMCs possess a novel IgA receptor, but its identity has remained elusive. Mesangial 
cell activation following IgA binding and receptor signalling could underlie the 
mesangial cellular proliferation and extracellular matrix accumulation seen in IgA 
nephropathy. A better understanding of these potentially receptor mediated events is 
an important step toward defining the pathophysiology of IgA nephropathy more 
clearly.
Initial reports of FcaRI expression by HMCs had yielded conflicting results. In 
accordance with work subsequently published by other authors we failed to detect 
FcaRI message or protein expression by HMCs using a variety of techniques. 
Another report had suggested that HMCs expressed a novel FcaRI variant that perhaps 
mediated mesangial deposition of IgA. We examined HMCs for expression of such a
xiv
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variant using real time polymerase chain reaction to provide relative quantification of 
FcaRI exons. These investigations provided no evidence for expression of an FcaRI 
variant by cultured HMCs.
Mesangial cells were then assessed for expression of the human homologue of a novel 
IgA and IgM-binding receptor described on murine macrophages and B lymphocytes. 
We hypothesised that this Fca/pR could be involved in the mesangial deposition of 
IgA if it were expressed in human kidney. Fca/pR gene expression was detected in 
human renal cortex, isolated glomeruli and in primary cultures of HMCs. Receptor 
expression levels were substantially augmented by incubation of HMCs with the 
inflammatory cytokine, IL-la. The predicted full length coding sequence for human 
Fca/pR was then isolated and cloned from an HMC line and the protein expressed in 
transfected cells. The human Fca/pR protein was approximately 58kDa in weight and 
was minimally A-glycosylated. As predicted from the characteristics of the murine 
homologue, the expressed human Fca/pR was able to bind IgA and IgM, but not IgG. 
The genomic organisation of human Fca/pR was elucidated and two variant 
transcripts were discovered. One alternatively spliced transcript was the result of an 
out of frame deletion of an entire exon that resulted in a shift of reading frame and the 
production of a novel amino acid sequence. Levels of this AEC3 transcript in HMCs 
were also regulated by IL-la. The coding sequence of this variant was cloned and 
expressed in a heterologous system. Experimental data confirmed the predictions of 
TV-linked glycosylation and a membrane spanning sequence but immunoglobulin 
binding by this protein was not detected. Localisation of fluorescently tagged fusion 
proteins suggested that the Fca/pR AEC3 protein was retained within the endoplasmic 
reticulum (ER) in contrast to wildtype receptor which was expressed on the cell 
surface. It was hypothesised that retention of the protein within the ER was due to a 
motif within the cytoplasmic tail and that cell surface expression would only occur 
under circumstances in which this motif was overridden.
In IgA nephropathy, progressive renal damage is associated with tubulointerstitial 
fibrosis. In proteinuric glomerulopathies renal tubular cells are exposed to abnormal
xv
Summary
types and amounts of filtered protein including immunoglobulins such as IgG and IgA, 
and it was hypothesised that an interaction between tubular cells and filtered 
immunoglobulins may involve specific cellular receptors. Expression of potential 
receptors by cultured proximal tubular cells (PTCs) was investigated. None of the 
classical Fc receptors for IgG were present in PTCs although expression of the 
neonatal Fc receptor which may play a role in IgG recycling from tubular filtrate was 
demonstrated. However, PTCs expressed the Fca/pR and once again transcript levels 
were regulated by IL-la. Expression of Fca/pR protein by tubular cells in normal 
kidney sections was confirmed by immunohistochemistry.
In conclusion, expression of the novel human Fca/pR was demonstrated in renal 
mesangial cells and proximal tubule. The receptor coding sequence was cloned and 
characteristics of the Fca/pR were defined. The Fca/pR or a variant form could 
mediate the renal response to injury associated with IgM and IgA immune complexes 
and is a candidate receptor for the mesangial response to IgA immune complexes in 
IgA nephropathy.
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Chapter 1
Chapter 1 
Introduction 
1.1. IgA Nephropathy
1.1.1. Overview of IgA nephropathy
The renal disease process that was to become known as immunoglobulin A (IgA) 
nephropathy was first described 38 years ago by Berger and Hinglais (Berger & 
Hinglais, 1968). The initial short report described intercapillary deposits of IgA 
present in all glomeruli of renal biopsies from 25 patients with proteinuria and 
microscopic haematuria. Over the intervening years, IgA nephropathy has been 
recognised as the most prevalent form of glomerulonephritis on a worldwide basis 
(Levy & Berger, 1988). Although the clinical course and consequences of the 
condition have been extensively described, the molecular pathogenesis of IgA 
nephropathy remains incompletely defined.
1.1.2. Diagnosis of IgA nephropathy
The diagnosis of IgA nephropathy requires histological examination of a renal biopsy 
specimen. Light microscopic features alone are non-diagnostic and range from the 
finding of normal kidney to a diffuse or focal, mesangio-proliferative 
glomerulonephritis. Definitive diagnosis depends on immunofluorescence techniques 
employing specific antibodies recognising IgA to reveal the characteristic deposits of 
IgA within the kidney. These IgA deposits are usually present in the glomerular 
mesangium but can also be seen within the walls of glomerular capillaries in some 
patients. Electron microscopy examination typically shows the presence of granular 
electron-dense deposits representing immune complexes located within the
17
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mesangium. Typical light microscopic, immunofluorescent and electron microscopic 
features of IgA nephropathy are shown in figure 1.1. Immunofluorescence staining 
often reveals co-localisation of other immune system components with glomerular 
IgA. Most prominent among these is complement factor C3 although IgG and IgM 
may also be present. Progressive IgA nephropathy leading to end stage renal disease is 
associated with atrophy and fibrosis within the tubulointerstitial compartment. These 
latter changes are common to a range of conditions leading to renal failure and may 
represent ultimate renal damage along a final common pathway. Although 
approximately one half of patients with IgA nephropathy have serum concentrations of 
IgA above the normal range (Layward et al, 1993; Leung et al, 2001), this measure is 
insufficiently sensitive or specific to be of diagnostic value.
1.1.3. Clinical features of IgA nephropathy
IgA nephropathy is seen with variable frequency in different racial groups such that it 
is most common in Asians and Caucasians but seen less commonly in Black 
populations (Levy & Berger, 1988). This variation is thought to reflect a combination 
of screening and biopsy policies in different countries together with genetic 
differences in disease susceptibility. The incidence is highest in young adults and 
males are more commonly affected than females.
The mode of presentation is variable, with isolated microscopic or dipstick haematuria 
often in association with a mild to moderate degree of proteinuria being the most 
frequent. This finding of dipstick haematuria is often detected in asymptomatic 
subjects following a routine urinalysis examination. An alternative scenario is 
presentation with a single episode or recurrent episodes of macroscopic haematuria 
typically during or following an upper respiratory tract infection and this presentation 
tends to be more prevalent in younger patients. A smaller number of patients will 
present with nephrotic syndrome or with a rapidly progressive glomerulonephritis and 
crescent formation. The clinical importance of IgA nephropathy is that up to 25% of 
patients will develop end stage renal disease over a follow up period of 20 years
18
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(Rekola et al, 1991; Johnston et al, 1992). None of the clinical factors associated with 
progressive renal disease is specific for IgA nephropathy and variations between 
different geographical centres in rates of progression probably reflect an effect of lead 
time bias and a higher proportion of more mildly affected individuals in some centres 
(Geddes et al, 2003). Predictive factors identified for progression to end stage renal 
disease include younger age, degree of proteinuria, elevation of serum creatinine at 
presentation and the presence of hypertension (D'Amico, 1992; Geddes et al, 2003). 
Patients who experience episodic macroscopic haematuria are believed to have a lower 
risk of progression to end stage renal disease. The histological features most strongly 
associated with progressive disease are also common to other glomerular pathologies 
and include tubular atrophy, interstitial fibrosis and the presence of crescents.
It is also likely that a large number of cases of undiagnosed or “silent” IgA 
nephropathy are present within the general population. A case series of 200 patients 
undergoing autopsy following death from a traumatic cause and with no prior history 
of renal disease revealed that eight (4%) had mesangial deposits of IgA on 
immunofluorescence examination (Sinniah, 1983). The glomeruli appeared normal in 
all but one case which exhibited mesangial hypercellularity.
Regression of the histological features of IgA nephropathy including mesangial 
cellular proliferation and interstitial mononuclear cell infiltration has been 
documented (Hotta et al, 2002). It is possible that such improvements could occur 
spontaneously but in this study they were described following repeat renal biopsy after 
treatment. Of 35 patients in whom haematuria had resolved, the extent of mesangial 
IgA had improved in 26 patients, including eight patients in whom mesangial IgA 
deposits had resolved completely.
Henoch-Schonlein purpura (HSP) is a systemic vasculitis with renal involvement that 
is histologically indistinguishable from IgA nephropathy. The condition usually 
appears in childhood or adolescence and other manifestations include cutaneous,
19
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rheumatological and gastrointestinal symptoms. It is unclear which elements of the 
pathogenesis of HSP may be shared with IgA nephropathy.
1.1.4. Treatment of IgA nephropathy
The principles of treatment in IgA nephropathy are similar to those in other glomerular 
and progressive renal diseases. These include the control of hypertension and the use 
of agents that inhibit the renin-angiotensin system to reduce proteinuria (Russo et al, 
2001). In addition, the use of other immunomodulatory agents has been suggested but 
no universal consensus exists as to their value. These agents include corticosteroids 
(Pozzi et al, 1999; Katafuchi et al, 2003), azathioprine (Yoshikawa et al, 1999), 
cyclosporine (Cattran, 1991) and mycophenolate mofetil. A reduction in proteinuria 
has been observed following treatment with mycophenolate (Tang et al, 2005) but 
progression to renal replacement therapy was not prevented (Frisch et al, 2005). 
Exceptions to this consensus are the subset of IgA nephropathy patients who present 
with nephrotic syndrome and who may derive benefit from corticosteroids and patients 
with rapidly progressive IgA nephropathy with crescent formation who may benefit 
from immunosuppression with cyclophosphamide.
The role of fish oil in the treatment of IgA nephropathy has been examined in several 
trials. It has been hypothesised that fatty acids contained in fish oil may alter 
eicosanoid production and have advantageous effects on cell membrane fluidity. 
Initial studies reported no benefit (Bennett et al, 1989) but a later, larger randomised 
trial of 106 patients suggested a benefit for fish oil in reducing the rate of renal decline 
independently of differences in proteinuria and blood pressure control (Donadio et al, 
1994). Doubts about the validity of this trial centre on the placebo group who 
received olive oil, and in whom the decline in renal function was steeper than would 
normally be anticipated. A subsequent meta-analysis concluded that there was a non­
significant benefit of fish oil in the treatment of IgA nephropathy (Dillon, 1997).
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1.1.5. IgA nephropathy and renal transplantation
IgA nephropathy is associated with a high incidence of histologically recurrent disease 
in renal allografts with rates of up to 60% reported (Berger, 1988; Odum et al, 1994). 
This process is not without consequence, as recurrent disease is believed to be 
responsible for graft dysfunction and ultimately graft failure in a proportion of 
patients. However, an accurate estimate of the contribution to premature graft loss is 
difficult to establish due primarily to selective biopsy policies and coexisting chronic 
allograft nephropathy. A recent review of published series estimated that 15% of renal 
transplant recipients with primary IgA nephropathy developed graft dysfunction due to 
recurrent disease and that 7% had graft loss attributable to this cause (Floege, 2003). 
Despite the risk of recurrent IgA nephropathy, the long-term allograft survival rate in 
these patients is comparable to renal transplant recipients with other primary renal 
diseases (Ponticelli et al, 2001). Cyclosporine-based immunosuppression regimens do 
not appear to be associated with lower rates of recurrent IgA nephropathy. Similarly, 
regimens containing mycophenolate mofetil seem to be associated with comparable 
rates of recurrent IgA nephropathy to azathioprine-based immunosuppression 
(Chandrakantan et al, 2005). Case reports describing inadvertent transplantation of 
donor kidneys with mesangial IgA deposits provide an interesting insight to 
mechanisms regulating deposition of IgA. Repeat histological examination has shown 
that mesangial IgA deposits can resolve promptly when the affected kidney is 
transplanted into a recipient with a primary renal disease other than IgA nephropathy 
(Sanfilippo et al, 1982; Silva et al, 1982). These observations suggest that a systemic 
abnormality in IgA production or clearance is at least one factor required for 
mesangial deposition of IgA.
1.2. The Human IgA System
21
Chapter 1
1.2.1. Metabolism and function of IgA
Approximately 70 mg/kg of IgA is produced each day in humans, which is more than 
any other antibody isotype. However, due to loss of the protein in external secretions 
and to the longer half-life of circulating IgG, IgA is present at lower serum 
concentrations (2-4g/l) than IgG (8-16g/l). The molecule is synthesised by B 
lymphocytes and plasma cells present in the bone marrow, lymphoid tissue, the serum 
and at mucosal surfaces. Isotype switching to IgA production by naive B cells is at 
least partially regulated by the cytokines interleukin-10 and transforming growth 
factor-0 (Defrance et al, 1992). IgA is the predominant isotype found at mucosal 
surfaces such as the respiratory, urogenital and gastrointestinal tracts. The 
physiological function of IgA is to bind and subsequently neutralise pathogenic 
bacteria, viruses and toxins. Following specific binding of IgA to a target epitope, 
attachment of the pathogen to cells of the mucosal epithelial surface may be inhibited 
or the opsonised particle may be recognised and internalised by immune cells such as 
neutrophils or monocytes bearing specific IgA receptors. Despite the apparent central 
importance of IgA in protection of mucosal surfaces from infection, its absence is 
compatible with a virtually normal life as evidenced by individuals with a selective 
IgA deficiency. This genetic condition affects approximately 1 in 700 of the 
population and results in only slightly higher rates of respiratory tract infection in 
some of those affected.
Hepatic clearance is the predominant route for removal of IgA from the circulation. In 
humans, this process appears to be mediated by the asialoglycoprotein receptor which 
is expressed by hepatocytes (Tomana et al, 1988). This receptor recognises IgA and 
other glycosylated proteins through terminal galactose and A-acetylgalactosamine 
moieties and the protein is subsequently internalised and degraded within the 
hepatocyte prior to excretion in bile. However, expression of the specific IgA receptor 
FcaRI (CD89) by hepatic Kupffer cells has also been reported and so these cells could 
also play a role in catabolism of IgA (van Egmond et al, 2000). An alternative 
potential route of clearance is through internalisation and degradation by circulating 
myeloid cells which bear FcaRI (Launay et al, 1999).
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1.2.2. Structure of IgA
In common with other antibody isotypes, the monomeric IgA subunit consists of two 
disulphide-linked immunoglobulin heavy chains each of which is linked by another 
disulphide bond to an immunoglobulin light chain (figure 1.2.). Heavy chain constant 
region sequences are common to a particular isotype whereas the two types of light 
chain (kappa and lambda) are utilised by all isotypes. In humans, two subclasses of 
IgA exist, IgAl and IgA2, which have slight differences between the amino acid 
sequences of the heavy chain constant region. IgAl possesses a unique proline-rich 18 
amino acid “hinge region” between the CHI and CH2 domains that includes several 
serine and threonine residues which have the potential to bear O-linked carbohydrate 
groups. IgA2 is considered to be the phylogenetically older type with the subsequent 
insertion of the hinge region later in evolution to form IgAl. In addition to the 
monomeric form, IgA can also exist in dimeric and higher polymeric forms. In the 
circulation, the monomeric form predominates (>95%) and IgAl is the more abundant 
subclass (85%).
IgA in the mucosal compartment is almost exclusively in a polymeric form. Dimeric 
IgA produced by B lymphocytes includes an extra associated protein unit termed the 
joining (J) chain. This type of IgA (as well as IgM) binds specifically to the polymeric 
immunoglobulin receptor (PIGR) which is present on the basolateral surface of 
epithelial cells (Mostov, 1994). The antibody-receptor complex is internalised and 
translocated across the cell to the apical surface where it is released following 
proteolytic cleavage. A portion of the PIGR, termed the secretory component, remains 
in association with the antibody following release and this complex of dimeric IgA, J 
chain and secretory component is known as secretory IgA.
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1.3. IgA Receptors
1.3.1. Overview of Fc receptors
Fc receptors (FcRs) are specialised cellular receptors that recognise and bind the 
constant region of immunoglobulin heavy chains. They act as crucial links between 
the humoral and cellular branches of the immune system. Each antibody isotype is 
recognised by one or more specific Fc receptors. Thus, IgG is recognised by FcyRs, 
IgA by FcaRs and IgE by FceRs. Activation of the FcR following binding of the 
appropriate ligand can initiate a variety of cellular responses including antigen 
presentation, antibody-dependent cellular cytotoxicity, phagocytosis, production of 
reactive oxygen species or release of cytokines and other inflammatory mediators. 
The most extensively characterised FcRs are members of the immunoglobulin 
superfamily group of receptors and include the high and low affinity receptors for IgG 
(FcyRI, FcyRII & FcyRIII), the medium affinity receptor for IgA (FcaRI) and the high 
affinity receptor for IgE (FceRI). Several of these receptors are dependent on an 
associated molecule, the FcR y chain, for signal transduction. The FcR y chain is a 
membrane-spanning protein that possesses an immunoreceptor tyrosine-based 
activation motif (ITAM) which becomes phosphorylated following receptor activation 
and subsequently recruits additional downstream signalling components.
1.3.2. Fc alpha receptor I (CD89)
Fc alpha receptor I (FcaRI or CD89) is the classical receptor for IgA. The receptor 
was cloned in 1990 and the gene has been mapped to chromosome 19 (Maliszewski et 
al, 1990; Kremer et al, 1992). This type 1 transmembrane protein is predominantly 
expressed by circulating myeloid cells (neutrophils, monocytes, eosinophils) and has 
also been found on tissue macrophages and some dendritic antigen presenting cells 
(Monteiro et al, 1990; Geissmann et al, 2001). Different immune cells exhibit 
variable receptor glycosylation resulting in a receptor size between 55 and 100 kDa.
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FcaRI is composed of two extracellular immunoglobulin type domains with the 
membrane distal EC1 domain containing the IgA binding site (de Wit et al, 1995; 
Morton et al, 1999; Wines et al, 1999) (figure 1.3.). The location of the ligand 
binding site in the EC1 domain of FcaRI is distinct from the arrangement in FcyRs 
and the FceR where the respective ligand binding sites reside in the membrane 
proximal EC2 domains. The receptor has a single 19 amino acid transmembrane 
region and a 41 amino acid cytoplasmic tail. The cytoplasmic tail does not contain 
any recognised signalling motifs but FcaRI has an electrostatic association with the 
common FcR y chain homodimer via a positively charged arginine residue in the 
transmembrane region (Morton et al, 1995). The FcR y chain contains an ITAM motif 
which mediates downstream receptor signalling. Receptor aggregation following 
cross-linking by ligand induces tyrosine phosphorylation of the associated FcR y chain 
homodimer (Pfefferkom & Yeaman, 1994). FcaRI has been detected without 
associated FcR y chain on the cell surfaces of monocytes and neutrophils. It appears 
that the presence or absence of FcR y chain underlies distinct endocytic pathways 
whereby IgA bound to non-associated FcaRI is recycled towards the cell surface and 
protected from intracellular degradation (Launay et al, 1999).
FcaRI affinity for ligand can be modulated in the presence of certain cytokines. 
Priming of eosinophils with either interleukin-4, interleukin-5 or granulocyte- 
macrophage colony stimulating factor resulted in a rapid and transient increase in 
receptor binding of IgA-coated beads (Bracke et al, 1997). The timescale of the 
observation led to the hypothesis that a direct effect on the receptor was responsible as 
opposed to increased synthesis or surface expression of FcaRI. Further work using 
site directed mutagenesis demonstrated that a serine (S263) in the cytoplasmic tail of 
FcaRI influenced receptor affinity for IgA (Bracke et al, 2001). Mutation to an 
alanine residue resulted in constitutive ligand binding whereas mutation to aspartate 
significantly reduced binding even in the presence of cytokine. It was proposed that 
receptor affinity was controlled by cytokines in the extracellular environment through 
a mechanism (perhaps phosphorylation) involving the intracellular domain of the 
receptor -  a phenomenon termed “inside-out” signalling.
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FcaRI is a medium affinity receptor (Ka ~ 106 M '1) for both IgAl and IgA2 and binds 
polymeric IgA more avidly than the monomeric form (Monteiro et al, 1990; Wines et 
al, 1999). Binding of IgA to cells transfected with FcaRI was most efficient with 
complexes containing five or six IgA molecules (Reterink et al, 1997). The crystal 
structure of the interaction between FcaRI and IgA has been elucidated, demonstrating 
that two FcaRI molecules associate with a single IgA molecule (Herr et al, 2003). 
This is in contrast to IgG-FcyRIII and IgE-FceRI interactions which display 1:1 
stoichiometry. Various mediators have been reported to increase expression of FcaRI 
in freshly isolated monocytes. These include lipopolysaccharide, tumour necrosis 
factor-a, IL-1 and granulocyte-monocyte colony stimulating factor (Shen et al, 1994). 
In each case an increase in FcaRI transcript levels was observed and IgA-mediated 
phagocytosis was enhanced. In cultured monocytes, FcaRI transcript and cell surface 
protein levels were negatively regulated by transforming growth factor-P 1 (Reterink et 
al, 1996). In addition, treatment of monocytes with TGF-pl produced reduced 
amounts of IL-6 in response to stimulation with IgA.
Multiple alternatively spliced forms of FcaRI mRNA have been described in 
circulating myeloid cells and in alveolar macrophages (Morton et al, 1996; Patry et al, 
1996; Pleass et al, 1996). These include transcripts lacking the entire EC2 exon 
(AEC2) and the membrane-proximal 66 nucleotides of the same exon (A66EC2). 
Treatment of alveolar macrophages with V-glycanase revealed an FcaRI protein 
backbone 4 kDa smaller than wildtype consistent with the expression of the A66EC2 
transcript by these cells (Patry et al, 1996). Although the AEC2 variant has not been 
identified as a naturally occurring protein, cells transfected with the cDNA are able to 
bind secretory but not serum IgA (Pleass et al, 1996). The inflammatory cytokine 
tumour necrosis factor-a (TNF-a) appears to regulate the ratio of AEC2/wildtype 
transcript in neutrophils and monocytes and a reduction in the AEC2/wildtype 
transcript ratio was observed in neutrophils from patients with pneumonia (Togo et al,
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2003). These alternatively spliced forms of FcaRI and regulation of their expression 
by inflammatory cytokines may serve to extend the functional diversity of the receptor.
1.3.3. Polymeric immunoglobulin receptor
The polymeric immunoglobulin receptor is present on the basolateral surface of 
epithelial cells and recognises and binds dimeric IgA and pentameric IgM present in 
the serum. It functions to transport these molecules across the cell to be released at the 
apical surface into the mucosal compartment of the immune system (Mostov et al, 
1984; Mostov, 1994).
1.3.4. Asialoglycoprotein receptor
The asialoglycoprotein receptor (ASGPR) is a heterodimer of HI and H2 subunits and 
is expressed on the surface membranes of hepatocytes. It mediates internalisation of 
circulating glycoproteins bearing terminal galactose and A-acetylgalactosamine groups 
(Stockert, 1995). This hepatic route is the principal mechanism of IgA clearance from 
the circulation. In addition ASGPR has been described on rat renal mesangial cells 
and a role in the pathogenesis of human IgA nephropathy has been suggested (Gomez- 
Guerrero et al, 1998).
1.3.5. Fc alpha/mu receptor
The Fc alpha/mu receptor (Fca/pR) was initially described on murine B lymphocytes 
and macrophages (Shibuya et al, 2000). The existence of an Fc receptor for IgM had 
been hypothesised and the receptor was identified by probing a T cell leukaemia cell 
line cDNA library using a mouse monoclonal IgM. The receptor gene codes for an 
approximately 70kDa membrane-spanning glycoprotein with an extracellular 
immunoglobulin-like domain. The receptor was able to bind IgM with high affinity 
(Ka ~ 109 M '1) and IgA with lower affinity (Ka ~ 108 M '1). Cells expressing Fca/pR 
were able to internalise IgM-coated beads and this function was dependent on a di-
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leucine motif in the cytoplasmic tail of the receptor. A human homologue of Fca/pR 
was also described which mapped to a region of chromosome 1 (lq32.3) in close 
proximity to the genes for other Fc receptors including FcyRs I-III, FcsR and the 
polymeric immunoglobulin receptor. Both mouse and human Fca/pRs share a motif 
present in the immunoglobulin-like domain with the polymeric immunoglobulin 
receptor. Expression of mouse Fca/pR was demonstrated in several tissues including 
spleen, thymus, kidney, liver and intestine. More recently the expression of Fca/pR in 
the mouse central nervous system has been examined as observations had suggested a 
modulating role for IgM in the pathogenesis of multiple sclerosis (Nakahara et al, 
2003). Fca/pR was demonstrated in mouse forebrain using immunocytochemistry as 
well as in cultured oligodendrocytes and myelin.
1.3.6. Transferrin receptor
The transferrin receptor (TfR) is a 180kDa homodimer which in addition to 
recognising transferrin, appears to bind IgAl (Moura et al, 2001). Both monomeric 
and polymeric forms of IgAl, but not IgA2, were initially reported to be recognised by 
the receptor. TfR expression has been shown to be upregulated on glomerular 
mesangial cells in patients with IgA nephropathy and IgAl binding to mesangial cells 
in culture is specifically reduced by blocking antibodies for the receptor and by 
transferrin.
1.3.7. Other IgA receptors
In addition to the characterised IgA receptors there is some evidence that other as yet 
unidentified receptors for IgA may be present on some cell types. The human colonic 
adenocarcinoma cell line, HT29/19A was shown to bind monomeric and heat 
aggregated IgAl in a manner consistent with the presence of a specific low affinity 
receptor with Ka ~ 107 M '1 (Kitamura et al, 2000). The association was not inhibited 
by either IgG, IgM, asialo-orosomucoid or secretory IgA suggesting that the polymeric 
immunoglobulin receptor, asialoglycoprotein receptor and Fca/pR were not
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responsible. Expression of neither FcaRI mRNA nor protein was detected. This work 
predated the recognition of TfR as an IgA receptor and although IgA2 binding to 
HT29/19A cells was not assessed, it is not possible to exclude that IgAl binding to 
these cells was mediated by TfR in a similar manner to the initial report by Moura et 
al.
Another report documented binding of IgA to Peyer’s patch M cells in a mouse model 
(Mantis et al, 2002). M cells are specialised epithelial cells that deliver mucosal 
antigens from the intestinal lumen to underlying lymphoid tissue. The apical surfaces 
of human M cells were also found to be coated with IgA when biopsies of normal 
terminal ileum were examined after immunofluorescent staining. No specific IgA 
receptor was identified on murine M cells and expression of candidate receptors was 
not assessed in human M cells.
1.4. Mechanisms of IgA nephropathy
1.4.1. IgA glycosylation
The most consistent abnormalities described in IgA nephropathy are related to aberrant 
glycosylation of the IgAl molecule. IgAl is unique amongst immunoglobulins and 
unusual amongst serum proteins in possessing Olinked carbohydrate groups attached 
to amino acids in the hinge region. The molecule also bears AM inked carbohydrate 
groups in common with other immunoglobulin types and many other serum proteins. 
In IgAl the AMinked carbohydrates are present in the CH2 domain and in the tail­
piece extension of the CH3 domain (Yoo & Morrison, 2005). The IgAl hinge region 
contains five serine (Ser) and four threonine (Thr) residues per heavy chain, each of 
which has the potential to bear Olinked glycans via hydroxyl groups. Analysis of
998  910  9*19 •normal serum IgAl suggests that Thr , Ser and Ser support Olmked glycans
• • 9 9 c  9 'I Awhile sites at Thr and Thr are incompletely occupied (Mattu et al, 1998). These
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carbohydrate side chains are based on an Olinked A-acetylgalactosamine (GalNAc) 
unit which may be pl,3-linked to a galactose (Gal) group. In turn the solitary GalNAc 
unit or the GalNAc/ p i ,3-Gal moiety may be crowned with one or two sialic acid 
groups. Thus the profile of IgAl Oglycosylation in an individual subject is 
heterogeneous depending on whether a particular serine or threonine residue possesses 
a carbohydrate side chain and on the composition and structure of the groups present 
(reviewed in Novak et al, 2001). These variable hinge O-glycoforms are illustrated in 
figure 1.4.
Several groups using different methods have now demonstrated the characteristic 
glycosylation abnormalities of serum IgAl in IgA nephropathy. The observation that 
IgA from patients with IgA nephropathy bound with reduced affinity to the lectin 
jacalin led to the hypothesis that alterations in IgA glycosylation may be important in 
disease pathogenesis (Andre et al, 1990). The O-glycosylation profile of IgAl has 
been studied by employing GalNAc-specific lectins such as Vicia villosa and Helix 
aspersa. These studies demonstrate lectin binding patterns consistent with increased 
exposure of the core GalNAc unit on the O-linked carbohydrate side chains indicating 
a reduction in the number of galactose groups in IgA nephropathy patients (Allen et al, 
1995; Tomana et al, 1997). Another study concluded that the deficiency in 
galactosylation in IgAl from patients was restricted to the monomeric fraction (Leung 
et al, 1999). The same study showed that the normally galactosylated polymeric IgAl 
from IgA nephropathy patients instead showed increased sialylation -  consistent with 
an earlier study which examined sialylation of total IgAl from patients (Baharaki et al, 
1996). Further work suggested that the increased sialylation of IgAl from patients 
was restricted to >.-IgAl (Leung et al, 2002).
In another study, a polyclonal antiserum was generated against the IgAl hinge peptide 
sequence and its reactivity against different preparations of IgA was evaluated 
(Kokubo et al, 1999). Reactivity of the antibody was significantly higher with IgAl 
purified from IgA nephropathy patients in comparison with healthy controls and 
subjects with other renal diseases. These findings were consistent with increased
30
Chapter 1
exposure of the hinge peptide core in IgA nephropathy due to fewer or less bulky O- 
linked oligosaccharide side chains.
More sophisticated techniques to examine carbohydrate structures at the IgAl hinge 
have been applied subsequently. Matrix-assisted laser desorption ionisation time-of- 
flight (MALDI-TOF) mass spectrometry has confirmed heterogeneity of O- 
glycosylation at the hinge region of normal serum IgAl. Analysis of hinge peptides 
demonstrated between two and five GalNAc groups with variable numbers of 
galactose residues (Novak et al, 2000). Similar heterogeneity of hinge O-glycans was 
observed with a myeloma IgAl protein. A comparison of serum IgAl from IgA 
nephropathy patients and controls using MALDI-TOF mass spectrometry was 
consistent with results from earlier lectin-binding assays indicating reduced Gal and/or 
GalNAc groups in hinge glycopeptides from patients (Hiki et al, 1998). Similarly, 
fluorophore-assisted carbohydrate electrophoresis (FACE) demonstrated a 
significantly higher proportion of lone hinge GalNAc groups in serum IgAl from IgA 
nephropathy patients (Allen et al, 1999) and electrospray ionization liquid mass 
spectrometry showed a reduction in GalNAc, Gal and sialic acid groups in IgAl from 
patients with IgA nephropathy compared with normal subjects and patients with other 
primary glomerulonephritides (Odani et al, 2000).
The mechanism responsible for the production of underglycosylated IgAl in IgA 
nephropathy is not clear. The Cl inhibitor protein is another circulating protein with 
O-linked carbohydrate groups, but no abnormalities in its glycosylation pattern were 
detected in patients with IgA nephropathy (Allen et al, 1995). This makes non­
specific abnormal manufacture or degradation of O-glycans unlikely explanations for 
underglycosylation. There are no differences in the peptide sequence at the hinge 
region of IgAl in IgA nephropathy patients which could potentially limit the number 
of sites for O-glycans (Greer et al, 1998). The only functional abnormality identified 
thus far is reduced activity of the enzyme, (31,3 galactosyltransferase in B lymphocytes 
from IgA nephropathy patients (Allen et al, 1997). This enzyme mediates the addition 
of Gal to GalNAc in the manufacture of the O-linked carbohydrate side chains of
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IgAl. Reduced enzyme activity appears to be confined to B lymphocytes in IgA 
nephropathy patients as no differences were observed in T lymphocytes or monocytes 
between patients and controls. However, factors regulating both p i,3 
galactosyltransferase activity as well as the activities of many other glycosyltransferase 
enzymes likely to be involved in the post-translational modification of IgAl are not 
well understood. It is also possible that the prevailing local cytokine environment 
could be a factor involved in the mechanism responsible for plasma cells producing 
different glycoforms of IgAl (Chintalacharuvu & Emancipator, 1997). This cytokine 
profile could be a reflection of the immunoregulatory balance between Thl and Th2 
lymphocyte subsets at a particular point in time.
1.4.2. Functional effects of abnormal IgA glycosylation
There is considerable evidence to suggest that the aberrant glycosylation of serum 
IgAl seen in IgA nephropathy has functional consequences which could be relevant to 
disease pathogenesis. It has been postulated that abnormal glycosylation may affect 
IgAl clearance from the circulation, perhaps via the hepatic asialoglycoprotein 
receptor, or independently promote mesangial deposition either through non-specific 
interactions with matrix components or via a specific cellular receptor. Additionally, 
the propensity to form aggregates of IgAl may be increased by abnormal 
glycosylation, and exposure of hinge region epitopes which would otherwise be 
masked could result in the generation of anti-IgAl antibodies which could alter IgAl 
antigen binding or increase the tendency to form macromolecular IgA l.
In experiments where rat kidneys were perfused with fractionated IgAl from IgA 
nephropathy patients, the electrochemically neutral fraction and the fraction with high 
affinity for jacalin were deposited within glomerular capillaries and the mesangium 
within a few hours (Hiki et al, 1999). Analysis of this “glomerulophilic” IgAl using 
gas-phase hydrazinolysis and lectin binding was consistent with underglycosylation of 
the hinge region. In contrast, IgA preparations from healthy controls did not 
accumulate in the rat kidneys following perfusion. Similar deposition was observed
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when rat kidneys were perfused with normal human IgAl which had been 
enzymatically treated to remove Gal and sialic acid groups (Sano et al, 2002).
Higher molecular weight aggregates of circulating IgAl may be more susceptible to 
mesangial deposition and evidence supports the notion that such aggregation may be 
associated with underglycosylation of the IgAl hinge region. IgAl from IgA 
nephropathy patients formed multimeric aggregates following heating to 63 °C in vitro 
more readily than IgAl preparations from normal subjects (Hiki et al, 1996). 
Enzymatically deglycosylated IgAl from normal subjects also showed a spontaneous 
tendency to self-aggregate not observed in the native form (Kokubo et al, 1998). In 
the same study, the multimeric IgAl produced through enzymatic deglycosylation had 
significantly higher affinity for the mesangial extracellular matrix components 
laminin, fibronectin and type IV collagen in an in vitro binding assay. Similarly IgA 
from patients with IgA nephropathy was shown to bind more avidly to collagen 
compared to IgA purified from patients with HIV infection (van den Wall Bake et al,
1992). In separate work it was demonstrated that serum IgAl from a proportion of 
IgA nephropathy patients possessed affinity for IgAl and this interaction was 
considered to underlie IgAl self-aggregation and perhaps promote glomerular 
deposition (Hiki et al, 1991; Kokubo et al, 1997). This IgAl-IgAl interaction was 
tested in competitive inhibition assays using various hinge region components 
(Kokubo et al, 1997). Minor inhibition of the interaction was observed with 
exogenous Gal and GalNAc but significant inhibition of the IgAl-IgAl interaction 
was demonstrated with the addition of exogenous synthesised hinge peptide (20-mer). 
These findings implicate the hinge region amino acid sequence and these carbohydrate 
groups in the formation of IgA aggregates. Thus the normal Olinked carbohydrate 
groups of the IgAl hinge region may function to prevent self-aggregation and to 
inhibit interaction with extracellular matrix components.
Differential IgAl glycosylation may also mediate distinct responses at the glomerular 
level. Mesangial cells express integrins which link the cellular cytoskeleton to 
components of the extracellular matrix and subsequently modulate several important
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activities including cellular proliferation, enzyme production and expression of 
various genes. When cultured human mesangial cells were incubated with 
enzymatically deglycosylated IgA, expression of a vp3 integrin was enhanced by up to 
5-fold from basal levels (Peruzzi et al, 2000). Similar enhancement of mesangial cell 
integrin expression was also observed following incubation with IgA fractions from 
IgA nephropathy patients showing increased exposure of GalNAc when compared 
with IgA from healthy controls. The same authors have also shown a reduction in 
expression and production of vascular endothelial growth factor (VEGF) by cultured 
human mesangial cells exposed to enzymatically deglycosylated IgA (Amore et al,
2000). VEGF is a vasoactive peptide implicated in capillary repair mechanisms 
following renal injury and this down regulation by abnormally O-glycosylated IgA 
appeared to be mediated via enhancement of nitric oxide synthase activity. Whether 
IgA purified from the serum of patients with IgA nephropathy has the same effect has 
not been reported. Both in vitro deglycosylated normal IgA and IgA fractionated 
glycoforms of molecular weight between 250 and 500kD from IgA nephropathy 
patients significantly inhibited the proliferation of cultured human mesangial cells and 
also appeared to exert a pro-apoptotic effect on these cells (Amore et al, 2001).
1.4.3. Immune response in IgA nephropathy
The IgA immune response appears to be augmented in IgA nephropathy as when B 
lymphocytes from IgA nephropathy patients were transformed in vitro with Epstein- 
Barr virus, IgAl production was significantly higher when compared to controls 
(Layward et al, 1994). Whether the IgA that is ultimately deposited in the glomerular 
mesangium originates from bone marrow plasma cells or from cells in the mucosal 
compartment of the immune system is unresolved. The observation that episodic 
macroscopic haematuria is often associated with respiratory tract infections in subjects 
with IgA nephropathy led to the suggestion that mucosal IgA produced in response to 
infection was subsequently routed to the kidney via the systemic immune 
compartment. However, circumstantial evidence tends to favour the systemic immune 
system being the origin of glomerular IgA as abnormalities in the systemic immune
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response have been documented in patients with IgA nephropathy. A higher 
proportion of tonsillar plasma cells in IgA nephropathy patients express mRNA for J- 
chain when compared to cells from normal subjects (Harper et al, 1995). This implies 
a shift towards increased polymeric IgA production in the systemic immune 
compartment in IgA nephropathy. Similar results were obtained when bone marrow 
plasma cells were examined from patients with IgA nephropathy (Harper et al, 1996). 
IgA nephropathy patients also produced a higher proportion of polymeric IgA and 
demonstrated a prolonged IgA immune response following systemic immunisation 
with tetanus toxoid when compared to normal control subjects (Layward et al, 1992).
In contrast, most studies have suggested down regulation of IgA production in the 
mucosal immune response in patients with IgA nephropathy. The proportion of IgA- 
producing plasma cells in duodenal biopsies from IgA nephropathy patients appears to 
be reduced and fewer of these cells express J-chain mRNA when compared to controls 
(Harper et al, 1994). Consistent with this is the response of IgA nephropathy patients 
following intra-nasal immunisation with cholera toxin subunit B where significantly 
fewer IgAl-secreting cells and less antigen-specific IgAl were found in the circulation 
when compared with controls (de Fijter et al, 1996). However, patients with IgA 
nephropathy and Helicobacter pylori infection appeared to have higher levels of 
Helicobacter-specific IgA compared with controls, in addition to altered IgG isotype 
switching (Barratt et al, 1999). These different responses to mucosal antigen may 
reflect chronic versus transient exposure or may be a function of the specific antigens.
Publication of recent work examining the involvement of mucosally derived secretory 
IgA in IgA nephropathy may lead to renewed interest in the role of the mucosal 
immune system in the condition (Oortwijn et al, 2006). In this study, serum levels of 
secretory IgA in patients were not significantly elevated compared with controls but 
did seem to be associated with the degree of haematuria. Binding of secretory IgA to 
cultured human mesangial cells was demonstrated and this was associated with 
production of interleukin-6 by these cells. This observation is at odds with the
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perceived anti-inflammatory properties of secretory IgA but may be of significance in 
the pathogenesis of IgA nephropathy.
Populations of regulatory T lymphocytes are also altered in patients with IgA 
nephropathy. There was reduced usage of specific variable (V) genes in y5-T cells 
from the intestinal mucosae of patients compared to controls (Olive et al, 1997). A 
further study confirmed that V region usage was unaltered in circulating T cells of 
patients but that the mucosal abnormality was mirrored in V region usage in bone 
marrow T cells with reduced expression of Vy3 and V83 in IgA nephropathy patients 
(Buck et al, 2002). It was hypothesised that this abnormality may influence the 
mucosal and systemic immune responses to certain antigens and could be a factor in 
the abnormal production of IgA in IgA nephropathy. Alternatively it is possible that 
the abnormalities arose as a consequence of selective depletion of these particular T 
cell subsets in response to a specific antigenic challenge associated with disease. In 
addition to T cell regulation, production of IgA by plasma cells is influenced by 
antigen presenting cells. Dendritic cells generated from patients with IgA nephropathy 
had a reduced ability in vitro to induce IgA production by naive B cells in comparison 
to dendritic cells derived from controls (Eijgenraam et al, 2005). This functional 
hyporesponsiveness of IgA nephropathy dendritic cells was apparent only in the 
presence of IL-10 and appeared to be dependent on a membrane-bound dendritic cell 
factor. These findings may provide some insight to the mechanisms underlying 
reduced mucosal immune responsiveness in IgA nephropathy patients.
Although various dietary and infectious antigens such as gliadin, cytomegalovirus, and 
Haemophilus parainfluenzae have been proposed as the targets of the immune 
response in IgA nephropathy, the data are conflicting. No consistent exogenous 
antigen has been described either in circulating immune complexes or in mesangial 
deposits of IgA. However, it is possible that the immune response generated is the 
result of exposure to several different antigenic stimuli or to a particular combination 
of antigens. Alternatively, by the time the disease phenotype is recognised, perhaps
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the initiating antigen has disappeared or been cleared by the immune system leading to 
difficulty in retrospective identification.
1.4.4. Circulating IgA immune complexes
Evidence suggests that a proportion of serum IgA circulates in complexes with other 
immunoglobulins. IgA was found to be present in association with IgG and IgM in 
one study, and levels of these IgA circulating immune complexes (CIC) were higher in 
patients with either IgA nephropathy or Henoch-Schonlein nephritis when compared 
to healthy controls (Coppo et al, 1982). Additionally, IgA CIC levels showed 
significant correlation with histological disease activity and the degree of microscopic 
haematuria. Later work with IgAl from IgA nephropathy patients exhibiting lectin 
binding properties characteristic of deficient hinge region galactosylation confirmed 
that IgAl was present in complexes with IgG (Tomana et al, 1997). Importantly this 
study also suggested that the majority of under-galactosylated IgAl from patients was 
present in the high molecular mass IgAl fractions associated with IgG antibodies as 
opposed to fractions containing monomeric IgAl. In addition, there appeared to be no 
difference in galactose content between the uncomplexed IgAl fractions of patients 
and controls. The basis of this association between serum IgAl and IgG in the 
formation of CICs was defined in further work which demonstrated a specific 
antibody-antigen interaction where IgG recognised glycan-based epitopes in the hinge 
region of IgAl (Tomana et al, 1999). The predominant anti-glycan antibody present 
in the CICs was IgG2 but a small proportion was of IgAl isotype and subclass. Anti- 
glycan IgG and IgAl antibodies were also detected in the sera of healthy subjects but 
at lower levels than found in IgA nephropathy patients. IgAl present in CICs 
appeared to be in a polymeric form as indicated by the presence of J-chain. It was 
proposed that abnormal exposure of IgAl hinge region GalNAc groups in IgA 
nephropathy leads to the generation of antibodies specific for epitopes which would 
otherwise be masked or that the exposed hinge region epitopes are recognised by 
preformed naturally occurring antibodies which recognise similar carbohydrate-based 
epitopes of microorganisms.
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Some functional characteristics of galactose-deficient IgAl-containing CICs isolated 
from IgA nephropathy patients have been assessed in studies using cultured human 
mesangial cells (HMC) in vitro. These CICs bound to HMCs with a higher affinity 
than uncomplexed IgAl and were subsequently internalised and metabolised (Novak 
et al, 2002). The CICs also appeared to have a modulatory effect on the in vitro 
proliferation of HMCs. CIC fractions of molecular weight 800-900 kDa isolated from 
IgA nephropathy patients promoted HMC proliferation as assessed by H-thymidine 
incorporation whereas CICs in the range 700-800 kDa exerted an inhibitory effect on 
HMC proliferation (Novak et al, 2005). IgA-containing CICs of molecular weight 
800-900 kDa isolated from healthy controls also stimulated HMC proliferation but by 
a reduced amount compared with those from IgA nephropathy patients. CICs of 
molecular weight 800-900 kDa isolated from a single patient with IgA nephropathy 
during an episode of macroscopic haematuria exerted a greater stimulatory effect on 
HMC proliferation than CICs isolated from the same subject in the absence of 
macroscopic haematuria. Thus CICs from IgA nephropathy patients are responsible 
for distinct functional effects dependent on size and may also possess particular 
characteristics at different phases of the natural history of the condition.
IgA-CICs containing fibronectin have also been described in IgA nephropathy patients 
but evidence for a pathogenic function is lacking (Lai et al, 1996a). The anti­
inflammatory protein, uteroglobin inhibited the formation of these IgA-fibronectin 
CICs and it was hypothesised that this property may prevent the mesangial deposition 
of IgA. Supporting evidence for such a role came from two separate uteroglobin 
“knockout” mouse models which displayed features of human IgA nephropathy with 
haematuria, proteinuria, glomerular deposition of IgA and IgA-fibronectin CICs 
(Zheng et al, 1999). However, further investigation did not support a role for 
uteroglobin in human IgA nephropathy as levels of uteroglobin were not significantly 
altered between patients and controls and in fact there appeared to be increased 
incorporation of uteroglobin into IgA-fibronectin CICs in IgA nephropathy patients 
(Coppo et al, 2002).
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The presence of IgA-containing CICs in IgA nephropathy patients could lead to 
reduced hepatic clearance of IgA through diminished exposure to ASGPR on 
hepatocytes. Alternatively, IgA in the complexed form may be preferentially 
deposited within the glomerular mesangium. This latter mechanism may represent 
“mesangial trapping” due to the physical size of IgA-CICs or could be due to an 
altered interaction with mesangial matrix components or a specific mesangial receptor.
1.4.5. FcaRI-lgA complexes
Circulating, soluble complexes of FcaRI and its ligand, IgA have also been implicated 
in the pathogenesis of IgA nephropathy. A soluble 30kDa version of FcaRI capable of 
binding IgA in a dose-dependent manner was shed from monocytic cells following 
either IgA binding or crosslinking with specific antibody (van Zandbergen et al,
1999). An active signalling event and the presence of the FcR y chain molecule were 
required for FcaRI shedding. It has been suggested that proteolytic cleavage of cell 
surface receptors and the release of a soluble form in this manner represents a 
mechanism of fine adjustment resulting in functional receptor down-regulation and 
avoidance of prolonged receptor activation. The presence of covalently-linked FcaRI- 
IgA complexes was subsequently demonstrated in human sera but only in high 
molecular mass fractions (van der Boog et al, 2002). It was proposed that this 
interaction contributed to the formation of circulating polymeric IgA. Dimeric IgA, 
defined by the presence of J-chain, was not associated with soluble FcaRI.
Two separate research groups have examined the potential role of FcaRI-lgA 
complexes in IgA nephropathy but with apparently conflicting conclusions. Using an 
ELISA-based assay, one group found that 40% of IgA nephropathy patients had high 
levels of circulating FcaRI-lgA complexes and levels in sera from patients with other 
renal and immune complex diseases were not significantly different from healthy 
controls (Launay et al, 2000). When a transgenic mouse model expressing human 
FcaRI on monocytes and macrophages was generated, extensive mesangial IgA
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deposition in association with proteinuria and microscopic haematuria was observed. 
The spontaneous development of this phenotype resembling human IgA nephropathy 
was found to be dependent on soluble FcaRI which was released following interaction 
of mouse polymeric IgA with the transgenic receptor. However, soluble FcaRI was 
not detected as a component of mesangial deposits. This group has subsequently 
reported the development of IgA deposition and microscopic haematuria in this mouse 
model to be independent of the FcR y chain (Arcos-Fajardo et al, 2004).
A study which quantified levels of soluble FcaRI in human sera performed by a 
separate group using a dot-blot assay found no differences between controls and IgA 
nephropathy patients with limited or extensive clinical disease (van der Boog et al, 
2003). The discrepancy with previous results seemed to be due to the methodology of 
quantification. It appeared that ELISA systems did not detect covalently linked 
circulating FcaRI-lgA complexes whereas theses complexes were identifiable and 
measurable using the dot-blot assay. A significant conformational alteration following 
covalent linkage was considered to be the reason why ELISA systems were unable to 
detect soluble FcaRI-lgA complexes. In a different approach taken to test the effect of 
soluble FcaRI in an animal model, this same group injected soluble recombinant 
human FcaRI into mice. In contrast to the effects observed in mice expressing the 
human FcaRI transgene, no mesangial IgA deposition was seen despite high 
circulating levels of FcaRI (van der Boog et al, 2004). Instead, rapid clearance of 
FcaRI from the circulation with subsequent deposition of FcaRI in the liver occurred. 
Using three different methods, it appeared in this study that mouse IgA was unable to 
bind to soluble human FcaRI. These results implied that the presence of circulating 
human FcaRI alone in the transgenic mouse model was insufficient to explain the 
renal phenotype or that alternatively there is some crucial difference between 
recombinant human soluble FcaRI and human circulating FcaRI in the transgenic 
model. The role of soluble FcaRI in the pathogenesis of human IgA nephropathy 
therefore remains unclear.
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1.4.6. Characteristics of mesangial IgA
Immunohistochemical staining of renal biopsy sections using polyclonal antisera and 
monoclonal antibodies has been utilised in order to characterise the nature of IgA 
deposited in the mesangium in IgA nephropathy. IgAl is consistently present and was 
the predominant subclass in cases where IgA2 was co-deposited (Conley et al, 1980; 
Lomax-Smith et al, 1983). Whether IgA2 was present did not correlate with any 
clinical or other pathological feature (Hisano et al, 2001). Secretory component was 
not detected thus favouring a systemic as opposed to a mucosal origin of the 
glomerular IgA. Both kappa and lambda light chains have been detected in mesangial 
IgA deposits with the latter present invariably and predominantly in cases of co­
localisation (Lai et al, 1988). It has been demonstrated that multimeric IgA is present 
in the mesangium although whether this is the exclusive form or what amount of 
monomeric IgA may also be present is unknown as there have been no quantitative 
measurements (Tomino et al, 1982). This polymeric species of IgA recovered from 
the mesangium had a more anionic charge profile in comparison with serum IgA 
(Monteiro et al, 1985). A recent report described the recovery of secretory IgA from 
the transplanted kidney of a patient with recurrent IgA nephropathy (Oortwijn et al, 
2006). Previous studies using immunohistochemical methods had not detected 
secretory IgA within renal IgA deposits. Similarly, these investigators were unable to 
detect secretory IgA in this kidney using these immunohistochemical techniques and 
suggested that alternative reagents and methodologies should be developed to detect 
mesangial secretory IgA.
A crucial link in understanding the pathogenesis of IgA nephropathy was facilitated by 
the detailed examination of mesangial IgA. Previous techniques were insufficiently 
sensitive to determine the nature of hinge region glycosylation in the small amounts of 
mesangial IgAl recoverable from individual needle biopsy specimens from patients 
with IgA nephropathy. The central role proposed for deficient hinge region 
galactosylation in circulating IgAl was validated when mass spectrometry was used to 
analyse a sample of IgAl pooled from 290 renal biopsy specimens of patients with 
IgA nephropathy (Hiki et al, 2001). The profile of hinge region glycopeptides from
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these subjects showed reduced galactosylation consistent with the abnormality seen in 
serum IgAl in IgA nephropathy.
The same abnormality was demonstrated in IgAl recovered from nephrectomy 
specimens from three subjects with biopsy proven IgA nephropathy (Allen et al,
2001). In this report comparison was made between serum IgAl and glomerular IgAl 
from each subject using lectin binding assays for terminal GalNAc. In each case lectin 
binding to glomerular IgAl was higher than that observed with the corresponding 
serum IgAl for each patient. Therefore, in addition to supporting the notion of 
reduced hinge region galactosylation in glomerular IgAl, these findings also suggested 
that serum IgAl glycoforms displaying the most profound abnormalities in O- 
glycosylation might be selectively deposited within the kidney. Thus the species of 
IgAl of which the disease-defining glomerular deposits are composed appears to share 
the characteristic aberrant hinge region glycosylation of serum IgAl.
1.4.7. The tubulointerstitium in IgA nephropathy
Tubulointerstitial damage leading to progressive fibrosis is the final common pathway 
of renal damage in many chronic kidney diseases (D'Amico et al, 1995). In IgA 
nephropathy, the extent of interstitial scarring correlates with progression to end stage 
renal disease (Freese et al, 1998). Possible mechanisms of tubular damage in IgA 
nephropathy and other glomerulonephritides include a toxic effect of proteinuria, the 
release of cytokines and other inflammatory mediators into the local microcirculation 
from glomerular and tubular cells and the subsequent recruitment and infiltration of 
inflammatory cells. Increased urinary concentrations of IgA have been demonstrated 
in patients with IgA nephropathy and it is likely that tubular cells are exposed to IgAl 
or IgAl-containing immune complexes that appear in the glomerular filtrate due to 
loss of integrity of the glomerular filtration barrier (Galla et al, 1985). Indeed the 
presence of IgA deposits on renal tubular cells has been demonstrated by 
immunofluorescence in a small proportion of patients with IgA nephropathy (Frasca et 
al, 1982). In addition to a direct toxic effect, these complexes may specifically
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activate tubular epithelial cells via surface receptors initiating or contributing to 
processes leading to tubulointerstitial damage.
Recent work has demonstrated binding of IgA to cultured proximal tubular cells using 
IgA isolated from both patients with IgA nephropathy and controls (Chan et al, 2005). 
Although there was increased binding of patient-derived IgA, the overall level of 
binding was approximately one tenth of that observed with cultured human mesangial 
cells and neither activation nor proliferation of tubular cells following IgA binding 
occurred. In contrast, tubular cell proliferation and production of inflammatory 
mediators was induced following incubation with medium from mesangial cells 
cultured in the presence of IgA isolated from patients with IgA nephropathy. 
Synthesis of these mediators appeared to be dependent on the presence of mesangial 
cell derived tumour necrosis factor-a in the culture medium. These results support the 
hypothesis of glomerulotubular communication via soluble mediators in the 
pathogenesis of IgA nephropathy.
1.4.8. Animal models of IgA nephropathy
Various animal models displaying features similar to human IgA nephropathy have 
been described. The ddY mouse model spontaneously develops a pattern of renal 
injury analogous to human IgA nephropathy with mesangial deposition of IgA, IgG, 
IgM and C3 in association with proteinuria and mesangial cell proliferation (Imai et al, 
1985). The effects of various modulators of the natural history of this model have 
been examined and reported. The HIGA (high IgA) strain of ddY mice was 
established by selective outbreeding to generate a similar model with high serum IgA 
levels. The immune defect in HIGA mice appeared to be multigenic but the 
glomerular deposition of IgA in these animals was associated with a locus on 
chromosome 15 (Nogaki et al, 2005). As previously discussed, mice with germline 
disruptions in the uteroglobin gene develop symptoms similar to human IgA 
nephropathy and the formation of IgA-fibronectin complexes is promoted but these 
findings do not appear to be relevant to the mechanism of development of human
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disease. Similarly, transgenic mice expressing human FcaRI on monocytic cells 
developed renal disease with mesangial IgA deposition and other features of IgA 
nephropathy. Over-expression of megsin in transgenic mice induced immune complex 
deposition, mesangial cell proliferation and enhanced mesangial matrix production 
(Miyata et al, 2002) (see section 1.6.2.1.).
There are significant limitations inherent in applying these findings to the 
pathogenesis of human IgA nephropathy due to fundamental biological differences 
between the human and murine IgA systems. No IgA receptor analogous to human 
FcaRI appears to be present in mice and distinct systems of IgA disposal dependent on 
the polymeric immunoglobulin receptor are believed to operate. However, the most 
crucial difference between the species is that mouse IgA lacks the hinge region which 
characterises human IgAl so lacks the capacity to bear the O-linked glycans which 
appear to play a central role in human disease. Therefore, it seems unlikely that mouse 
models of disease will provide the reliable tool required to dissect the complex 
mechanisms of mesangial IgAl deposition in IgA nephropathy.
1.5. Mesangial deposition of IgA
1.5.1. Interaction between IgA and the mesangial cell
A key missing link in elucidating the pathogenesis of IgA nephropathy is the failure to 
identify a mechanism for mesangial IgA deposition and subsequent mesangial cell 
activation. It therefore follows that the nature of interactions between circulating 
serum IgA or IgA-containing immune complexes and the mesangial cell is central to 
this process. Some of the functional consequences of abnormal IgAl hinge region 
glycosylation which promote IgAl self-aggregation or binding to mesangial matrix 
components as discussed earlier may be significant. An alternative concept is 
expression by mesangial cells of a specific receptor or multiple types of receptor for
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IgA and that the affinity of this specific interaction may be modulated by variations in 
hinge region glycosylation or the molecular form of IgAl or by other physiochemical 
properties of IgAl. It is also conceivable that a mesangial cell receptor binds to a 
component of IgAl-containing immune complexes distinct from IgA, such as IgG.
IgAl binds to cultured human mesangial cells (HMC) in vitro in a dose-dependent, 
saturable manner which can be specifically inhibited and this suggests expression of a 
specific IgA receptor by these cells (Diven et al, 1998; Barratt et al, 2000; Leung et al,
2000). This interaction was specifically inhibited by IgA and the Fc portion of IgA but 
not by IgG, IgM, asialo-orosomucoid or the Fab portion of IgA. HMCs appear to 
exhibit a higher affinity for polymeric IgAl and may preferentially bind polymeric 
IgAl bearing lambda light chains (Lai et al, 1996b; Barratt et al, 2000). One report 
estimated an affinity constant (Ka) for the interaction between monomeric IgA and 
HMCs to be 2.3 x 106 M '1 but showed no difference in the affinity of HMCs for 
monomeric compared with in vitro heat aggregated IgAl (Diven et al, 1998). The 
electrostatic charge of polymeric IgAl influences its association with HMCs in vitro 
with the most anionic species displaying increased binding (Leung et al, 2001). In this 
study the higher absolute levels of anionic polymeric IgAl from sera of patients with 
IgA nephropathy led to significantly increased binding to HMCs in vitro when 
compared to control sera. This correlates with previous work demonstrating the 
relatively anionic nature of eluates of mesangial IgA (Monteiro et al, 1985).
1.5.2. Mesangial cell receptors
Several responses other than modulation of proliferation can be induced following IgA 
binding to HMCs. These include release of cytokines such as interleukin-1 and 
interleukin-6 (Chen et al, 1994) and production of the matrix components flbronectin 
and collagen (Lopez-Armada et al, 1996). IgA is capable of activating the alternative 
complement pathway (Janoff et al, 1999) and this may contribute further to glomerular 
inflammation. Activation of the alternative complement cascade in IgA nephropathy 
is suggested by the frequent presence of the C3 component in the mesangium and in
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vivo activation of this system has been demonstrated in 75% of patients on serial 
measurements (Wyatt et al, 1987). The complement system can also be activated 
through the lectin pathway and the glomerular deposition of mannose-binding lectin 
(MBL) and MBL-associated serine protease 1 in association with IgA deposits in at 
least a proportion of patients supports this mechanism of inflammation in IgA 
nephropathy (Endo et al, 1998). The parallel responses of HMC activation and 
cytokine production together with activation of the complement system probably 
initiate and maintain the processes of intrarenal inflammation leading to 
glomerulosclerosis.
An obvious candidate receptor to mediate the interaction between HMCs and IgA is 
FcaRI (CD89). An early report demonstrated that HMCs could bind IgA and a 
60kDa putative IgA receptor was identified in these cells (Gomez-Guerrero et al,
1993). Hybridisation of mRNA to a specific FcaRI probe in northern blotting 
indicated that these HMCs expressed this receptor. Further work extended these 
findings by showing enhanced expression of FcaRI by HMCs in response to 
inflammatory cytokines (Bagheri et al, 1997). A third study supported these results 
and described association of FcaRI with the FcR y chain in HMCs as well as mRNA 
expression of the AEC2 splice variant (Suzuki et al, 1999b). Other investigators 
demonstrated expression of FcaRI in 40% of microdissected glomeruli from IgA 
nephropathy patients although it is possible that this result reflected expression of 
receptor by infiltrating blood-borne cells (Kashem et al, 1997).
However, these findings were subsequently contradicted by a series of reports which 
failed to detect mRNA or protein expression of FcaRI or its splice variants by HMCs 
in culture or in renal biopsy sections while confirming IgA binding by these cells in 
addition to demonstrating activation following stimulation by IgA (Diven et al, 1998; 
Westerhuis et al, 1999; Leung et al, 2000). Furthermore, the My43 antibody which 
competitively inhibits binding of IgA to FcaRI did not reduce IgA binding to HMCs 
(Westerhuis et al, 1999; Leung et al, 2000). The explanation for these discrepant 
results is not entirely clear although pertinent factors may include differences in HMC
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preparations and passage numbers of cells used perhaps leading to either loss of 
receptor expression with increasing passage or contamination of cultures with 
infiltrating monocytic cells or tissue macrophages bearing FcaRI. A further study 
failed to detect expression of wildtype FcaRI by HMCs which were able to bind IgA 
but a novel mRNA transcript related to but distinct from FcaRI was described (Barratt 
et al, 2000).
Other candidate receptors for IgA binding to HMCs include the polymeric 
immunoglobulin receptor (PIGR) and asialoglycoprotein receptor (ASGPR). 
However, the inability of their respective alternative ligands, IgM and asialo- 
orosomucoid, to competitively inhibit IgA binding to HMCs does not support a role 
for these receptors in mediating IgA binding to HMCs. Furthermore, flow cytometry 
and nested reverse transcription-PCR did not detect expression of either PIGR or 
ASGPR by cultured HMCs (Leung et al, 2000; Novak et al, 2002).
The transferrin receptor (TfR, CD71) has been proposed to function as an IgAl 
receptor on HMCs (Moura et al, 2001). Although initially reported to have a higher 
affinity for monomeric compared to polymeric IgAl it now appears that TfR binds 
only polymeric IgAl and that earlier results were confounded by contamination of 
monomeric IgAl preparations with transferrin (Moura et al, 2004). The TfR did not 
have affinity for IgA2 in either the monomeric or polymeric form. TfR expressed by 
HMCs mediated endocytosis following polymeric IgAl binding and polymeric IgAl 
derived from IgA nephropathy patients bound more avidly to TfR. The finding that 
glycosylation of polymeric IgAl modulated association with TfR is of particular 
significance and is the likely reason why IgA2 does not bind to TfR. Deletion of 
either N- or O-linked glycosylation sites on polymeric IgAl abolished binding to TfR 
completely whereas enzymatic treatment to remove both sialic acid and pi,3-galactose 
groups significantly enhanced binding to TfR. These results are consistent with and 
may explain earlier observations of increased binding of higher molecular weight 
fractions of IgAl from IgA nephropathy patients. More recent work demonstrated that 
binding of polymeric IgAl to HMCs led to a dose-dependent enhancement of TfR
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expression and that HMC production of IL-6 and TGF-P dependent on TfR was 
induced (Moura et al, 2005). Augmentation of HMC TfR expression was also 
observed when cells were incubated for 72 hours with sera from IgA nephropathy 
patients when compared to HMCs exposed to normal control sera. This effect was 
reduced when IgA was depleted from the patient sera, excluding the possibility of 
substantial cell activation by other factors such as cytokines. The effect also appeared 
to be independent of IgA concentration in the sera.
Expression of TfR has also been examined in renal biopsy specimens from patients 
with IgA nephropathy and other glomerular diseases (Haddad et al, 2003). 
Glomerular TfR expression was not specific for IgA nephropathy but instead seemed 
to be associated with mesangial cellular proliferation. However, the pattern of 
glomerular TfR expression appeared to co-localise with mesangial IgA deposits in 
patients with IgA nephropathy. The TfR therefore fulfils many of the criteria for a 
receptor mediating the mesangial deposition of IgA in IgA nephropathy.
Expression by cultured HMCs of Fc receptors for IgG has been described under 
certain conditions. Treatment of these cells with interferon-y (IFN-y) in combination 
with lipopolysaccharide led to detection of FcyRIII (CD 16) transcript and protein 
(Radeke et al, 1994). This receptor appeared to mediate production of interleukin-6 
by HMCs following stimulation by IgG immune complexes. Another report by the 
same group described functional FcyRI (CD64) expression following stimulation of 
HMCs in culture with IFN-y (Uciechowski et al, 1998). The implication of these 
findings is that circulating immune complexes comprising IgA together with IgG 
could be expected to activate intrinsic mesangial cells under appropriate inflammatory 
conditions and IgG Fc receptors could potentially be a factor in the localisation of IgA 
to the mesangium. Genetic polymorphisms of FcyRII and FcyRIII have been reported 
to be associated with severity of, but not susceptibility to, IgA nephropathy in 
Japanese patients (Tanaka et al, 2005). The FcyRII allele related to IgA nephropathy 
severity was associated with a lower receptor affinity for IgG while the FcyRIII 
polymorphism was associated with a high affinity receptor. These differences were
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hypothesised to reflect distinct underlying effector mechanisms of immune complex 
clearance.
1.6. Genetics of IgA nephropathy
1.6.1. Racial variation in prevalence of IgA nephropathy
IgA nephropathy does not display features of classic Mendelian inheritance where a 
single gene locus is responsible for the phenotype. However, population studies 
suggest that genetic factors are important in the development and perhaps progression 
of the condition. The prevalence appears highest in eastern Asian populations and 
lowest among black African and American ethnic groups (Levy & Berger, 1988). In 
addition, the disease association with male gender observed in Caucasian subjects 
appears to be reversed in Black populations where females are predominantly affected 
(Jennette et al, 1985). This variation between populations cannot be explained 
entirely by differences in biopsy policies and is considered to represent genetically 
associated variability in disease susceptibility.
1.6.2. Candidate gene polymorphisms
Variability in many biologically plausible candidate genes potentially involved in the 
pathogenesis of IgA nephropathy has been explored in order to elucidate any 
associations with either disease susceptibility or progression. The earliest studies of 
genetic polymorphisms in IgA nephropathy examined the genes of the human major 
histocompatibility (MHC) locus (reviewed in Hsu et al, 2000). Initial reports 
suggested an association with the HLA-Bw35 and HLA-DR4 antigens and 
susceptibility to IgA nephropathy. However these associations were not consistently 
demonstrated in subsequent studies probably due to variations in biopsy policy, racial 
differences and heterogeneity of susceptibility genes. Similarly, an association
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between IgA nephropathy and the MHC class II allele HLA-DQB1 was proposed but 
following refinements in typing methodologies this finding was refuted by all but one 
study. In this study of Japanese subjects, two HLA-DQB1 alleles were reported to be 
protective for IgA nephropathy.
Allelic variations in genes encoding the T-cell receptor (TCR) have also been 
examined in IgA nephropathy patients and controls. In a case-control study of 40 
European patients with IgA nephropathy an association was found with a TCR Cp 
polymorphism (Rambausek et al, 1993) and the same polymorphism was associated 
with disease progression in a series of 34 Japanese patients (Nagasawa et al, 1995). 
An allele of the TCR Cot gene was associated with susceptibility but not with disease 
progression in a case control study that included 53 Chinese patients with IgA 
nephropathy (Li et al, 1997).
The insertion/deletion (I/D) polymorphism in intron 16 of the angiotensin converting 
enzyme (ACE) gene has been extensively characterised and examined in several 
pathophysiological conditions. Subjects homozygous for the D allele have serum and 
tissue levels of ACE up to three times higher than those homozygous for the I allele 
and this has been associated with many aspects of cardiovascular disease including 
hypertension, left ventricular hypertrophy and myocardial infarction (Danser et al, 
1995). In renal disease, the higher levels of serum angiotensin II generated as a 
consequence of the DD genotype are believed to lead to an adverse glomerular 
reaction to injury through altered intraglomerular haemodynamic responses and 
promotion of smooth muscle cell and mesangial cell proliferation (Jardine, 1995). 
Possession of the ACE DD genotype has been associated with earlier progression of 
both adult polycystic kidney disease and type 1 diabetic nephropathy to end stage renal 
failure (Baboolal et al, 1997; Vleming et al, 1999). There are several published series 
in both Caucasian and Asian populations examining ACE I/D genotype in IgA 
nephropathy (reviewed in Hsu et al, 2000). Overall these earlier studies suggested an 
association between homozygosity for the D allele and progression to end stage renal 
disease in patients with IgA nephropathy. In one study the DD genotype conferred an
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independent hazard ratio of 3.6 for reduced renal survival in multivariate analysis 
(Stratta et al, 1999). However, later studies performed with larger numbers of patients 
and with superior stratification of risk yielded opposite results. A series of 274 
Caucasian men with IgA nephropathy and another study of 527 Japanese patients, each 
with mean follow up in excess of five years, found no significant association between 
the ACE D allele and disease progression (Frimat et al, 2000; Suzuki et al, 2000). 
The contradictory results of earlier studies are likely to be explained by various 
weaknesses including relatively small sample sizes, heterogeneous populations and 
poor risk stratification of progression. The ACE I/D genotype did not appear to be 
associated with disease susceptibility. The largest study examining the effect of 
polymorphisms in the angiotensinogen gene and in the angiotensin II type 1 receptor 
gene with progression of IgA nephropathy showed no significant association whereas 
smaller studies have shown conflicting results (Frimat et al, 2000).
Polymorphisms in numerous other genetic loci have been reported to be associated 
with disease susceptibility or progression of IgA nephropathy to end stage renal 
disease. These include the genes for transforming growth factor-pl, plasminogen 
activator inhibitor-1, TNF-a, polymeric immunoglobulin receptor, interleukin-10, 
uteroglobin, nephrin, CD 14, E-selectin, L-selectin, interleukin-4, interferon-y and 
mannose-binding protein. A well characterised functional polymorphism in the CCR5 
chemokine receptor has been reported to be associated with late progression of IgA 
nephropathy (Berthoux et al, 2006). Renal transplant recipients homozygous for this 
allele were previously shown to have significantly better long term graft survival. As 
discussed previously (section 1.5.2.), allelic variations in Fc receptors for IgG (FcyRII 
and FcyRIII) have been associated with severity of IgA nephropathy in Japanese 
patients (Tanaka et al, 2005).
At least two different polymorphisms have been described in the promoter region of 
the FcaRI gene. In one study of 90 Japanese patients with IgA nephropathy the 
distribution of genetic polymorphisms was reported to be significantly different in 
comparison to patients with other primary glomerulonephritides and healthy controls
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(Tsuge et al, 2001). However, a similar study comparing 151 Japanese patients with 
IgA nephropathy with healthy controls and those with other glomerular disease 
showed no association between these polymorphisms in the promoter of FcaRI and 
disease susceptibility (Narita et al, 2001). The significance of all these reported 
associations is limited by the inherent weakness of small-scale case control studies in a 
similar manner to the ACE I/D polymorphism story.
I.6.2.I. Megsin gene polymorphisms
The protein megsin is a member of the serine protease inhibitor superfamily first 
identified in the mesangium where it is primarily expressed. Increased renal 
expression of megsin has been associated with mesangial proliferation and matrix 
expansion in IgA nephropathy and other glomerulonephritides although its precise role 
in these processes is not clear (Suzuki et al, 1999a). Over-expression in a transgenic 
mouse model led to immune complex deposition, mesangial matrix expansion and 
mesangial cell proliferation (Miyata et al, 2002). Two polymorphisms (C2093T and 
C2180T) have been described in the 3’ untranslated region of the megsin gene. An 
initial case control study of 110 European IgA nephropathy patients failed to show any 
association between the C2093T polymorphism and disease (Szelestei et al, 2000). 
However, a later study using a more powerful family-based approach in a Chinese 
population showed an association between both polymorphisms and susceptibility to 
IgA nephropathy (Li et al, 2004). The association was examined in 423 patients with 
IgA nephropathy by genotyping each patient along with both parents or unaffected 
siblings when two parents were not available for study. Both megsin polymorphisms 
were significantly more likely to have been transmitted to a subject who subsequently 
developed IgA nephropathy thereby implicating these variations in contribution to 
disease susceptibility. This strategy highlights important differences compared to the 
case control approach (albeit in different racial backgrounds) and this large family- 
based cohort should provide a powerful tool to examine the significance of other 
genetic polymorphisms in this population.
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1.6.3. Familial IgA nephropathy
An increased frequency of urinary abnormalities has been reported in relatives of 
patients with IgA nephropathy. In one series of patients with IgA nephropathy, 61 of 
269 asymptomatic first-degree relatives displayed such abnormalities (Schena, 1995). 
Further evidence for a role of genetic factors in the pathogenesis of IgA nephropathy 
comes from reports of affected individuals from within the same family. Such parent- 
child and sibling pairs have been documented in a variety of ethnic backgrounds 
(reviewed in Hsu et al, 2000). No association with HLA type has been observed and 
this is consistent with results from the later case-control studies examining HLA type 
and susceptibility to IgA nephropathy. Several multiplex kindreds from a range of 
geographical and racial backgrounds where several members in different generations 
have IgA nephropathy have also been described and these familial forms of IgA 
nephropathy appear to be clinically indistinguishable from sporadic cases of the 
disease. One such family from Kentucky, where 14 members had biopsy proven IgA 
nephropathy, had a total of 176 family members clinically assessed (Julian et al, 
1985). A further 17 had evidence of clinical glomerulonephritis and an additional six 
family members had “chronic nephritis” noted on death certificates. Six of those with 
biopsy confirmed disease had a common ancestor. The pattern of inheritance with 
male-to-male transmission and no gender imbalance suggested autosomal dominant 
transmission with variable penetrance. In a separate series of familial IgA 
nephropathy in Italian kindreds the renal survival appeared to be significantly poorer 
compared with sporadic disease (Schena et al, 2002) but no difference in renal 
survival has been reported in other families (Julian et al, 1988). Together these 
reports indicate that a distinct form of IgA nephropathy with a strong genetic basis is 
present within some families. Although histologically indistinguishable from the 
sporadic form, it is unclear what degree of overlap may exist in the pathogenesis of 
familial IgA nephropathy.
These extended kindreds with familial IgA nephropathy potentially offer an alternative 
tool to the case-control study to identify genes that may be important in disease 
susceptibility or progression, thus avoiding the problems inherent in case-control
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studies. Twenty-four kindreds from Italy together with six kindreds from the United 
States were subjected to linkage analysis in order to identify relevant genetic loci 
(Gharavi et al, 2000). These kindreds included 94 members affected with IgA 
nephropathy (60 with biopsy proven disease), 48 unaffected members and 21 with 
status unknown due to age being less than 40 years. The initial approach was to 
examine whether disease was linked to any of a number of candidate genes potentially 
involved in the pathogenesis of IgA nephropathy including the immunoglobulin genes, 
the MHC locus, the galactosyltransferase genes and the genes for uteroglobin and 
FcaRI. No evidence of linkage to any of these loci was found in these families. 
Subsequently a genome-wide scan using 384 markers distributed at regular intervals 
throughout the genome was performed. This demonstrated linkage of the disease trait 
in 60% of kindreds to a locus designated IGAN1 at 6q22-23 with a maximum lod 
score of 5.6. The region of IGAN1 was estimated to contain between 100 and 200 loci 
of individual genes but there were no known candidates to explain the trait. There 
were no obvious clinical or demographic features associated with linkage to IGAN1 
compared with absence of linkage in different families. The pattern of inheritance 
within the kindreds corresponded best to a dominant model with incomplete 
penetrance.
1.7. Aims of this project
The principal aim of this work was to identify potential immunoglobulin receptors 
expressed in the kidney which may play a role in the pathogenesis of immune 
complex-mediated renal disease. In particular it was hoped to clarify whether human 
mesangial cells expressed the classical IgA receptor, FcaRI or a variant form of this 
receptor.
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Figure 1.1. Histological features of IgA nephropathy
Typical histological features o f IgA nephropathy. (A) Light microscopy o f a 
glomerulus. (B) Immunofluorescence o f a glomerulus using an anti-IgA antibody 
showing mesangial distribution o f IgA. (C) Electron microscopy showing granular 
dense deposits representing immune complexes in the mesangium.
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Figure 1.2. Structure of IgAl
Each monomer of IgAl is composed of two immunoglobulin heavy (H) chains 
(shaded ovals) and two immunoglobulin light (L) chains (unfilled ovals). Each oval 
represents an immunoglobulin superfamily domain. The individual chains are linked 
by disulphide bonds (dashed lines). The molecule can be proteolytically cleaved into 
the Fc portion which mediates effector functions via specific receptors (FcRs) and the 
Fab fragment which contains the highly variable antigen binding site (variable (V) 
domains). IgAl possesses a unique hinge region which distinguishes it from the 
phylogenetically older IgA2 subclass. The hinge region peptide sequence can bear O- 
linked carbohydrate groups (filled stars). The positions of TV-linked carbohydrate 
groups are indicated by unfilled stars.
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Figure 1.3. Structure of FcaRI (CD89)
FcaRI is a transmembrane protein with 2 extracellular domains (EC1 and EC2). The 
IgA binding site is located within the EC1 domain. The receptor is associated with the 
disulphide-linked (dashed line) FcR y chain homodimer (FcRy) via a positively 
charged residue in the transmembrane region (+). Each FcR y chain possesses an 
IT AM motif which mediates signal transduction for the receptor complex.
EC1
EC2
Cell
membrane
r  I
FcRy
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1.4. Possible patterns of 0-linked glycosylation at the IgAl hinge region
Each glycan side chain is 0-linked to either a serine or threonine reside in the IgAl 
hinge region. Galactose (Gal) moieties are p 1,3-linked to a core jV-acetyl 
galactosamine (GalNAc) unit. Sialic acid (NANA) groups may be a2,6-linked to 
GalNAc or associated with Gal subunits via an a2,3 link.
1. Ser/Thr —  O — GalNAc
 a2>6
2. Ser/Thr —  O —  GalNAc — £  n a n a  >
3. Ser/Thr —  O
01,3
GalNAc Gal
4. Ser/Thr —  O — GalNAc NANA
5.
01,3
Ser/Thr —  O —  GalNAc Gal
a2,6
NANA
a2,3
Ser/Thr —  O —  GalNAc Gal NANA
a2,6
NANA
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Chapter 2 
Materials and Methods 
2.1. Materials
2.1.1. Biochemicals
Unless otherwise stated, all chemicals were obtained form Sigma, Poole, UK. All 
tissue culture reagents were purchased from Life Technologies, Paisley, UK.
2.1.2. Immunochemicals
The antibodies used in this study are detailed in table 2.1.
2.2. Cell biology techniques
2.2.1. Cell culture
2.2.1.1. Human mesangial cells
Primary human mesangial cell (HMC) cultures were established from glomeruli 
obtained from the normal pole of tumour nephrectomy specimens using a sequential 
sieving technique. Ethics approval was obtained from the local hospital ethics 
committee and patients gave informed consent for the use of tissue. Portions of renal
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cortex were dissected and forced through a series of sieves to obtain glomeruli which 
were seeded into RPMI 1640 supplemented with 10% fetal calf serum, L-glutamine 
(2mM), penicillin (100 units/ml), streptomycin (lOmg/ml), insulin (lOpg/ml), 
transferrin (5.5pg/ml), and selenium (6.7ng/ml) and maintained at 37°C, 5% CO2 in a 
water saturated atmosphere. HMCs grew in characteristic clumps and were typically 
harvested for use between passages 2-4. Purity of cultures was confirmed by positive 
indirect immunohistochemical staining for actin and vimentin and negative staining 
for factor VIII related antigen.
In some experiments confluent HMCs were stimulated by the addition of either IL- 
la , IL-6 or TNF-a in measured concentrations for 24 hours. These cytokines were 
obtained from AMS Biotechnology, Abingdon, UK. In other experiments HMCs were 
incubated with dibutyryl cyclic AMP obtained from Sigma.
2.2.I.2. Other cell lines
The COS-7 human fibroblast cell line (American Type Culture Collection (ATCC), 
Manassas, VA, USA) was maintained in Dulbecco's modified eagle medium (DMEM) 
supplemented with 10% fetal calf serum, L-glutamine (2mM), penicillin (100 
units/ml) and streptomycin (lOmg/ml). Chinese hamster ovary (CHO-K1) cells 
(European Collection of Cell Cultures, Salisbury, UK) and U937 cells (ATCC) were 
cultured in Ham’s F12 and RPMI 1640 media respectively and supplemented as 
above. The human hepatocellular carcinoma cell line, HepG2 (ATCC) was cultured in 
minimum essential medium supplemented as above.
Primary cultures of human proximal tubular cells (PTCs) were a generous gift from Dr 
James McLay (University of Aberdeen, UK). PTC cultures had been prepared from 
normal poles of nephrectomy specimens by mincing, collagenase digestion then 
separation on a Percoll gradient (Mistry et al, 2001). PTCs were maintained in 
DMEM/Ham’s F I2 supplemented as above and were used after two passages.
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Immortalised cell lines were routinely sub-passaged 2-3 times per week. These cell 
lines were all maintained at 37°C, 5% CO2 in a water saturated atmosphere.
2.2.2. Transfection of cells
COS-7 or CHO-K1 cells were transfected using FuGENE 6 transfection reagent 
(Roche Molecular Biochemicals, Indianapolis, IN, USA) when the cells were 
approximately 50% confluent. A ratio of 3 pi transfection reagent to lpg plasmid 
DNA was used. Transfection reagent and DNA were mixed in serum free medium 
before addition to the cells for 48 hours.
2.2.3. Flow cytometry
COS-7 or CHO-K1 cells were detached using a rubber scraper and single cell 
suspensions formed by passage through a fine bore pipette. Cells were washed with 
ice cold phosphate buffered saline (PBS, Oxoid, Basingstoke, UK) pH 7.3 comprising 
0.16M sodium chloride, 3mM potassium chloride, 8mM disodium hydrogen 
phosphate and ImM potassium dihydrogen phosphate containing 0.1% bovine serum 
albumin (BSA). Between 0.5-1.0 x 106 cells per sample were resuspended in 50pl 
PBS/0.1% BSA with the appropriate amount of biotin labelled primary antibody. 
Following 45 minutes incubation on ice, cells were washed twice and incubated for a 
further 30 minutes with streptavidin conjugated to a fluorescent label (streptavidin- 
DTAF, Jackson Laboratories, West Grove, PA, USA). Cells were then analysed using 
a Coulter Epics XL FACScan (Beckman Coulter, Fullerton, CA, USA).
2.2.4. Fluorescence microscopy
In antibody binding experiments transfected COS-7 or CHO-K1 cells were grown on 
glass coverslips for 48 hours. The cells were then washed with ice cold PBS/0.1% 
BSA and incubated with primary antibody in PBS/0.1% BSA for 45 minutes at 4°C. 
Following two further washes the cells were incubated with the appropriate secondary
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antibody or detection reagent for 30-45 minutes before mounting with DAPI- 
containing mounting medium (Vector Labs, Burlinghame, CA, USA) to counterstain 
cell nuclei. In some experiments primary antibodies directly labelled with fluorescein 
were used. Antibody binding to cells was analysed using a fluorescence microscopy 
imaging system (Improvision, Coventry, UK).
For immunohistochemistry experiments cells grown on glass coverslips were fixed 
with 3% paraformaldehyde then permeablised with 0.1% Triton-XlOO in PBS for 8 
minutes at room temperature. Cells were then incubated with 4% goat serum and 2% 
BSA to block non-specific binding. Rabbit anti-calnexin and anti-caveolin primary 
antibodies were incubated overnight at 4°C at concentrations of 1:200 and 2.5pg/ml 
respectively in blocking buffer. After washing with PBS, a Texas Red-labelled anti­
rabbit antibody was applied for one hour at a concentration of lOpg/ml. Nuclei were 
stained with benzimide (lOpg/ml in PBS) for 3 minutes prior to four further washes 
with PBS.
In some experiments transfected cells were incubated with polymeric myeloma IgAl 
(a gift from Dr Jan Novak, University of Birmingham at Alabama, USA) at a 
concentration of 50pg/ml in 5% normal human serum for one hour on ice. IgA 
binding was detected with a Texas Red conjugated goat anti-human IgA antiserum at a 
concentration of 15pg/ml in 4% goat serum. Cells were then fixed with 
paraformaldehyde and stained with benzimide as above prior to visualisation with 
fluorescence microscopy.
2.3. Molecular biology
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2.3.1. RNA extraction
Total cellular RNA was extracted from cells using TRIzol Reagent (Life 
Technologies). Cells grown in suspension were pelleted by centrifugation then lysed 
with repetitive pipetting in TRIzol, using 1ml of reagent per 5-10 x 106 cells. 
Adherent cells were detached by trypsinisation or scraping then pelleted and lysed. 
RNA was also extracted from a fragment of renal cortex and from microdissected 
glomeruli in a similar fashion. Samples were incubated for 5 minutes at room 
temperature to allow dissociation of nucleoprotein complexes before the addition of 
0.2ml of chloroform per 1ml of TRIzol. The samples were shaken thoroughly by hand 
for 15 seconds then incubated for a further 3 minutes at room temperature. 
Centrifugation at 13,000rpm for 15 minutes was then performed at 4°C in a 
microfuge. Following centrifugation the upper aqueous layer containing the RNA was 
transferred to a separate tube and 0.5ml of isopropanol was added to precipitate RNA. 
Samples were incubated at room temperature for 10 minutes followed by further 
centrifugation at 13,000rpm for 10 minutes at 4°C. The RNA precipitate was then 
washed using 1ml of 75% ethanol in diethylpyrocarbonate (DEPC) treated water 
followed by vortexing then centrifugation at 9,000rpm for 5 minutes at 4°C. The final 
RNA pellet was allowed to air dry for 5-10 minutes then dissolved in DEPC treated 
water (typically 30pl volume). RNA concentration was determined by measuring 
absorbance at 260nm and purity was estimated by checking the 260nm:280nm 
absorbance ratio. RNA samples were stored at -70°C.
2.3.2. First strand cDNA synthesis
First strand cDNA synthesis was performed using a Superscript first strand synthesis 
system (Life Technologies). Between 1-3 pg of total RNA was incubated with lpl of 
lOmM dNTP mix and lp l of oligo (dT) (0.5 pg/pl) in a total volume of lOpl for 5 
minutes at 65°C then placed on ice. Reaction mixture containing 2pi of lOx reverse 
transcription buffer, 4pl of 25mM magnesium chloride, 2pl of 0.1 M DTT and lpl of 
RNase inhibitor per sample was prepared and added. The samples were then
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incubated at 42°C for 2 minutes before lpl (50 units) of Superscript II reverse 
transcriptase was added. Reverse transcription controls were also performed in some 
experiments in which case no enzyme was added. The reverse transcription reaction 
was allowed to proceed at 42°C for 50 minutes before termination by heating to 70°C 
for 15 minutes. Samples were then diluted 1:5 to a final volume of lOOpl with 
distilled water and stored at -20°C.
2.3.3. Polymerase chain reaction
Polymerase chain reaction (PCR) was performed using a Techne Progene 
thermocycler, a PTC-150 minicycler or a PTC-200 gradient cycler (MJ Research Inc). 
Mastermix containing lOx PCR buffer, 25mM magnesium chloride (final 
concentration 1.5mM), dNTP mix (final concentration 200pM of each dNTP) and 
forward and reverse primers (final concentration of each 300nM) was prepared and 
added to each tube. Template cDNA in a volume of 5pi or distilled water as control 
was then added before the addition of enzyme. For routine PCR, 5 units per reaction 
of Taq DNA polymerase (Promega, Madison, WI, USA) were used. In experiments 
where high fidelity was required, 2.5 units of pfu polymerase (Stratagene, La Jolla, 
CA, USA) were added to each reaction instead. A "modified hot start" technique was 
used where the samples were kept on ice after the addition of enzyme then placed in 
the cycler with the block already heated to a denaturing temperature. The following 
thermal cycling profile was used. Samples were denatured at 94°C for 90 seconds. 
Between 30-40 cycles of: denaturation at 94°C for 30 seconds, primer annealing for 60 
seconds at a temperature determined by the specific primer combination and DNA 
extension at 72°C for at least 60 seconds were performed. The extension time was 
lengthened if the product length was greater than 1000 base pairs or when using pfu 
polymerase. A final extension at 72°C was then performed for 5-10 minutes. 
Oligonucleotide primers were synthesised by MWG-Biotech, Ebersberg, Germany.
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2.3.3.1. Real time polymerase chain reaction
Real time PCR was used to determine relative quantification of mRNA transcripts 
following reverse transcription. The Gene AMP 5700 Sequence Detection System and 
SYBR Green Core Reagents were utilised (PE Biosystems, Foster City, CA, USA). In 
this system primers are designed to generate a small DNA product to maximise 
reaction efficiency and the reaction takes place in the presence of SYBR Green dye 
which fluoresces on binding to double stranded DNA. Fluorescence is measured at 
the end of each PCR cycle and increases exponentially as the reaction progresses. For 
each reaction the threshold cycle (Ct) is calculated based on the point at which a 
statistically significant increase in the amount of PCR product is detected. The 
threshold cycle inversely reflects the number of target sequences present in each 
sample prior to amplification (Higuchi et al, 1993). These kinetics are illustrated in 
figure 2.1.
Primers for real time PCR were designed using Primer Express software (PE 
Biosystems) with melting points (Tm) 58-60°C and target amplicons of around 100 
base pairs. Reactions were performed in 20pl volumes in triplicate in 96-well optical 
reaction plates with optical caps. SYBR Green PCR Master Mix (PE Biosystems) 
supplied at 2x concentration and containing optimised buffer components, 
deoxynucleotides and AmpliTaq Gold polymerase was used. Each reaction was 
performed with either 2.5pl diluted cDNA or reverse transcription control as described 
above. Forward and reverse primers were each present at a concentration of 300nM. 
The thermal cycling profile started with a 10 minute incubation at 95°C to permit 
automated “hot start” of enzyme activity followed by 40 cycles of a 15 second melt 
step at 95°C and a 1 minute anneal/extend step at 60°C. Results were analysed using 
GeneAmp 5700 SDS software. In order to assess specificity of amplified product and 
avoid spurious results from “primer-dimer” formation and amplification, dissociation 
curves showing product melting points were assessed and samples of product were run 
and visualised on agarose gels.
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2.3.4. Agarose gel electrophoresis of DNA
DNA samples were mixed with 6x blue/orange loading buffer (Promega) and run on 
agarose gels with tris-acetate (TAE) electrophoresis buffer (0.04M Tris-acetate, 
0.001M EDTA). Gel concentration varied between 1-2% depending on the degree of 
separation required. The gels were then stained for 10 minutes in a solution of 
ethidium bromide in TAE (lpg/ml) and the bands visualised on an ultraviolet 
transilluminator. Images were recorded either on Polaroid film or on a digital imaging 
system (EASY plus, Herolab).
2.3.5. Gel extraction and purification of DNA
DNA extraction from agarose was performed using a QIAquick Gel Extraction Kit 
(Qiagen). Each DNA fragment to be used was excised using a clean scalpel blade and 
placed in an Eppendorf tube. The gel slices were then incubated at 50°C for 10 
minutes in buffer QG until the agarose had dissolved. Approximately 1 gel volume of 
isopropanol (150jnl) was added and each sample placed in a spin column. DNA was 
applied to the membrane by centrifugation for 1 minute at maximum speed in a 
microfuge. The flow-through was discarded and the membrane washed with 750pl of 
buffer PE before further centrifugation. This flow-through was also discarded and the 
column spun again to remove all traces of wash buffer. The column was then placed 
into a clean Eppendorf tube and the bound DNA eluted by the addition of 50pl of 
buffer EB followed by centrifugation for 1 minute.
2.3.6. Subcloning of DNA
2.3.6.1. Ligation of DNA into vector
The TOPO TA cloning system (Invitrogen, Groningen, The Netherlands) was used to 
subclone PCR products into vectors. Different vectors were used depending on the
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application. The pCR4-TOPO (figure A.I.) vector was used to subclone PCR 
products for routine sequencing and pcDNA3.1 /V5-His-TOPO (figure A.2.) was used 
as an expression vector for full length gene sequences. Constructs expressing a green 
fluorescent protein tag were generated by subcloning into the pcDNA3.1/CT-GFP- 
TOPO vector (figure A.3.). The TOPO system exploits the property of Taq DNA 
polymerase to add a single 3’ deoxyadenosine (A) overhang to each strand of 
synthesised DNA. The linearised vectors contain complementary 3’ overhanging 
deoxythymidine (T) residues and the enzyme topoisomerase I to facilitate insertion 
and ligation of PCR products. Where PCR products were generated using pfu 
polymerase, 3’ deoxyadenosine overhangs were added following amplification. This 
was achieved by incubation of the gel purified product with 0.5 unit of Taq 
polymerase for 10 minutes at 72°C in the presence of deoxyadenosine nucleotides. 
For each cloning reaction 4pi of fresh PCR product was mixed with lp l of vector and 
lpl of salt solution (1.2M sodium chloride and 0.06M magnesium chloride) and 
incubated at room temperature for 5 minutes.
2.3.6.2. Transformation of competent Escherichia coli
Transformation competent One Shot TOP 10 E. coli (Invitrogen) were utilised. A 
single aliquot of competent cells (50pl) was gently mixed with 2pl of plasmid DNA 
from the ligation step and incubated on ice for 20 minutes. Cells were then heat 
shocked at 42°C for 30 seconds followed by incubation on ice for 2 minutes. 
Following the addition of 250pl SOC medium (Invitrogen) cells were gently mixed for 
1 hour at 37°C then aliquots spread on prewarmed LB (Luria-Bertani) agar (Life 
Technologies) selective plates containing 100 pg/ml ampicillin. Plates were incubated 
overnight at 37°C.
2.3.6.3. Purification of plasmid DNA
For minipreparations of DNA, 4-10 colonies were selected from each ampicillin 
selective plate and used to inoculate separate 5ml aliquots of LB medium containing
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1OOpg/ml ampicillin. Cultures were grown overnight at 37°C with continuous 
shaking. DNA was purified using the QIAprep Miniprep system (Qiagen, Crawley, 
UK) according to the manufacturer’s instructions. Briefly, alkaline lysis of pelleted 
bacterial cells was followed by application of supernatants to columns containing a 
silica-gel membrane. Plasmid DNA was adsorbed selectively to these membranes and 
washed prior to elution and collection.
A Qiagen Plasmid Maxi Kit was used for the purification of larger quantities of 
transfection grade plasmid DNA. Bacterial cultures in 100ml volumes were grown 
overnight and pelleted cells lysed. Precipitated cell debris including bacterial genomic 
DNA was separated from soluble plasmid DNA by centrifugation and the supernatants 
applied to DNA binding membranes. Following washing the DNA was eluted then 
precipitated by the addition of isopropanol prior to centrifugation. DNA pellets were 
washed with 70% ethanol then air dried before dissolving in TE buffer pH 8.0 (lOmM 
Tris-Cl pH 8.0, ImM EDTA). DNA was quantified and assessed using 
spectrophotometry and agarose gel electrophoresis.
2.3.6.4. Restriction enzyme digests
Typically, 1 pg of plasmid DNA was digested in a 20pl volume containing 2pi of an 
appropriate lOx reaction buffer and 1 pi of enzyme. Reactions were incubated for a 
period of time between 2 hours and overnight at 37°C. The products of digestion were 
resolved on agarose gels and visualised using ultraviolet light as previously described.
2.3.6.5. DNA sequencing
Sequencing of plasmid DNA was performed commercially by MWG-Biotech. For 
routine sequencing to check the identity of PCR products, DNA was subcloned into 
the pCR4-TOPO vector (Invitrogen) and the sequencing read was started from either 
or both of the T3 and T7 priming sites incorporated into the vector. Each sample 
containing 5-10pg of plasmid DNA was made up to 200pl volume with distilled water
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then 20pl 3M sodium acetate pH 5.2 and 500pl 100% ethanol were added. DNA was 
precipitated by microcentrifugation at 13,000rpm at 4°C for 10 minutes. Pellets of 
DNA were then washed with 500pl 70% ethanol and either vacuum dried for 10 
minutes with gentle centrifugation or air dried for 1 hour. Sequence data were 
analysed using the GCG software package (Accelrys, Cambridge, UK).
2.3.7. 3’ rapid amplification of cDNA ends (RACE)
A 3’ RACE system (Life Technologies) was used to identify potential novel 
transcripts of FcaRI expressed by human mesangial cells. This technique permits the 
identification of these unknown mRNAs by exploiting the naturally occurring poly (A) 
tail for use as a priming site for subsequent PCR amplification. First strand cDNA 
synthesis was performed using 2.5pg of RNA and an oligo-dT adaptor primer then 
RNase H was added in order to remove the original RNA template. PCR 
amplification using an FcaRI specific sense primer and an abridged universal 
amplification primer complementary to the adaptor sequence used to prime the first 
strand cDNA synthesis was then performed. PCR products were identified on agarose 
gel electrophoresis and bands of interest were purified, subcloned and sequenced.
2.4. Biochemical assays and methods
2.4.1. Preparation of cell lysates
Adherent cells were lysed by the direct addition of ice-cold lysis buffer (1% (v/v) 
Triton X-100, 50mM Tris-HCl pH 7.5, 0.25% (w/v) sodium deoxycholate, 150mM 
sodium chloride, ImM EDTA, ImM vanadate and ImM sodium fluoride) containing 
protease inhibitors (ImM phenylmethylsulfonyl fluoride and lpg/ml each of 
chymostatin, leupeptin, antipain and pepstatin). Cells in suspension were pelleted by 
centrifugation and medium was removed prior to the addition of lysis buffer.
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Following 30 minutes of tumbling motion at 4°C, insoluble debris was removed by 
centrifugation at 15 OOOg for 15 minutes at 4°C.
Protein concentrations of lysates were estimated using the Bio-Rad protein assay 
system which is based on the Bradford Coomassie brilliant blue dye binding system. 
A range of bovine serum albumin standards was used to construct a standard curve 
using spectrophotometry and protein samples were diluted to fall within the linear 
range of this curve. Protein concentrations of all samples were routinely measured in 
duplicate. Lysates were stored at -70° C prior to further usage.
2.4.2. Polyacrylamide gel electrophoresis
Proteins were resolved using the NuPAGE precast gel system (Invitrogen) which 
employs bis-tris buffered (pH 6.4) polyacrylamide gels, available at 3 different 
acrylamide concentrations (10%, 12% and 4-12% gradient gels) allowing a choice of 
different separation ranges. Additional control over separation can be achieved by 
selecting from two different running buffers. Protein samples of standardised amount 
(usually 5-10pg) were denatured in NuPAGE LDS (lithium dodecyl sulphate) sample 
buffer by heating to 70°C for 10 min. In order to reduce proteins, 50mM dithiothreitol 
was added immediately prior to sample denaturing.
2.4.3. immunoblotting
Proteins resolved by polyacrylamide gel electrophoresis were transferred to Protran 
nitrocellulose membranes (Schleicher & Schuell, Dassel, Germany) using the 
NuPAGE XCell II blotting apparatus and manufacturer’s transfer buffer which was 
supplemented freshly with methanol to a volume of 10% or 20% as appropriate. 
Transfer was performed at 30 volts for 60-80 minutes. Transfer efficiency and 
equality of loading were assessed by staining membranes with Ponceau S solution for 
5 minutes followed by washing with distilled water. Ponceau S was removed by
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washing with TBS (20mM Tris-HCl pH 7.6, 136mM sodium chloride) containing 
0.1% (v/v) Tween 20 (TBST).
The nitrocellulose membranes were then blocked in TBST with 4% (w/v) non-fat 
powdered milk (Marvel) for a minimum of 1 hour at room temperature. Blots were 
incubated with primary antibodies at the recommended concentration in TBST 
overnight at 4°C. Three washes of 10 minutes each using TBST were then carried out 
prior to incubation with the appropriate horseradish peroxidase conjugated secondary 
antibody for 2-4 hours in TBST at room temperature. Blots were then washed 
extensively with large volumes of TBST (typically 6 x 1 0  minute washes) followed by 
a final wash in TBS prior to developing. Protein bands were visualised by enhanced 
chemiluminescence (Amersham) and autoradiography.
2.4.4. Membrane preparation
Adherent cells were washed twice in cold nuclear preparation buffer (lOmM Tris-HCl 
pH 7.4, 2mM magnesium chloride, 140mM sodium chloride). Cells were then lysed 
by the addition of nuclear preparation buffer containing 2% (v/v) Tween 40, protease 
inhibitors (ImM phenylmethylsulfonyl fluoride and lpg/ml each of chymostatin, 
leupeptin, antipain and pepstatin) and phosphatase inhibitors (ImM vanadate and 
ImM sodium fluoride) followed by three freeze-thaw cycles using dry ice. Cell debris 
and nuclei were removed by centrifugation at 15,000g for 5 minutes and membranes 
were recovered by ultracentrifugation of the supernatant at 100,000g at 4°C for 1 hour 
(Bunce et al, 1988). Following ultracentrifugation the supernatant represents the 
cytosolic fraction. Membrane pellets were resuspended in cold nuclear preparation 
buffer.
2.4.5. N-glycanase assay
Lysates of some transfected cells were treated overnight at 37°C with 5 milliunits of 
recombinant TV-glycanase (Glyko, Upper Heyford, UK) prior to immunoblotting, in
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order to remove any TV-linked carbohydrate groups. A control lysate without the 
addition of TV-glycanase was treated in the same manner.
2.5. Bioinformatics tools
Various bioinformatics tools available through the internet were used to analyse amino 
acid sequences of proteins of interest. These included the PSORT tool 
(http://psort.hgc.ip) and the “DAS” Transmembrane Prediction Server 
(http://www.sbc.su.se/~miklos/DAS/maindas.html) for prediction of features such as 
signal peptide and transmembrane sequences. The PROSITE database of protein 
families and domains (http://ca.expasv.org/prosite) was accessed to identify domain 
similarities and the NetNGlyc 1.0 server (http://www.cbs.dtu.dk/services/NetNGlvc) 
was used to identify likely sites for TV-glycosylation. The NetPhos 2.0 server 
(http://www.cbs.dtu.dk/services/NetPhos) was used to identify potential sites for 
tyrosine, serine and threonine phosphorylation. A peptide mass calculator at 
http://ca.expasv.org/tools/peptide-mass.html was also utilised. The GPI Prediction 
Server (http://mendel.imp.univie.ac.at/sat/gpi/gpi server.html) was accessed in order 
to assess the likelihood of a protein possessing a GPI (glycosylphosphatidylinositol) 
anchor.
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Figure 2.1. Kinetics of real time PCR
An amplification plot representing fluorescence signal versus cycle number. The 
threshold cycle (Ct) is defined as the point when a statistically significant rise in the 
amount of DNA product is detected.
Sample
Threshold
No Template ControlBaseline
o 5 10 15 20 25 30 35 40
Cycle Number
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Table 2.1. Antibodies
Antibody (clone) Application Manufacturer
biotin-IgA FACS, IHC Jackson
biotin-IgM FACS, IHC Jackson
biotin-IgG FACS, IHC Jackson
FITC-IgA IHC Jackson
FITC-IgM IHC Jackson
FITC-IgG IHC Jackson
anti-CD89 (Mip-8a) IB Serotec
anti-V5 IB Invitrogen
HRP-anti mouse IgG IB Amersham
anti-caveolin IHC BD Biosciences
anti-calnexin IHC Stressgen
Texas Red goat anti-rabbit IgG IHC Jackson
Texas Red goat anti-human IgA IHC Jackson
anti-FcyRIIa (IV3) IB Medarex
FACS: fluorescent activated cell scanning 
IHC: immunohistochemistry 
IB: immunoblotting
HRP: horseradish peroxidase (conjugated)
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Manufacturers
Jackson Laboratories, West Grove, PA, USA
Invitrogen, Groningen, The Netherlands
Serotec, Oxford, UK
BD Biosciences, San Jose, CA, USA
Stressgen Biotechnologies, Victoria, BC, Canada
Medarex, Princeton, NJ, USA
Amersham Pharmacia Biotech, Little Chalfont, UK
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Table 2.2.
Target
P actin
CD89
CD89
CD89
CD89
CD89
Fca/pR
Fca/pR
Fca/pR
Oligonucleotide sequences
Name Sequence (5’ -> 3’) Product
p actin-for 
P actin-rev
89-F2
89-R2
89-ecl-for2
EC 1-for 
EC 1-rev
EC2-for
EC2-rev
TMC-for
TMC-rev
amr-forl
amr-rev
amr-rtf
amr-rtr
amr-for80 
amr-rev 1693
GGG GTA TGC CCT CCC CCA TGC CAT CCT GCG
TTG GCG TAC AGG TCT TTG CGG ATG TCC ACG
CGC TTA AGA TGG ACC CCA AAC AGA CCA C
GCT CTA GAT TAC TTG CAG ACA CTT GGT G
CAA ACA AGG CAG GGC GCT ATC
TCC CTT GGA TGG ATC TGT GAA
TCT TCT GCC TAT CTC TCG GTA CGT
CTC AGC ACA CAT CCC ATT TGA TAG
GAG AAG TTG GCC GGG TGT T
CAC AGC CAT ACG GCA CTG AA
GGT GTT CGT GCA AAG GTC AAT
GAC AAC TAC CAA GGC TGA TAG G
TCT GTC CCT CAG GGT CCT GGA T
TGC TAC CTC TGC GGC ATT G
AGA CGC TGT TCC ATA GGA TCT CA
AGG AGG GCA GGA TGG AAA ATG
GGG TCC TGG ATT TCT CTC TG
482bp
880bp
106bp
96bp
lOlbp
702bp
144bp
1614bp
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Fca/pR
Fca/pR
Fca/pR
Fca/pR
PIGR
FcRn
FcyRI
FcyRIIb
FcyRIII
ASGPR
amr-for54
amr-revl516
amr-rev 1559
amr-rev 1559g
amr-rev 1693g
PIGR-for
PIGR-rev
FcRn-for
FcRn-rev
I-for
I-rev
II-for 
Ilb-rev
III-for 
III-rev
H2-for
H2-rev
CTT TAC CAC AAT CTC ACG TCA C
CTT CCT TTG CAA TAG AAC CAG AG
AGG TGA CCC TTT CTG CCT CCT
GAG GTG ACC CTT TCT GCC TCC T
GGG GTC CTG GAT TTC TCT CTG
GCC CGA GCT GGT TTA TGA AG
AGC CGT GAC ATT CCC TGG TA
CAA AGC TTT GGG GGG AAA AG
TGC AGG TAA GCA CGG AAA AG
CAT GTG GTT CTT GAC AAC TCT GCT CC
TGA AAC CAG ACA GGA GTT GGT AAC TGG
GCA CAG GAA ACA TAG GCT ACA CG
GGT GAT TGT GTT CTC AGC CCC
ATG TGG CAG CTG CTC CTC CCA ACT G
GGT GAT GTT CAC AGT CTC TGA AGA CAC
GCA GGC TGA ATC CCA GGA GA
CCA TTG AAG AGG CTG ACG AT
1463bp
694bp
359bp
876bp
287bp
567bp
1072bp
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Human mesangial cells do not express FcaRI
3.1. Introduction
FcaRI (CD89) operates as a medium affinity cell surface receptor for IgAl and IgA2. 
Expression is predominantly by circulating monocytes, tissue macrophages, 
neutrophils and eosinophils, although dendritic cells also bearing the molecule have 
been described (Monteiro et al, 1990; Geissmann et al, 2001). In common with other 
Fc receptors, FcaRI assists in the coordination of the immune response by acting as a 
functional link between antibodies generated by the humoral immune system and the 
effector cells of the cellular immune system. Engagement of the receptor by ligand 
may initiate several cellular responses including internalisation and intracellular 
killing of antibody-coated organisms, presentation of antigens and production of 
inflammatory mediators including cytokines. The FcaRI glycoprotein is expressed at 
the cell surface in association with the FcR y chain homodimer (figure 1.3.) 
(Pfefferkom & Yeaman, 1994). The FcR y chain contains an activating signal motif 
(ITAM) which modulates signal transduction via FcaRI by tyrosine phosphorylation.
The signalling cascade initiated following FcaRI cross-linking involves recruitment of 
the Src family non-receptor protein tyrosine kinase, p56lyn to the complex of FcaRI 
and FcR y chain (Guile et al, 1998). Phosphorylation of several targets including the 
FcR y ITAMs and the cellular protein p72syk then ensues which leads to p72syk 
association with the receptor complex. Subsequently, modulation of a multimeric 
adaptor protein complex containing tyrosine phosphorylated Cbl, She, SHIP, Grb2 and 
Crkl occurs with recruitment of Sos and activation of the Ras kinase pathway (Park et 
al, 1999). Activation of the Rafl-MEK-MAP and phosphoinositide 3-kinase 
pathways then takes place which leads to cellular effector functions including release
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of inflammatory mediators, antigen presentation and phagocytosis with intracellular 
killing.
Following receptor cross-linking by ligand, FcaRI redistributes to cholesterol-rich 
glycolipid rafts in the plasma membrane (Lang et al, 1999). These rafts function as 
platforms to facilitate the co-localisation of receptor complexes with downstream 
components of the signalling pathway, and form polar caps in the cell membrane. The 
process of FcaRI recruitment to rafts was found to be independent of FcR y chain in 
contrast to the translocation of p56Iyn to rafts which was dependent on the presence of 
FcR y chain. In further work examining signalling events after FcaRI cross-linking it 
was demonstrated that a wide variety of signalling effectors including Blk and Syk 
tyrosine kinases, protein kinase C and phosphoinositide 3-kinase were recruited to 
lipid rafts following FcaRI cross-linking (Lang et al, 2002).
The gene coding for FcaRI is located on chromosome 19 in contrast to all other FcR 
genes which are situated on chromosome 1 (Kremer et al, 1992). The FcaRI gene 
comprises five exons spanning approximately 12kB of genome and codes for a type 1 
transmembrane protein of 266 amino acids (de Wit et al, 1995). The first two exons 
(SI and S2) encode the hydrophobic signal peptide which is cleaved to produce the 
mature protein during translocation from the endoplasmic reticulum to the cell surface. 
Each of the EC1 and EC2 exons encodes an extracellular immunoglobulin-like 
domain with the former containing the IgA binding site. A single exon (TM/C) 
encodes both the 19 amino acid membrane-spanning region and the 41 amino acid 
cytoplasmic tail.
Several distinct transcripts, based on alternative splicing of FcaRI mRNA have been 
described (Morton et al, 1996; Patry et al, 1996; Pleass et al, 1996). These include a 
version with complete deletion of the 288 base pairs comprising the EC2 exon (AEC2) 
and another lacking the membrane-proximal 66 nucleotides of EC2 (A66EC2). 
Although there is some evidence that at least the protein product of the A66EC2 
transcript is expressed in nature by cells (Patry et al, 1996), the precise purpose or
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relevance of these variant transcripts is not known. A further variant of FcaRI 
designated FcaRb has been described in eosinophils and neutrophils (van Dijk et al, 
1996). The FcaRb transcript encodes a truncated form of receptor lacking the TM/C 
exon but containing extra sequence coding for an additional 23 amino acids which 
extend the EC2 exon until a new stop codon is reached. The majority of this protein is 
released in a soluble form but a proportion was also found to be membrane associated 
and cells transfected with this cDNA were able to bind IgA. The nature of FcaRb 
membrane association was not clear but did not appear to be mediated by a glycosyl 
phosphatidyl inositiol anchor. Although FcaRb appears to bind IgA, no tyrosine 
phosphorylation or calcium mobilisation was induced following receptor cross-linking 
despite co-expression of the FcR y chain homodimer. The absence of a conventional 
membrane-spanning region in FcaRb is likely to preclude a functional association 
with the FcRy chain and this may explain the inability of FcaRb to mediate signal 
transduction.
Reports of FcaRI expression on circulating immune cells in IgA nephropathy patients 
have generated conflicting results. Using flow cytometry, a Japanese group described 
enhanced expression of FcaRI on both neutrophils and monocytes from patients with 
IgA nephropathy (Kashem et al, 1994; Kashem et al, 1996). However, later work 
from a European group showed reduced FcaRI expression in both neutrophils and 
monocytes from IgA nephropathy subjects (Grossetete et al, 1998). Down-regulation 
of FcaRI by these cells was mediated by IgAl, with polymeric IgAl exerting a more 
powerful negative effect on receptor expression than the monomeric form. Also of 
interest was the finding that FcaRI on patient monocytes and neutrophils was of a 
higher molecular weight (60-85 kDa) in comparison to FcaRI on cells from controls 
(55-75 kDa), consistent with altered post-translational modification in IgA 
nephropathy. Additionally, endogenous IgAl bound to the higher molecular weight 
version of FcaRI with greater affinity and this was postulated to be the mechanism of 
receptor down-regulation.
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Whether or not human mesangial cells (HMC) express FcaRI is of considerable 
significance as this receptor could potentially mediate the mesangial accumulation of 
IgAl and activation of HMCs towards an inflammatory phenotype in IgA 
nephropathy. Several research groups published work between 1993 and 1999 that 
supported the notion of FcaRI expression by HMCs (Gomez-Guerrero et al, 1993; 
Bagheri et al, 1997; Kashem et al, 1997; Suzuki et al, 1999b) (see section 1.5.2.). 
However, these findings were contradicted by a report describing cellular activation of 
HMCs following IgAl binding in the absence of detectable FcaRI at either the mRNA 
or protein level (Diven et al, 1998).
A further report confirmed dose-dependent binding of IgA by cultured HMCs but 
again failed to detect expression of either FcaRI protein or wildtype transcript (Barratt 
et al, 2000). The possibility of expression by HMCs of a novel IgA receptor protein 
was raised by the observation that IgA binding to these cells was not inhibited by the 
My43 antibody which blocks ligand binding to FcaRI. FcaRI expression was not 
induced following incubation of HMCs with activating mediators nor was any soluble 
receptor protein detected in cell culture medium. Neither was expression of the 
FcaRb isoform detected. Employing a strategy designed to identify the expression of 
different FcaRI transcripts by using RT-PCR with nine different combinations of 
primer pairings, these investigators demonstrated expression of three novel FcaRI- 
related transcripts by HMCs. These transcripts were detected using a sense 
oligonucleotide primer homologous to sequence in the EC1 exon of FcaRI and an 
antisense primer to the TM/C exon. The three transcripts detected corresponded to 
fragments of wildtype FcaRI, and the AEC2 and A66EC2 splice variants. However, 
the association between these transcripts and the FcaRI gene was unclear and the 
natures of the upstream and downstream coding sequences were not determined. The 
authors concluded that IgA binding to HMCs was mediated by a novel receptor related 
to, but distinct from, FcaRI.
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3.2. Results
3.2.1. FcaRI mRNA is not expressed by human mesangial cells
To determine whether HMCs express wildtype FcaRI, polymerase chain reaction 
(PCR) was performed using cDNA generated from four separate primary human 
mesangial cell cultures. U937 cells constitutively express FcaRI and this cDNA was 
used as a positive control. COS-7 cells do not express any Fc receptors and cDNA 
from these cells was used as a negative control. The primer combination used was 
“89-F2” and “89-R2” (table 2.2.)
The expression of FcaRI by U937 cells was confirmed by the presence of a band 
corresponding to a predicted size of 880 base pairs representing wildtype FcaRI 
(figure 3.1.). The lower band present in this lane represents the AEC2 splice variant at 
592 base pairs. The identities of both these products were confirmed by sequencing. 
No PCR products were seen with any of the four HMC cDNAs or the negative control 
COS-7 cDNA. Equal expression of the ubiquitous housekeeping gene, p actin was 
confirmed for all samples indicating comparable quantities and qualities of cDNA in 
each case (figure 3.1. lower panel). Therefore, HMCs do not express mRNA for either 
wildtype FcaRI or the AEC2 or A66EC2 splice variants.
3.2.2. FcaRI protein is not expressed by human mesangial cells
In order to examine FcaRI protein expression, whole cell lysates were prepared using 
U937, COS-7 and human mesangial cells. The cellular proteins were separated using 
electrophoresis and immunoblotted using the Mip-8a monoclonal antibody which is 
specific for FcaRI.
FcaRI protein expression by U937 cells was visualised as a smeared band of 
approximately 55-70 kDa (figure 3.2.). The smeared appearance of the band is
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consistent with variable glycosylation of the receptor. No FcaRI protein expression 
was detected with either COS-7 cells or HMCs.
3.2.3. FcaRI EC2-related novel transcripts are not expressed by human 
mesangial cells
3.2.3.I. 3’ RACE
If HMC binding of IgA and activation by IgA is independent of wildtype FcaRI then 
these cells may express a novel variant form of the classical receptor. The partial 
FcaRI-related transcripts based on the EC2 exon of the receptor and described by 
Barratt could represent such novel receptors distinct from wildtype FcaRI and 
therefore would not be detected by either standard PCR approaches or by antisera to 
wildtype FcaRI. We used 3’ rapid amplification of cDNA ends (RACE) in 
conjunction with a sense primer complementary to sequence in the distal portion of the 
EC1 exon of FcaRI in an attempt to characterise the downstream sequences of any 
novel transcripts expressed in HMCs. RNA from four HMC lines, COS-7 cells and 
U937 cells was reverse transcribed using the adaptor primer supplied in the 3’ RACE 
system. PCR was subsequently performed using an FcaRI gene-specific primer (89- 
ecl-for2; table 2.2.) and the antisense universal adaptor primer.
A band of approximately 1,600 base pairs was present in each of the four HMC 
samples and the U937 cell sample (figure 3.3.). In addition these samples all 
generated a second product of approximately 400 base pairs. In contrast COS-7 cells 
demonstrated a different pattern with the presence of a band of approximately 200 
base pairs and no 1,600 base pair product. The presence of these bands in HMCs 
suggested possible expression of FcaRI-related transcripts by these cells. As expected 
these bands were absent in reverse transcription control samples and were dependent 
on the presence of the gene-specific primer (data not shown). The 1,600 base pair
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products from an HMC line and from the U937 cells and the 400 base pair product 
from the HMC line were excised and gel purified prior to subcloning and sequencing.
Sequencing of the 1,600 base pair product from U937 cells yielded partial FcaRI 
sequence comprising the EC1 and EC2 exons as expected. The 1,600 base pair band 
from the HMC line comprised sequence from a proto-oncogene designated UFO 
(NCBI accession number X66029) which encodes a tyrosine kinase receptor (Schulz et 
al, 1993). The 400 base pair band from HMCs represented sequence from the 3- 
phosphoglycerate dehydrogenase (PHGDH) gene (Cho et al, 2000) (NCBI accession 
number NM 006623) which is known to be expressed at high levels in human kidney. 
No FcaRI-related sequence was detected in the products generated from HMCs by 3’ 
RACE. The identification of sequence for the UFO and PHDGH genes in HMCs was 
likely to be artefactual owing to low stringency priming in the PCR step due to the 
presence of a single gene-specific primer, combined with extremely low or absent 
expression of FcaRI-related transcripts in these cells.
3.2.3.2. Real time PCR
We next employed an alternative strategy to identify any novel FcaRI-related 
transcripts in HMCs. Real time PCR was used to determine relative quantification of 
different FcaRI exons expressed within the same cell line and between different cells. 
In order to maximise efficiency, primers were designed to amplify short 
(approximately 100 base pairs) sequences of different FcaRI exons and these were 
quantified and compared using real time PCR. It was hypothesised that if a variant 
transcript containing the EC2 exon of FcaRI but with novel upstream and downstream 
sequence was expressed by HMCs that the relative expression of the amplicon for the 
EC2 exon would be higher than for the EC1 and TM/C exons. A diagrammatic 
representation of the target sequences generated by the primers is illustrated in figure
3.4. Amplicons A, B and C correspond to sequence in the EC1, EC2 and TM/C exons 
of FcaRI respectively. Primer sequences (EC 1-for, EC 1-rev, EC2-for, EC2-rev, 
TMC-for and TMC-rev) are shown in table 2.2.
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First strand cDNA reverse transcribed from four primary HMC lines was used for real 
time PCR together with cDNA from U937 cells and COS-7 cells as positive and 
negative controls respectively. Matching reverse transcription controls where reverse 
transcriptase enzyme had been omitted were included for each sample. Each reaction 
was performed in triplicate and the mean threshold cycle (Ct) determined. If a reaction 
efficiency of virtually 100% is assumed then the relative amount of transcript in the 
original sample is halved for each single unit increase in the threshold cycle. To 
determine whether a particular mean Ct was of biological significance in this highly 
sensitive system it was compared with the mean Ct of the matching reverse 
transcription control by subtraction and the difference expressed as ACt. As the 
amplicons generated for the FcaRI exons were intra-exonic and did not cross exon 
boundaries, calculation of the ACt controlled for the presence of trace amounts of 
genomic DNA in the starting RNA samples. This approach also controlled for other 
potential confounding factors including any reverse transcriptase activity of the DNA 
polymerase, contamination of the system by product and formation and amplification 
of primer dimers.
The results of real time PCR for the FcaRI exons are expressed as mean Ct and ACt in 
table 3.1. For U937 cells the ACt for each amplicon was approximately 7 in 
comparison to COS-7 cells where the difference between cDNA and reverse 
transcription controls was around zero for each amplicon. This is consistent with 
expression of FcaRI by U937 cells but not COS-7 cells as expected. Mean threshold 
cycles for U937 cells were around 20 whereas those for the four HMC lines ranged 
from 31.1 to 36.6. Therefore, if HMCs do express transcript for FcaRI then levels 
must be extremely low at between 2000 and 65,000-fold less than the constitutive 
expression level in U937 cells.
When the mean Ct for expression of each FcaRI amplicon in the four HMC lines was 
compared with the corresponding reverse transcription control to generate the ACt 
value the results were close to zero, ranging from -0.5 to 2.1. Combined with the
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finding of high mean threshold cycles for these samples it was concluded that these 
HMCs did not express FcaRI transcript at biologically significant levels. In addition, 
these data provided no support for expression of a novel EC2-related FcaRI transcript 
by these HMCs as the ACt values for amplicon B (EC2 exon) were close to zero for 
each HMC line.
HMCs and U937 cells were next stimulated for 24 hours with either ImM dibutyryl 
cyclic AMP (dbcAMP) or with a combination of IL -la and TNF-a each at a 
concentration of 50ng/ml in an attempt to induce expression of FcaRI. IL-1 and TNF- 
a  have both been implicated in the pathogenesis of IgA nephropathy (Yoshioka et al, 
1993) and dbcAMP has been shown to enhance expression of FcaRI in U937 cells 
(Cameron et al, 2001). Table 3.2. shows the results of real time PCR for the TM/C 
exon of FcaRI (amplicon C) for these stimulated cells. Expression of FcaRI by U937 
cells was increased by approximately 2-fold following incubation with dbcAMP with 
ACt increasing from 8.2 to 9.4 while the combination of IL -la  and TNF-a reduced the 
ACt value to 7.6. Once again high mean Ct values were observed with HMCs and no 
significant effect following stimulation was seen. These results demonstrate that these 
biological modulators did not induce expression of FcaRI by HMCs.
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3.3. Discussion
Using a variety of techniques and approaches our results demonstrate that HMCs 
express neither message nor protein for the classical IgA Fc receptor, FcaRI. 
Additionally we could find no evidence for the expression of a novel transcript or 
variant form of the receptor by these cells.
These results are in disagreement with the series of initial reports from different 
research groups that documented FcaRI expression by HMCs (Gomez-Guerrero et al, 
1993; Bagheri et al, 1997; Kashem et al, 1997; Suzuki et al, 1999b). Collectively 
these authors also described enhanced expression of FcaRI in response to 
inflammatory cytokines, correlation between glomerular FcaRI expression and 
histological renal damage and a physical association between FcaRI and the FcR y 
chain. Our results are in accordance with later published reports that described IgA 
binding by HMCs and subsequent cellular activation in the absence of FcaRI 
expression (Diven et al, 1998; Westerhuis et al, 1999; Barratt et al, 2000; Leung et al, 
2000). There are several possible explanations for these discrepancies based primarily 
on likely differences in HMC harvesting techniques, culture and propagation. It could 
be hypothesised that prolonged culture or varying culture conditions lead to loss of the 
receptor from the cell surface, although one of these later studies failed to detect 
FcaRI expression in renal biopsy sections (Westerhuis et al, 1999). Another 
possibility is the presence in HMC cultures of contaminating cells such as tissue 
macrophages that express FcaRI. Even a very low number of such cells could lead to 
a spurious positive result in a sensitive RT-PCR system.
Using RT-PCR and immunoblotting we were unable to detect FcaRI expression by 
HMCs. These findings were extended by the use of real time PCR which permitted a 
relative quantification of expression. In comparison with the clear constitutive levels 
of FcaRI expression by U937 cells, the threshold cycles obtained with HMC cDNA 
were extremely high and did not differ in biological significance from the reverse 
transcription reverse controls. By applying the same methodology to quantify each of
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three FcaRI exons it was possible to exclude significant expression of a novel 
transcript containing these elements of FcaRI sequence.
Similarly, we attempted to directly identify any novel sequence downstream from the 
distal part of the EC1 exon that was expressed by HMCs by using 3’ RACE. 
Although this approach was speculative it would be expected to yield useful sequence 
information in the presence of the novel variants described by Barratt et al. Using 
control U937 cells, elements of FcaRI sequence were detected by 3’RACE but 
material from HMCs yielded only artefactual gene sequences almost certainly due to 
the absence of specific target expression by these cells which permitted subsequent 
low stringency priming and amplification.
FcaRI expression by HMCs was an attractive initial contender to mediate the 
mesangial deposition of IgA in IgA nephropathy. Despite support for its candidacy 
from multiple early data, our results together with findings subsequently published in 
the literature effectively discount this possibility. It remains possible that FcaRI does 
play a role elsewhere in the pathogenesis of IgA nephropathy either on blood-borne 
cells such as neutrophils and monocytes or on tissue macrophages involved perhaps in 
a clearance mechanism or as a soluble circulating IgA receptor. However, it appears 
almost certain that alternative mechanisms or receptors are responsible for IgA- 
induced activation of HMCs and the mesangial accumulation of IgA that defines IgA 
nephropathy.
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Figure 3.1. RT-PCR for FcaRI showing expression in U937 cells but not in 
human mesangial cells.
FcaRI mRNA expression was examined in four separate human mesangial cell 
(HMC) lines using RT-PCR. U937 cell cDNA was used as a positive control and 
cDNA from COS-7 cells as a negative control. The lower panel shows expression of 
the housekeeping gene (3 actin for each sample. The figures to the left represent 
molecular size in base pairs.
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Figure 3.2. Immunoblot for FcaRI showing expression in U937 cells but not in 
a human mesangial cell line.
FcaRI protein expression was examined in U937, COS-7 and cultured human 
mesangial cells (HMC). Cell lysates were separated by electrophoresis and 
immunoblotted using the Mip-8a antibody. The figures to the left represent molecular 
weight in kDa.
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Figure 3.3. 3’ RACE using FcaRI gene-specific priming showing a product of
approximately 1,600 base pairs in U937 cells and in human mesangial cells.
RNA from U397 cells, COS-7 cells and four human mesangial cell lines was subjected 
to 3 ’ RACE using a primer specific for sequence in the distal part o f the EC1 exon o f 
FcaRI. The figures to the sides represent molecular size in base pairs.
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Figure 3.4. Diagrammatic overview of FcaRI sequences targeted in real time 
PCR
Amplicons A, B and C represent target sequences in the EC1, EC2 and TM/C exons of 
FcaRI respectively. The size molecular size (base pairs) o f each exon is shown 
underneath.
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Table 3.1. Real time PCR for EC1, EC2 and EC3 exons of FcaRI
Real time PCR for each exon was performed using cDNA from U937 cells, COS-7 
cells and four separate HMC cell lines in parallel with the appropriate reverse 
transcription controls (RT-CON). Reactions were performed in triplicate and mean 
threshold cycles (Ct) are shown for each amplicon along with the difference in mean 
Ct between samples and controls (ACt).
Amplicon cDNA RT-CON AC*
U937 A 19.8 26.7 6.9
B 19.3 26.0 6.7
C 20.3 27.4 7.1
COS-7 A 37.9 37.6 -0.3
B 30.9 31.2 0.3
C 40 40 0
HMC-1 A 34.4 34.8 0.4
B 31.7 31.3 -0.4
C 34.7 34.2 -0.5
HMC-2 A 36.6 38.6 2
B 32.2 32.8 0.6
C 36.4 38.5 2.1
HMC-3 A 33.6 33.6 0
B 31.1 32.2 1.1
C 33.7 33.3 -0.4
HMC-4 A 33.0 34.1 1.1
B 31.6 31.6 0
C 33.5 34.1 0.6
93
Chapter 3
Table 3.2. Real time PCR for TM/C exon of FcaRI following stimulation of 
U937 cells and HMCs
Real time PCR for the TM/C exon of FcaRI (amplicon C) was performed using cDNA 
from U937 cells and from an HMC line following 24 hours stimulation with either 
ImM dibutyryl cyclic AMP (dbcAMP) or a combination of IL -la and TNF-a each at 
50ng/ml. Reactions were performed in parallel with the appropriate reverse 
transcription controls (RT-CON) and in triplicate. Mean threshold cycles (Ct) are 
shown along with the difference in mean Ct between samples and controls (ACt).
cDNA RT-CON ACt
U937 Unstimulated 21.3 29.5 8.2
dbcAMP 19.1 28.5 9.4
IL-la + TNF-a 21.0 28.6 7.6
HMC Unstimulated 37.3 38.8 1.5
dbcAMP 37.3 37.4 0.1
IL -la + TNF-a 34.8 34.7 -0.1
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Human mesangial cells express Fca/pR
4.1. Introduction
Genes encoding Fc receptors for IgG, IgE and IgA had been identified and their 
products extensively characterised for several years before a specific Fc receptor for 
IgM was discovered in 2000. IgM is the antibody isotype produced in the primary 
humoral immune response following immunisation or after the immune system has 
encountered a new microbial antigen and the existence of an Fc receptor for IgM had 
been predicted. Numerous so called “natural antibodies” many of which have 
specificity for carbohydrate epitopes of microorganisms are also of the IgM isotype 
but the mechanism of downstream effector functions following antibody-antigen 
interaction was unclear. The polymeric immunoglobulin receptor (PIGR) expressed 
on epithelial cells and performing the specialised function of polymeric IgA and IgM 
transport across epithelial surfaces was the only receptor for IgM identified prior to 
this time. However, although the PIGR is closely related in structure and in 
chromosomal location to the FcyRs and the FceR, it is not a true Fc receptor as its 
function depends on the presence of the joining (J) chain in the structure of its ligands 
rather than the Fc portion of immunoglobulin. The newly described Fc receptor for 
IgM was also able to bind IgA and was designated as the Fc alpha/mu receptor 
(Fcoc/pR) (Shibuya et al, 2000).
The Fca/pR was discovered as the consequence of a deliberate attempt to identify an 
FcR for IgM. A cDNA library derived from a mouse T cell leukaemia line was 
transfected into COS-7 cells and screened using a mouse monoclonal IgM as a probe. 
An open reading frame from the cDNA clone isolated predicted a type 1 
transmembrane protein with a 32 amino acid signal peptide, a 423 amino acid 
extracellular region and a 60 amino acid intracellular segment. The presence of a
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single extracellular immunoglobulin domain was predicted, as were four potential 
sites for A-linked glycosylation. The extracellular region contained an amino acid 
sequence motif common to the polymeric immunoglobulin receptor and this was 
postulated to be involved in ligand binding. The cytoplasmic tail of the Fcot/pR 
contained a di-leucine motif but was devoid of any tyrosine-based signalling elements. 
Using RT-PCR, Fca/pR transcript was detected in several mouse tissues including 
thymus, spleen, liver, kidney, small and large intestines, testis and placenta. Using a 
monoclonal antibody raised against mouse Fca/pR, surface expression of the receptor 
was demonstrated on the majority of B lymphocytes and macrophages but not on 
granulocytes, NK cells or T lymphocytes. It was unclear whether the pattern of tissue 
expression described was a consequence of receptor expression by intrinsic cells or 
alternatively, was due to expression by infiltrating or resident haemopoietic cells 
bearing the receptor.
Expression of the mouse Fca/pR cDNA in transfected cells yielded a protein of 
approximately 70kDa present on the cell surface. Cells stably transfected with the 
receptor were able to specifically bind IgM in addition to monomeric and dimeric 
forms of IgA but were unable to bind any subclasses of IgG. Fca/pR binding affinity 
was determined using 125I-labelled mouse IgM and IgA with the receptor 
demonstrating high affinity for IgM (Ka = 2.85 x 109 M’1) and intermediate affinity for
Q 1
IgA (Ka = 3.01 x 10 M‘ ). A functional property for the receptor was confirmed with 
endocytosis of IgM-coated beads by stably transfected cells. The capacity of the 
receptor to mediate endocytosis was abolished by mutation of the di-leucine motif 
present in the cytoplasmic tail of Fca/pR. Finally it was also demonstrated that 
Fca/pR could mediate internalisation of IgM-coated bacteria by primary B 
lymphocytes in culture and that this process could be inhibited by pre-incubation with 
a blocking antibody against the receptor. The authors hypothesised that processing of 
opsonised microbes at an early stage of the immune response may be an important 
physiological function of Fca/pR and that it may also play a role in the subsequent 
presentation of antigen to T lymphocytes.
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Shibuya et al also identified a human homologue of Fca/pR which shared 49% amino 
acid identity to the mouse receptor. The gene for human Fca/pR mapped to a region 
of chromosome 1 (lq32.3) close to the genes for the PIGR, the FcyRs and the FceR. 
The predicted structure of the human Fca/pR was similar to the mouse receptor in that 
it contained a single extracellular immunoglobulin-like domain with potential TV- 
linked glycosylation sites and sequence motif shared with the PIGR together with a 
transmembrane region and cytoplasmic tail. However, in contrast to the mouse 
receptor the human Fca/pR did not possess the intracytoplasmic di-leucine motif 
necessary for endocytosis by the mouse Fca/pR. No other recognised signalling 
motifs were apparent in the cytoplasmic tail of the human Fcot/pR. No functional data 
were described for the human Fcot/pR and no information was presented on its tissue 
distribution.
We hypothesised that if the human form of Fca/pR also possessed the ability to bind 
IgA and was also expressed in human kidney, perhaps by mesangial cells, then this 
receptor could potentially play a role in the molecular pathogenesis of IgA 
nephropathy.
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4.2. Results
4.2.1. Fca/fjR mRNA is expressed in human kidney and by human 
mesangial ceils
To determine whether Fca/pR message could be detected in human renal tissue, 
polymerase chain reaction (PCR) was performed using cDNAs generated from normal 
renal cortex and from microdissected glomeruli from normal human kidney. PCR was 
also carried out using cDNAs from four separate primary HMC cultures, U937 cells 
and COS-7 cells. The primer combination used was “amr-forl” and “amr-rev” (table
2.2.) producing a predicted amplicon of 702 base pairs for wildtype Fca/pR.
The expression of Fca/pR mRNA in human renal cortex and in microdissected 
glomeruli was demonstrated by the presence of an appropriately sized band following 
PCR (figure 4.1.A). The upper band observed in this gel is the predicted size for the 
genomic fragment of DNA (2,328 base pairs). Figure 4.1.B confirms expression of 
Fca/pR mRNA by all four HMC lines examined and by U937 cells. No Fca/pR 
expression was detected in COS-7 cells. Full length sequencing of the PCR product 
from one HMC line was performed and this confirmed the presence of Fca/pR 
sequence.
Real time PCR was also used to assess expression of Fca/pR in these different cell 
types by comparing the difference in mean threshold cycles (ACt) between cDNA 
samples and reverse transcription controls as described in section 3.2.3.2. The primer 
combination used was “amr-rtf’ and “amr-rtr” (table 2.2.) and reactions were 
performed in triplicate. These results (table 4.1.) confirm expression of Fca/pR 
transcript by U937 cells and by all four HMC lines with ACt in the range from 3.1 to 
5.5 compared with a ACt for COS-7 cells of -0.7 consistent with no expression of 
Fca/pR.
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4.2.2. Fca/pR expression by human mesangial cells is specifically 
increased by IL-1 a
To determine whether Fca/pR message could be regulated by inflammatory cytokines, 
cultured HMCs were stimulated for 24 hours with either IL-1 a  or TNF-a at a 
concentration of 50ng/ml. Semi-quantitative RT-PCR was performed by reducing the 
number of PCR cycles to 35. Treatment with IL-1 a, but not with TNF-a, resulted in 
upregulation of Fca/pR expression when compared with unstimulated cells (figure
4.2.). There was no synergistic effect of both cytokines in combination and 
upregulation of receptor mRNA by IL-1 a  was confirmed in a second HMC line. 
Therefore, Fca/pR expression by HMCs is specifically upregulated by IL-1 a.
Real time PCR was next used to determine the magnitude of Fca/pR upregulation by 
IL-1 a. HMCs and U937 cells were stimulated for 24 hours with either ImM dibutyryl 
cyclic AMP (dbcAMP) or with 50ng/ml IL-1 a. The results in table 4.2. demonstrate 
no significant biological effect of either IL-1 a  or dbcAMP on Fca/pR expression by 
U937 cells. However, treatment of HMCs with IL-1 a  was associated with an increase 
in ACt value from 0.8 to 8.3 consistent with an approximately 180-fold increase in 
Fca/pR expression by these cells. Treatment of HMCs with dbcAMP caused a small 
increase in ACt value from 0.8 to 2.2.
4.2.3. Cloning and genomic organization of human Fca/pR
To further characterise the human homologue of Fca/pR the full length open reading 
frame was cloned from an HMC line. Primers were designed based on the database 
sequence (accession number E l5470; http://www.ncbi.nlm.nih.gov) predicted to 
containing the human receptor (Shibuya et al, 2000) and are shown in table 2.2. as 
“amr-for80” and “amr-revl693”. The reverse primer was designed to exclude the 
predicted native stop codon from the amplified sequence. RT-PCR using pfu 
polymerase was used to amplify a 1614 base pair fragment of DNA. This product was 
purified from an agarose gel and 3’ adenine overhangs were added by incubation with
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Taq polymerase. The fragment was then subcloned into the pcDNA3.1 /V5/His/TOPO 
expression plasmid in frame with a V5 epitope tag. Identity and orientation of the 
insert were confirmed by full length sequencing and restriction digest. The nucleotide 
sequence of the insert is shown in figure 4.3. and this was submitted to GenBank 
under accession number AY063125. The ATG translation initiation codon is at 
position 19 of this sequence. The nucleotide sequence of the cloned receptor, 
combined with data from the NCBI E l5470 sequence, was used to deduce the exon- 
intron structure of the gene by comparison with data from the NCBI human genome 
database (http ://www.ncbi.nlm.nih. gov/ genome/guide/human; reference number 
NT_021877.3 GI: 13635806; accessed 21/05/2001). The genomic organisation of the 
human Fca/pR gene is illustrated in figure 4.4. The location of the human Fca/pR 
gene was confirmed to be at chromosome lq32. The gene comprises 7 exons and 6 
introns spanning approximately 10,000 bases of genome. All of the intron-exon 
boundaries obey the splice site consensus rule (5’ GT/AG 3’) (Breathnach & 
Chambon, 1981) as shown in table 4.3.
4.2.4. Predicted amino acid sequence of human FcaZjuR
Translation of the open reading frame cloned from the human mesangial cell line 
predicted a protein composed of 532 amino acids and this sequence is shown in figure
4.5. Analysis of the sequence suggested a hydrophobic signal peptide comprising the 
first 16 amino acids and this would produce a mature protein of 516 amino acids after 
cleavage of the signal peptide. The nucleotide sequence for the signal peptide is 
contained within exon “SP” and into the start of exon “EC1”. A transmembrane 
region composed of 17 amino acids (positions 454-470) was also predicted with the 
resulting mature membrane-bound protein possessing a 62 amino acid cytoplasmic tail 
and an extracellular portion of 437 amino acids. Exons “TM” and “CY” contained the 
nucleotide sequences for the transmembrane and cytoplasmic regions respectively. 
The extracellular portion of the protein was coded by sequence in exons “EC1”, 
“EC2” and “EC3” with a single immunoglobulin-like domain present at amino acid 
positions 61-169 encoded by sequence in exon “EC2”. Two cysteine residues at
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positions 82 and 153 were predicted to form the disulphide bridge of this domain. 
Two potential sites for TV-linked glycosylation were identified at amino acid positions 
167 and 276 in the extracellular portion of the protein. A threonine residue at position 
479 and a serine residue at position 480 were detected as possible sites for 
phosphorylation in the cytoplasmic tail. No potential sites for tyrosine 
phosphorylation were identified in this intracellular portion of the protein. The 
predicted molecular weight of the mature protein following cleavage of the signal 
peptide was 55,409 Da.
4.2.5. Expression of the human Fca/pR protein
The cloned Fca/pR cDNA was used to transiently transfect COS-7 cells and lysates 
were prepared for immunoblotting. An antibody directed against the V5 epitope tag 
encoded by the expression plasmid was used to detect the protein. Expression of V5 
epitope-tagged Fca/pR fusion protein by transfected cells was demonstrated by 
immunoblotting (figure 4.6.A). The molecular weight of the tagged Fca/pR protein 
was approximately 63kDa under reducing conditions and there was no significant 
mobility shift observed under non-reducing conditions indicating that the receptor was 
expressed as a monomer. As the V5 tag accounts for about 5kDa of weight, the 
molecular mass of the native protein would be approximately 58kDa.
As the presence of sites for TV-linked glycosylation was predicted from the Fca/pR 
amino acid sequence, a lysate of COS-7 cells transfected with Fca/pR was incubated 
with A-glycanase to remove any TV-linked carbohydrate groups. Figure 4.6.B shows 
that the V5-tagged Fca/pR protein was only minimally JV-glycosylated, with N- 
glycanase treatment resulting in a mobility shift of around 3 kDa revealing a protein 
core of approximately 60 kDa.
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4.2.6. Human Fca/pR specifically binds IgA and IgM
In order to define the antibody binding characteristics of the human Fca/pR, 
transfected COS-7 or CHO-K1 cells were incubated with labeled IgA, IgM, or IgG 
antibodies and examined using fluorescence microscopy and flow cytometry. Cells 
transfected with irrelevant DNA in the same vector were used as controls. 
Fluorescence microscopy showed that cells transfected with Fca/pR cDNA were able 
to bind IgA and IgM but did not bind IgG (figure 4.7.), whereas cells transfected with 
irrelevant DNA did not bind immunoglobulin of any isotype (data not shown). The 
binding of IgM by transfected cells appeared to be stronger than that of IgA.
Flow cytometry of CHO-K1 cells transfected with human Fca/pR confirmed receptor 
binding of IgA and IgM (figure 4.8.) in the population of transiently transfected cells. 
Cells transfected with irrelevant DNA were used as negative controls for antibody 
binding.
4.2.7. Human mesangial ceils express variant Fca/pR transcripts
An additional product of approximately 1,300 base pairs in size can be seen in figure
4.2. following stimulation of HMCs with IL-1 a. This band could also be seen very 
faintly following RT-PCR of unstimulated HMCs (data not shown). The band was 
excised from agarose, gel purified, subcloned and sequenced. Sequencing revealed a 
distinct Fca/pR transcript with an in frame insertion of 624 base pairs of sequence 
which comprised the complete intron 5 of the genomic sequence. This intron 
separates exons EC3 and TM and is spliced out in the wild-type transcript. The 
sequence of this variant predicts that the first codon following divergence from the 
wild type sequence is TAA, a stop codon. As the exon coding for the transmembrane 
domain is downstream from this stop codon, translation of this larger transcript would 
theoretically result in the production of a soluble, circulating form of the receptor. 
This would be consistent with the existence of soluble forms of other Fc receptors 
which have been described, including FcaRI (van Zandbergen et al, 1999). The
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nucleotide sequence of this variant transcript was submitted to GenBank under 
accession number AY063126.
Following stimulation of two HMC lines with 50ng/ml IL-1 a  for 24 hours, RT-PCR 
for Fca/pR using an alternative set of primers demonstrated an additional, smaller 
product to that of the expected wildtype receptor as observed in figure 4.9.A. The 
forward primer used was complementary to sequence in exon “5’UTR” (amr-for54) 
and the antisense primer annealed to DNA in exon “TM” (amr-revl516) (table 2.2.). 
The amplicon representing wildtype Fca/pR was anticipated to be 1463 base pairs in 
size, and after subcloning and sequencing, the upper band in figure 4.9.A. was 
confirmed as the wildtype transcript. One of the lower bands in figure 4.9.A was 
excised, gel purified and subcloned into the pCR4-TOPO vector. Sequencing of this 
product revealed expression of an alternatively spliced transcript of the Fca/pR gene 
with an 802bp deletion corresponding to the entire EC3 exon. This Fca/pR AEC3 
variant transcript is represented in figure 4.9.B. Detection of the wildtype and AEC3 
transcripts with this primer set was optimal following stimulation of HMCs with IL- 
la . The failure to detect expression of these transcripts in the absence of IL- 
l a  stimulation is likely to be a consequence of reduced sensitivity of this particular 
primer combination.
4.2.8. Predicted amino acid sequence of the Fca/fiR AEC3 transcript
An open reading frame was identified within the Fca/pR AEC3 transcript sequence 
where the initial 516 nucleotides from the ATG start codon were shared with the 
sequence of the wildtype Fca/pR transcript. Due to deletion of the 802 base pairs 
comprising the EC3 exon, a shift in reading frame occurred starting from the DNA 
sequence of the TM exon and continuing distally. A stop codon was encountered 661 
base pairs distal to the start codon.
The predicted sequence of the Fca/pR AEC3 variant is identical to the first 172 amino 
acids of the wildtype receptor (figure 4.10.). Subsequently the out of frame deletion
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results in divergence of the predicted amino acid sequence from the wildtype receptor. 
The stop codon identified within the transcript sequence was located in exon “CY” at 
an earlier position than the stop codon in the frame coding for the wildtype receptor, 
resulting in a protein sequence shorter than wildtype receptor. The predicted product 
of the Fca/pR AEC3 variant is a protein of 220 amino acids which includes the same 
16 amino acid signal peptide of the wildtype receptor. The same extracellular 
immunoglobulin-like domain of the wildtype receptor was also maintained prior to 
sequence divergence. A single potential site for AMinked glycosylation was 
anticipated at position 167. The mature protein has a predicted molecular weight of 
23,112 Da following cleavage of the signal peptide. Sequence analysis also 
anticipated a distal membrane-spanning region (amino acids 184-202) encoded by the 
same exon (TM), but in an alternative reading frame from, the transmembrane region 
of the wildtype receptor. The resulting intracellular region is composed of 18 amino 
acids. Three potential sites for serine phosphorylation only (amino acids 206, 207 and 
219) were identified in the cytoplasmic tail. No potential sites for a 
glycosylphosphatidylinositol (GPI) anchor were identified.
The full length open reading frame of the Fca/pR AEC3 variant was subsequently 
cloned from a primary isolate of HMCs. Nucleotide sequences of the primers used are 
shown in table 2.2. as “amr-for80” and “amr-revl559”. The reverse primer was 
designed to exclude the predicted native stop codon from the target sequence and RT- 
PCR using pfu  polymerase was used to amplify a 678 base pair fragment of DNA. 
This product was purified from an agarose gel and 3’ adenine overhangs were added 
by incubation with Taq polymerase. The fragment was then subcloned into the 
pcDNA3.1/V5/His/TOPO expression plasmid in frame with a V5 epitope tag. Identity 
and orientation of the insert were confirmed by full length sequencing and restriction 
digest.
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4.2.9. Expression of the human Fca/pR AEC3 protein
The human Fca/pR AEC3 protein was expressed by transient transfection of CH0-K1 
cells. The protein was identified by immunoblotting of lysates using an antibody 
specific for the V5 epitope of the tagged protein. Cells transfected with either 
irrelevant DNA in the same vector or with wildtype Fca/pR cDNA were used as 
negative and positive controls respectively (figure 4.11.). As seen previously, the 
wildtype Fca/pR protein was present as a band of approximately 62 kDa. The Fca/pR 
AEC3 protein was detected as a pair of bands at approximately 29 and 26 kDa. The 
V5 tag contributes around 5kDa to the molecular weights of these proteins.
The Fca/pR AEC3 protein was predicted to possess a single A-linked glycosylation 
site (figure 4.10.). In order to test this prediction a lysate of CHO-K1 cells transfected 
with Fca/pR AEC3 cDNA was treated with A-glycanase to remove any TV-linked 
carbohydrate groups. The protein was detected using the anti-V5 antibody and 
compared with lysates of equal total weight from Fca/pR AEC3 cDNA transfected 
cells which had not been enzymatically treated and with cells transfected with 
irrelevant DNA. Figure 4.12. shows that the double band observed with cells 
transfected with Fca/pR AEC3 cDNA was resolved to a single band corresponding to 
the molecular weight of the lower band of the doublet at around 26kDa. Thus in cells 
transfected with Fca/pR AEC3 cDNA, the expressed protein exists in distinct non­
glycosylated and A-glycosylated forms. The A-glycosylated fraction appeared to be 
more abundant.
In order to test the prediction of a transmembrane region within the Fca/pR AEC3 
protein, membrane preparations of transfected CHO-K1 lysates were prepared. The 
membrane fractions were separated from cellular lysates using ultracentrifugation and 
these preparations were immunoblotted with the anti-V5 antibody. Figure 4.13. shows 
that wildtype Fca/pR and the Fca/pR AEC3 protein were present within the 
membrane fractions of lysates prepared from transfected cells. However, only a 
single band of approximately 29kDa (rather than a doublet) was detected in the
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membrane fraction of cells transfected with Fca/pR AEC3 cDNA, suggesting that only 
the /V-glycosylated form of the protein was present in association with a cellular 
membrane. The lower molecular weight unglycosylated form appeared in neither the 
membrane nor cytosolic fractions. The absence of this band could be explained by its 
localisation to the cell nucleus or to a nuclear membrane which would be removed 
with other cell debris early in the membrane preparation process. The 29kDa 
membrane-associated band representing Fca/pR AEC3 protein did not appear in the 
cytosolic fraction.
4.2.10. Fca/pR AEC3 protein does not bind IgA or IgM
To determine whether the Fca/pR AEC3 protein was capable of functioning as a cell 
surface immunoglobulin receptor, CHO-K1 cells transfected with Fca/pR AEC3 
cDNA were incubated with either IgA or IgM and examined for binding using flow 
cytometry and fluorescence microscopy. No significant antibody binding to 
transfected cells was observed as shown by flow cytometry in figure 4.14. Similarly, 
when cells transfected with Fca/pR AEC3 cDNA were incubated with IgA or IgM and 
examined using fluorescence microscopy, no antibody binding to cells was detected 
(data not shown).
4.2.11. Fca/pR AEC3 protein is not expressed at the cell surface in 
transfected cells
The apparent inability of Fca/pR AEC3 protein to bind IgA and IgM could be 
explained by the protein fulfilling a function distinct from the wildtype receptor. 
Alternatively, it was hypothesised that Fcoc/pR AEC3 protein produced by transfected 
cells may not be expressed at the cell surface. Therefore, in order to assess the cellular 
localisation and distribution of the protein, a green fluorescent protein (GFP) construct 
was engineered which would enable the tagged protein to be detected within 
transfected cells using fluorescence microscopy. Primers for PCR were designed to
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generate appropriate DNA inserts from the pcDNA3.1 /V5/His/TOPO expression 
vectors containing the coding sequences for wildtype Fca/pR and the Fca/pR AEC3 
variant to subclone into the pcDNA3.1/CT-GFP-TOPO vector. The inserts were 
cloned into this latter vector in frame with a C-terminal GFP label. The forward 
primer sequence used for each construct was “amr-for80” (table 2.2.). The reverse 
primers were “amr-revl693g” and “amr-1559g” for the wildtype and AEC3 variant 
constructs respectively. The orientation of each insert was determined by restriction 
digest analysis.
CHO-K1 cells were transiently transfected with the constructs coding for GFP-labelled 
Fca/pR and Fca/pR AEC3 proteins and examined using fluorescence microscopy. 
Figure 4.15.A shows that the GFP-labelled wildtype Fca/pR was distributed in a 
diffuse pattern throughout the cytoplasm of transfected cells. In contrast, the GFP- 
labelled Fca/pR AEC3 protein was observed in a different distribution with expressed 
protein localised in discrete polar caps at either end of the nucleus. In order to 
correlate these findings with ligand binding, cells transfected with each GFP-labelled 
construct were incubated with 50pg/ml of polymeric myeloma IgAl and examined 
using three fluorescence microscopy image overlays (figure 4.15.B). This confirmed 
the widespread cytoplasmic and membrane distribution of wildtype Fca/pR and IgA 
binding associated exclusively with cells expressing labelled Fca/pR. No IgA binding 
was observed with cells expressing Fca/pR AEC3 protein in the characteristic dense 
perinuclear caps. It was concluded that the cellular distribution of Fca/pR AEC3 
protein in transfected cells was distinct from that of wildtype receptor and that the 
variant protein was not expressed at the surface of transfected cells.
4.2.12. Fca/pR AEC3 protein expression is restricted to the endoplasmic 
reticulum in transfected cells
In order to define the intracellular localisation of the Fcot/pR AEC3 protein in more 
detail, transfected CHO-K1 cells expressing either GFP-labelled wildtype Fca/pR or
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GFP-labelled Fca/pR AEC3 were stained with antibodies for calnexin and caveolin. 
These primary antibodies were detected using a Texas Red-labelled secondary 
antibody and visualised using fluorescence microscopy. These images are shown in 
figures 4.16. and 4.17. for calnexin and caveolin respectively. Calnexin is a resident 
transmembrane endoplasmic reticulum (ER) protein which plays a role in the folding 
of newly synthesised proteins which are exported along the secretory pathway. Figure 
4.16. shows a degree of co-localisation between wildtype Fca/pR and calnexin. 
However, this was not exclusive and Fca/pR expression was apparent in areas other 
than the ER. In contrast, expression of GFP-labelled Fca/pR AEC3 protein by 
transfected cells was restricted to areas where calnexin was also detected.
Caveolin is a transmembrane protein present in membrane invaginations (caveolae) on 
the inner surface of the plasma membrane. It is also expressed in the trans-Golgi 
network and in intracellular transport vesicles. Figure 4.17. shows a difference 
between caveolin expression and the intracellular distribution of the Fca/pR and 
Fca/pR AEC3 proteins. Wildtype Fca/pR co-localised with areas of caveolin 
expression whereas the distribution of Fca/pR AEC3 protein was to distinct regions 
within the cell.
That wildtype Fca/pR protein was present with the ER in addition to co-localising to 
areas where caveolin is expressed is to be expected for a protein that is transported 
along the secretory pathway and destined for expression on the plasma membrane. In 
contrast, Fca/pR AEC3 protein expression appeared to be restricted to the ER and was 
not detected in areas where caveolin was detected. It was concluded that the Fca/pR 
AEC3 protein is specifically retained within the ER and is not transported any further 
along the secretory pathway towards the plasma membrane in this cell type under the 
conditions described.
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4.3. Discussion
These results document the expression of mRNA for the Fca/pR, together with two 
alternatively spliced forms, by human mesangial cells in culture. This is the first 
report to describe the cloning and subsequent expression of the human form of the 
receptor. The finding of a novel human IgA-binding receptor expressed by HMCs is 
of importance as such a receptor could potentially be involved in mediating immune 
complex deposition in IgA nephropathy.
Arguably, by the time Shibuya and colleagues had described the murine Fca/pR, the 
definitive identification of an Fc receptor for IgM had become overdue. Several 
reports dating from the late 1980s onwards had described specific binding of IgM by a 
number of haemopoietic cell types, while Fc receptors for the other main 
immunoglobulin isotypes had been identified, cloned and characterised in this period. 
A 60kDa receptor capable of binding IgM was identified on activated human B 
lymphocytes but expression was not detected on T lymphocytes nor on cells from the 
monocyte-macrophage lineage (Sanders et al, 1987). This molecule was further 
characterised as an Fc receptor for IgM with Olinked, but no TV-linked carbohydrate 
groups and appeared to be coupled to the cell membrane of B cells via a GPI-anchor 
(Ohno et al, 1990). Furthermore, this FcpR did not have affinity for IgA so was 
probably distinct from the yet to be described Fca/pR. Expression of an FcpR by 
natural killer (NK) cells had also been described (Pricop et al, 1993). This receptor 
was detected on the majority of resting NK cells and was shown to mediate signal 
transduction. It is unclear whether any characteristic other than IgM binding was 
shared with the previously described 60kDa FcpR. Similarly, a receptor that bound 
specifically to IgM and not to other immunoglobulin isotypes was described on T 
lymphocytes (Nakamura et al, 1993). The molecular size of this molecule was also 
around 60kDa but as it appeared not to be GPI-anchored the authors concluded that it 
was similar to but distinct from the FcpR present on activated B lymphocytes.
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The initial description of Fca/pR by Shibuya and colleagues had shown expression of 
the receptor by murine macrophages and B lymphocytes. In addition, transcript for the 
receptor was detected in several mouse tissues including kidney, leading us to 
speculate that human Fca/pR could be expressed by renal mesangial cells. This 
hypothesis was confirmed by the detection of message for Fca/pR in human renal 
cortex, in isolated human glomeruli and by all HMC lines examined. Our finding of 
Fca/pR transcript expression by HMCs has subsequently been confirmed by at least 
two other research groups (Chan et al, 2005; Hu et al, 2005). Expression of the 
receptor by HMCs was specifically enhanced by the inflammatory cytokine, IL- 
la . Using quantitative real time PCR we estimated that IL-1 a  increased HMC 
Fca/pR expression by a factor in excess of 100. Increased intrarenal levels of IL-1 
have been described in IgA nephropathy and appear to correlate with the degree of 
tubulointerstitial damage (Yoshioka et al, 1993). Therefore, the augmentation of 
HMC Fca/pR expression by IL-1 a  is likely to be of biological significance.
In the original description of the mouse Fca/pR, expression was demonstrated in 
haemopoietic and non-haemopoietic tissues but it was unclear whether detection of the 
receptor in the latter merely represented expression by infiltrating monocytes or B 
lymphocytes. A further study documented Fca/pR expression in non-haemopoietic 
central nervous system tissue where an antibody against the mouse receptor was used 
to show expression by oligodendrocytes, oligodendrocyte precursor cells and myelin 
fractions (Nakahara et al, 2003). Immunohistochemistry demonstrated staining for 
Fca/pR in mouse forebrains. It was hypothesised that Fca/pR could perhaps mediate 
a response to intrathecal IgM present in demyelinating conditions such as multiple 
sclerosis. Thus it was established that Fca/pR expression by non-haemopoietic cells 
such as HMCs was possible.
After we had cloned the receptor from an HMC line, the genomic organisation of 
human Fca/pR was elucidated by comparison of the cloned cDNA with the human 
genome sequence. These findings were in general agreement with data subsequently 
published by the researchers who originally described the murine Fca/pR, with the
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coding sequence for the human receptor being contained within six exons (Shimizu et 
al, 2001). However, one of the exon-intron boundaries derived from our cloned 
cDNA sequence (intron 6; 3’ splice acceptor) differs from that suggested by these 
other authors. The boundary site suggested by our data obeys the splice site consensus 
rule (5’ GT/AG 3’) whereas the exon boundary proposed by the other investigators 
does not.
Similarly, the features predicted by the amino acid sequence of our cloned cDNA for 
human Fca/pR were in broad agreement with those proposed by Shibuya and 
colleagues. These included a single extracellular immunoglobulin-like domain, two 
potential sites for A-glycosylation and a membrane-spanning region. However, 
whereas Shibuya et a l suggested a 10 amino acid signal peptide, our bioinformatics 
data predicted a signal peptide comprising the first 16 amino acids of the sequence, 
encoded by exons “SP” and “EC1”. The nucleotide sequence of a signal peptide 
composed of the first 10 amino acids would be contained entirely in exon “SP”. Our 
findings subsequently demonstrated that the human Fca/pR was membrane bound and 
expressed on the surface of transfected cells together with confirmation of the 
presence of A-linked carbohydrate modifications. Immunoblotting suggested a 
molecular weight for the deglycosylated mature protein of approximately 55kDa 
which corresponded with that predicted on the basis of amino acid sequence. The 
relatively light A-glycosylation of Fca/pR is in contrast to FcaRI which bears 
considerably more A-linked carbohydrate groups (Toyabe et al, 1997). These results 
were also the first description of the ligand binding specificity of the human Fca/pR 
wherein we observed IgM and IgA but not IgG binding in accordance with the 
characteristics described for the mouse receptor. Fca/pR is therefore unique among 
the known Fc receptors in that it displays dual affinity for different immunoglobulin 
isotypes.
We also identified two variant transcripts of the human Fca/pR gene which were both 
expressed by HMCs and upregulated following treatment with IL-1 a  in parallel with 
the effect of this cytokine on levels of wildtype receptor transcript. The significance
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of the intron 5 insertion variant, whose sequence would predict a soluble form of the 
receptor, is not clear and we did not extend this observation. This transcript is more 
appropriately considered to be a variant form rather than a true alternatively spliced 
transcript and may simply be an artefact of mRNA processing. In contrast, the 
Fca/pR AEC3 transcript is a true alternatively spliced product of the gene where the 
out of frame deletion results in a change of reading frame which produces a novel 
protein sequence.
Many of the features predicted for the wildtype Fca/pR were maintained for the 
Fca/pR AEC3 protein including the same signal peptide and immunoglobulin-like 
domain. As a consequence of the deleted sequence, only a single site for N- 
glycosylation was predicted for the Fca/pR AEC3 protein. Sequence analysis of the 
Fca/pR AEC3 protein also anticipated a distal membrane-spanning region encoded in 
the same exon (TM) as the wildtype receptor but in an alternative reading frame. Our 
experimental data derived after expression of the Fca/pR AEC3 protein in transfected 
cells confirmed the presence of AMinked carbohydrate groups and that the protein was 
membrane associated. Thus the same stretch of nucleotide sequence of the Fca/pR 
gene contains code for two distinct membrane-spanning regions within the two 
separate reading frames utilised by the wildtype receptor and the Fca/pR AEC3 
protein.
We were however, unable to detect immunoglobulin binding to cells transfected with 
the Fca/pR AEC3 cDNA. Expression by transfected cells of Fca/pR AEC3 protein 
bearing a GFP tag showed a distinct pattern of distribution when compared with GFP- 
linked wildtype Fca/pR. This pattern was consistent with absence of expression of 
the protein on the cell surface. Co-localisation studies employing immunofluorescent 
staining for calnexin and caveolin suggested that in contrast to wildtype Fca/pR, 
expression of Fca/pR AEC3 protein by these cells was restricted to the endoplasmic 
reticulum (ER). The membrane association of Fca/pR AEC3 protein demonstrated 
earlier must therefore be with ER membrane as opposed to plasma membrane.
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An unresolved issue of significance is whether the Fca/pR AEC3 protein has the 
potential to be expressed on a cell surface membrane either in a particular cell type or 
in specific circumstances. Until this question can be answered it will be difficult to 
determine whether the protein can also function as an immunoglobulin receptor akin 
to the wildtype Fca/pR. Due to its shorter length and the proximity of the 
immunoglobulin domain to the anchoring membrane, it was speculated that steric 
interference might preclude binding of IgM to the Fca/pR AEC3 protein due to the 
molecular mass and structure of the IgM pentamer. A property such as this may be the 
basis for functional diversification of the Fca/pR.
Retention of a protein in the ER can be mediated by specific retention or retrieval 
signals in the amino acid sequence (reviewed in Teasdale & Jackson, 1996). For 
example, the CHI domain of the IgM heavy chain bears a sequence that acts to hold 
the protein within the ER until association with an immunoglobulin light chain masks 
the motif and permits export from the ER (Cherayil et al, 1993). In this way the 
transport of aberrantly folded proteins or incompletely assembled multimeric 
complexes outwith the ER and along the exocytic pathway is prevented. Therefore, 
several potential explanations for restriction of the Fca/pR AEC3 protein to the ER 
could be advanced. The protein may be a constituent part of a larger multimeric 
complex expressed on the plasma membrane and absence of expression of the other 
(unidentified) components in these transfected cells may thus prevent export from the 
ER. When expressed in a native cell type, Fca/pR AEC3 protein transport to the cell 
surface could be under the control of signalling pathways leading to induction of 
expression of the requisite associated molecules. These events could be under the 
control of activating signalling pathways initiated by specific mediators such as 
cytokines or by a particular extracellular environment. The absence of either the 
associated molecules or of a specific extracellular signal may be responsible for ER 
retention or retrieval to the ER of the protein in these transfected cells. Examination 
of the amino acid sequence of the Fca/pR AEC3 protein cytoplasmic tail reveals a di­
arginine (RR) motif at position 214-215 (figure 4.10.). This motif has been reported
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to direct the retrieval of type II membrane proteins to the ER and would be a candidate 
retention/retrieval motif for the Fca/pR AEC3 protein (Schutze et al, 1994).
I
f
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Figure 4.1. RT-PCR for Fca/pR showing expression in renal tissue and in four 
human mesangial cell lines.
(A) Fca/pR  mRNA expression was assessed in specimens o f renal cortex and 
microdissected glomeruli using RT-PCR. The predicted Fca/pR  amplicon was 702 
base pairs in size. (B) Expression o f FcapR  mRNA was examined using RT-PCR in 
four separate human mesangial cell (HMC) lines, U937 cells and COS-7 cells. The 
figures to the left represent molecular size in base pairs.
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Figure 4.2. Semi-quantitative RT-PCR for Fca/pR demonstrating increased
receptor expression by human mesangial cells after treatment with IL -la
Cultured human mesangial cells were stimulated for 24 hours with IL -la  and TN F-a 
either alone or in combination, each at a concentration o f 50ng/ml and semi- 
quantitative RT-PCR for Fca/pR  was performed. The lower panel shows P actin 
expression for each sample. The figures to the left represent molecular size in base 
pairs.
Figure 4.3. Nucleotide sequence of human Fca/pR cloned from an HMC line
There was a single nucleotide difference at position 745 (A —» C) when compared to 
the E l5470 (immunity related factor) database sequence. This change represents a 
silent mutation for arginine.
1 AGGAGGGCAG GATGGAAAAT GCCCCTCTTC CTCATACTGT GCCTGCTACA
5 1 AGGTTCTTCT TTCGCCCTTC CACAAAAAAG ACCCCATCCG AGATGGCTGT
1 0 1 GGGAGGGCTC TCTCCCCTCC AGGACCCATC TCCGGGCCAT GGGAACACTC
1 5 1 AGGCCTTCCT CGCCCCTCTG CTGGCGGGAG GAGAGCTCCT TTGCAGCTCC
2 0 1 AAATTCATTG AAGGGCTCAA GGCTGGTGTC AGGGGAGCCT GGAGGAGCTG
2 5 1 TCACCATCCA GTGCCATTAT GCCCCCTCAT CTGTCAACAG GCACCAGAGG
3 0 1 AAGTACTGGT GCCGTCTGGG GCCCCCAAGA TGGATCTGCC AGACCATTGT
3 5 1 GTCCACCAAC CAGTATACTC ACCATCGCTA TCGTGACCGT GTGGCCCTCA
4 0 1 CAGACTTTCC ACAGAGAGGC TTGTTTGTGG TGAGGCTGTC CCAACTGTCC
4 5 1 CCGGATGACA TCGGATGCTA CCTCTGCGGC ATTGGAAGTG AAAACAACAT
5 0 1 GCTGTTCTTA AGCATGAATC TGACCATCTC TGCAGGTCCC GCCAGCACCC
5 5 1 TCCCCACAGC CACTCCAGCT GCTGGGGAGC TCACCATGAG ATCCTATGGA
6 0 1 ACAGCGTCTC CAGTGGCCAA CAGATGGACC CCAGGAACCA CCCAGACCTT
6 5 1 AGGACAGGGG ACAGCATGGG ACACAGTTGC TTCCACTCCA GGAACCAGCA
7 0 1 AGACTACAGC TTCAGCTGAG GGAAGACGAA CCCCAGGAGC AACCCGGCCA
7 5 1 GCAGCTCCAG GGACAGGCAG CTGGGCAGAG GGTTCTGTCA AAGCACCTGC
8 0 1 TCCGATTCCA GAGAGTCCAC CTTCAAAGAG CAGAAGCATG TCCAATACAA
8 5 1 CAGAAGGTGT TTGGGAGGGC ACCAGAAGCT CGGTGACAAA CAGGGCTAGA
9 0 1 GCCAGCAAGG ACAGGAGGGA GATGACAACT ACCAAGGCTG ATAGGCCAAG
9 5 1 GGAGGACATA GAGGGGGTCA GGATAGCTCT TGATGCAGCC AAAAAGGTCC
1 0 0 1 TAGGAACCAT TGGGCCACCA GCTCTGGTCT CAGAAACTTT GGCCTGGGAA
1 0 5 1 ATCCTCCCAC AAGCAACGCC AGTTTCTAAG CAACAATCTC AGGGTTCCAT
1 1 0 1 TGGAGAAACA ACTCCAGCTG CAGGCATGTG GACCTTGGGA ACTCCAGCTG
1 1 5 1 CAGATGTGTG GATCTTGGGA ACTCCAGCTG CAGATGTGTG GACCAGCATG
1 2 0 1 GAGGCAGCAT CTGGGGAAGG AAGCGCTGCA GGGGACCTAG ATGCTGCCAC
1 2 5 1 TGGAGACAGA GGTCCCCAAG CAACACTGAG CCAGACCCCG GCAGTAGGAC
1 3 0 1 CCTGGGGACC CCCTGGCAAG GAGTCCTCCG TGAAGCGTAC TTTTCCAGAA
1 3 5 1 GATGAAAGCA GCTCTCGGAC CCTGGCTCCT GTCTCTACCA TGCTGGCCCT
1 4 0 1 GTTTATGCTT ATGGCTCTGG TTCTATTGCA AAGGAAGCTC TGGAGAAGGA
1 4 5 1 GGACCTCTCA GGAGGCAGAA AGGGTCACCT TAATTCAGAT GACACATTTT
1 5 0 1 CTGGAAGTGA ACCCCCAAGC AGACCAGCTG CCCCATGTGG AAAGAAAGAT
1 5 5 1 GCTCCAGGAT GACTCTCTTC CTGCTGGGGC CAGCCTGACT GCCCCAGAGA
1 6 0 1 GAAATCCAGG ACCC
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Figure 4.4. Genomic organisation of human Fca/pR
The full length receptor was cloned from a human mesangial cell line and the 
sequence compared with the NCBI human genome database. The seven exons 
(shaded boxes) and six introns (numbered) are shown to scale, and the size o f each 
exon is indicated. Exon names were derived following analysis o f  the predicted amino 
acid sequence. 5 ’UTR represents the 5’ untranslated region and exon SP contains 
sequence for the signal peptide. Exons EC1, EC2 and EC3 code for the extracellular 
portion o f the receptor while exons TM and CY contain sequence for the 
transmembrane and cytoplasmic regions respectively.
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Figure 4.5. Predicted amino acid sequence of human Fca/pR
The amino acid sequence of human Fca/jiiR was derived by translation of the 
nucleotide sequence cloned from a human mesangial cell line. The predicted signal 
peptide and transmembrane regions are shown in bold. Cysteine residues contributing 
to the immunoglobulin domain (underlined) are emboldened (C) as are two potential 
sites for iV-glycosylation (N).
1 MPLFLILCLL QGSSFALPQK RPHPRWLWEG SLPSR TH LR A
41 M G TLRPSSPL CWREESSFAA PNSLKG SRLV SG EPG G AVTI
81 QCHYAPSSVN RHQRKYWCRL G P P R W IC Q TI VSTNQYTHHR
1 2 1 YRDRVALTDF PQRGLFVVRL SQ LSPD D IG C Y LC G IG SEN N
1 6 1 M L F L S M N L T I SAG PASTLPT ATPAAG ELTM RSYGTASPVA
2 0 1 NRWTPGTTQT LGQGTAWDTV A S TP G TS K TT ASAEGRRTPG
2 4 1 ATRPAAPGTG SWAEGSVKAP A P IP E S P P S K SRSMSNTTEG
2 8 1 VWEGTRSSVT NRARASKDRR EM TTTKADRP R E D IE G V R IA
3 2 1 LD AAKKVLG T IG P P A LV S E T L A W E ILP Q A T PVSKQQSQGS
3 6 1 IG ETTPAAG M W TLGTPAADV W ILG TP A A D V WTSMEAASGE
4 0 1 GSAAGDLDAA TGDRGPQATL SQTPAVGPWG PPGKESSVKR
4 4 1 TFPED ESSSR TLAPVSTMLA LFMLMALVLL QRKLWRRRTS
4 8 1 Q E A E R V T L IQ MTHFLEVNPQ ADQLPHVERK MLQDDSLPAG
5 2 1 ASLTAPER N P GP
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Figure 4.6. Fca/pR expression in transfected COS-7 cells
Immunoblots o f transfected COS-7 cell lysates were performed using an antibody 
specific for the V5 epitope tag. (A) Cells were transfected with either V5-tagged 
Fca/pR  cDNA (+) or with irrelevant DNA (-) in the same expression vector. Lysates 
were separated under reducing and non-reducing conditions. (B) A lysate from COS-7 
cells transfected with Fca/pR  cDNA (+) was treated for 24 hours with A-glycanase 
(*). The figures to the left represent molecular weight in kDa.
A  Fca/pR cDNA
+ +
64 — 4ft - mm
51 —
Reducing Non-reducing
B Fca/pR cDNA
+  +
64 —
51 —
*
N-glycanase
treated
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Figure 4.7. Fluorescence micrographs showing antibody binding to COS-7 
cells transfected with Fca/pR cDNA
COS-7 cells transfected with human F ca/pR  cDNA were incubated for 45 minutes at 
4°C with fluorescein-conjugated IgA, IgM or IgG each at a concentration o f lOpg/ml 
and examined using fluorescence microscopy. Green staining represents antibody 
binding and cell nuclei are stained blue.
igA
IgM
IgG
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Figure 4.8. Flow cytometry showing antibody binding to CHO-K1 cells 
transfected with Fca/pR cDNA
CHO-K1 cells transfected with either human Fca/pR cDNA (bold line) or with 
irrelevant DNA as a control (light line) were incubated with 375pg/ml IgA or 
250|iig/ml IgM as indicated and antibody binding assessed using flow cytometry. 
Fluorescence intensity is shown on the x-axis and the number of events is on the y- 
axis. Assessment of antibody binding in this population of transiently transfected cells 
was demonstrated more clearly using fluorescence microscopy.
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Figure 4.9. PCR for Fca/pR showing expression of an alternatively spliced 
transcript by human mesangial cells
(A) RT-PCR for F ca/pR  using a primer set annealing at the “5’UTR” and “TM ” exons 
was performed for two HMC lines. Some cells were stimulated with 50ng/ml IL- 
l a f o r  24 hours. The predicted size for wildtype Fca/pR  is 1463 base pairs. The 
figures to the left represent molecular size in base pairs. (B) Diagrammatic 
representation o f the Fca/pR  AEC3 splice variant showing exon usage.
HMC-1 HMC-2
IL-1a IL-1a
B
5’UTR
802bp deletion
EC1 EC2 CYTM
SP
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Figure 4.10. Predicted amino acid sequence of Fca/pR  AEC3 variant
The amino acid sequence encoded by the Fca/pR AEC3 variant was elucidated by 
translation of the nucleotide sequence detected in a human mesangial cell line. The 
predicted signal peptide and transmembrane regions are shown in bold. Cysteine 
residues contributing to the immunoglobulin domain (underlined) are emboldened (C) 
as is a single potential site for 7V-glycosylation (N). The amino acid sequence diverges 
from that of the wildtype receptor at position 173 and this region is italicised.
1 MPFFLILCLL QGSSFALPQK RPHPRWLWEG SLPSR TH LR A
41 M G TLRPSSPL CWREESSFAA PNSLKGSRLV SG EPG G AVTI
81 QCHYAPSSVN RHQRKYWCRL G P P R W IC Q TI VSTNQYTHHR
1 2 1 YR D RVALTDF PQRGLFVVRL SQ LSPD D IG C YLC G IG SEN N
1 6 1 M L F L S M N L T I SA VLFQKMKA ALGPWLLSLP CWPCLCLWLW
2 0 1 FYCKGSSGEG GPLRRQKGSP
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Figure 4.11. Fca/pR AEC3 protein expression in transfected CHO-K1 cells
Immunoblots o f transfected CHO-K1 cell lysates were performed using an antibody 
specific for the V5 epitope tag. Cells were transiently transfected with either 
irrelevant control DNA, wildtype Fca/pR  cDNA or Fca/pR  AEC3 cDNA in the 
pcDNA3.1/V5/His/TOPO vector.
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Figure 4.12. A fraction of Fca/pR AEC3 protein is jY-glycosylated in transfected 
cells
Immunoblotting o f transfected CHO-K1 cell lysates was performed using an antibody 
specific for the V5 epitope tag. Cells were transfected with either V5-tagged Fca/pR  
AEC3 cDNA or with irrelevant control DNA (CON) in the same expression vector. A 
lysate from cells transfected with Fca/pR  AEC3 cDNA was treated for 24 hours with 
A-glycanase (*). The figures to the left represent molecular weight in kDa.
z  Fca/p,R AEC3 
8  cDNA
39 —
28 —
19 —
*
N-glycanase 
treated
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Figure 4.13. Fca/pR AEC3 protein is expressed in a membrane-associated form
CHO-K1 cells were transfected with either wildtype Fca/pR  cDNA (lanes 1 and 3) or 
with F ca/pR  AEC3 cDNA (lanes 2 and 4). Membrane fractions were separated using 
ultracentrifugation and these preparations were immunoblotted with the anti-V5 
antibody together with cytosolic fractions from the same lysates. The figures to the 
left represent molecular weight in kDa.
1 2  3 4
97
Membrane Cytosolic
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Figure 4.14. Flow cytometry showing absence of IgA and IgM binding to CHO- 
K1 cells transfected with Fca/|iR AEC3 cDNA
CHO-K1 cells transfected with either human Fca/|iR AEC3 cDNA (bold line) or with 
irrelevant DNA as a control (light line) were incubated with 375jig/ml IgA or 
250|ig/ml IgM as indicated and antibody binding assessed using flow cytometry. 
Fluorescence intensity is shown on the x-axis and the number of events is on the y- 
axis.
t
i
IgA
IgM
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Figure 4.15. Fluorescence micrographs showing intracellular localisation of 
transfected Fca/pR and Fca/pR AEC3 proteins
(A) CHO-K1 cells were transiently transfected with green fluorescent protein (GFP)- 
labelled F ca/pR  or GFP-labelled Fca/pR  AEC3 cDNA. The transfected proteins were 
detected as green fluorescence on fluorescence microscopy and cell nuclei appear blue.
(B) CHO-K1 cells transfected with G FP-Fca/pR  or G FP-Fca/pR  AEC3 constructs 
were incubated with 50pg/ml o f polymeric IgA l. Red colour represents antibody 
binding.
Fca/pR Fca/pR AEC3
Fca/pR Fca/pR AEC3
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Figure 4.16. Fluorescence micrographs showing intracellular localisation of
transfected Fca/pR and Fca/pR AEC3 proteins with calnexin
CHO-K1 cells were transiently transfected with green fluorescent protein (GFP)- 
labelled Fca/pR  or GFP-labelled Fca/pR  AEC3 cDNA. Cells were then stained with 
an antibody specific for calnexin which was detected with a fluorescently labelled 
secondary antibody. The variability observed in calnexin staining requires further 
validation with other ER markers.
Fca/p,R Fca/jiR AEC3
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Figure 4.17. Fluorescence micrographs showing intracellular localisation of
transfected Fca/pR and Fca/pR AEC3 proteins with caveolin
CHO-K1 cells were transiently transfected with green fluorescent protein (GFP)- 
labelled Fca/pR  or GFP-labelled Fca/pR  AEC3 cDNA. Cells were then stained with 
an antibody specific for caveolin which was detected with a fluorescently labelled 
secondary antibody.
Fca/pR Fca/pR AEC3
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Table 4.1. Real time PCR for Fca/pR
Real time PCR for Fca/fjR was performed using cDNA from U937 cells, COS-7 cells 
and four separate HMC cell lines in parallel with the appropriate reverse transcription 
controls (RT-CON). Reactions were performed in triplicate and mean threshold cycles 
(Ct) are shown along with the difference in mean Ct between samples and controls 
(ACt).
cDNA RT-CON AC,
U937 31.6 36.7 5.1
COS-7 33.8 33.1 -0.7
HMC-1 28.3 33.8 5.5
HMC-2 31.1 34.2 3.1
HMC-3 28.0 31.8 3.8
HMC-4 27.5 32.3 4.8
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Table 4.2. Real time PCR for Fca/pR following stimulation of U937 cells and 
HMCs
Real time PCR for Fca/pR was performed using cDNA from U937 cells and from an 
HMC line following 24 hours stimulation with either ImM dibutyryl cyclic AMP 
(dbcAMP) or 50ng/ml IL-la. Reactions were performed in parallel with the 
appropriate reverse transcription controls (RT-CON) and in triplicate. Mean threshold 
cycles (Ct) are shown along with the difference in mean Ct between samples and 
controls (ACt).
cDNA RT-CON ACt
U937 Unstimulated 35.0 38.7 3.7
dbcAMP 33.6 36.2 2.6
IL-la 33.9 38.1 4.2
HMC Unstimulated 31.9 32.7 0.8
dbcAMP 31.1 33.3 2.2
IL-la 25.1 33.4 8.3
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Table 4.3. Human Fca/pR intron-exon boundaries
The intron-exon boundaries of human Fca/pR were derived by comparison of the 
cloned receptor with the human genome sequence. The splice site consensus elements 
are italicised. The initial 6 nucleotides of the adjacent 3’ exon are shown for each 
intron
Intron 5’ splice donor 3’ splice acceptor
Adjacent 3’ 
sequence
exon
name
1 GTAAGT TTGCAG GTCACC SP
2 GTGAGT CTGCAG GTTCTT EC1
3 GTACAA CTGCAG CTCCAA EC2
4 GTATGA ACACAG GTCCCG EC3
5 GTAACC CTGTAG TACTTT TM
6 GTGAGT CTGCAG CTCAGG CY
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Chapter 5 
Immunoglobulin receptor expression by renal proximal tubular cells
5.1. Introduction
In common with other renal pathologies, progressive IgA nephropathy is associated 
with histological changes of tubular and interstitial injury which lead eventually to end 
stage renal damage. The severity of tubulointerstitial fibrosis and scarring can be 
correlated with the rate of loss of renal function (Nath, 1992). In proteinuric 
glomerular diseases, several mechanisms leading to tubulointerstitial damage are 
believed to operate. These include a direct toxic effect of filtered proteins on tubular 
cells, overload of the normal tubular endocytic protein reabsorption processes and the 
effect of locally produced mediators of inflammation from either tubular cells or 
glomerular cells on cells of the tubulointerstitial compartment. The latter mechanism 
has been demonstrated with cultured HMCs exposed to sera from IgA nephropathy 
patients. These HMC supernatants subsequently activated cultured proximal tubular 
cells and this effect was mediated by TNF-a (Chan et al, 2005). A final common 
feature of tubulointerstitial damage is infiltration of the region with immune cells such 
as monocytes and lymphocytes which in turn release further inflammatory mediators 
into the local microenvironment.
An additional feature of tubulointerstitial fibrosis is the accumulation of extracellular 
matrix proteins such as fibronectin, laminin and various forms of collagen that replace 
the normal tissue architecture. Transforming growth factor-beta 1 (TGF-pi) 
production by tubular cells and interleukin-1 (IL-1) released by infiltrating 
mononuclear cells have been implicated in the processes leading to matrix deposition 
(Yamamoto et al, 1996). IL-1 p led to enhanced fibronectin production by cultured 
tubular cells and this was accompanied by increases in a-smooth muscle actin (a-
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SMA) expression, TGF-pl release and nitric oxide production. Fibronectin 
production induced by IL-1 p appeared to be dependent on TGF-pl, and IL-1 p had the 
additional effect of reducing proliferation of tubular cells. Induction of a-SMA 
expression by tubular cells is thought to be associated with “transdifferentiation” of 
these cells to a fibrotic myofibroblast phenotype (Ng et al, 1998). In this process, 
tubular cells progressively elongate, lose polarity, detach from their basement 
membranes and ultimately migrate through the damaged tubular basement membrane 
into the interstitium. In the rat model studied there was a significant association 
between the number of a-SMA positive tubular cells, the presence of a-SMA positive 
myofibroblasts and the degree of tubulointerstitial fibrosis.
Disruption of the normal glomerular filtration barrier in proteinuric nephropathies 
permits the abnormal passage of intact immunoglobulin molecules to the glomerular 
filtrate. As a consequence, proximal tubular cells can then be exposed to these 
molecules in potentially high concentrations. Levels of urinary IgG and IgA have been 
examined in patients with IgA nephropathy and with Henoch-Schonlein nephritis 
(Galla et al, 1985). Urinary concentrations of each immunoglobulin were higher in 
patients in comparison with controls and levels also correlated positively with serum 
creatinine concentration and the severity of proteinuria. Interestingly, urinary IgA 
from patients was almost exclusively in the monomeric form as opposed to the 
polymeric form which predominated in urine from healthy controls. A later study 
confirmed the finding of IgA and IgG in urine from patients with IgA nephropathy 
(Takahashi et al, 2004). These authors found that the cationic portion of IgG was 
absent from the urine of patients with proteinuric glomerulopathies and suggested that 
this was due to preferential reabsorption of this IgG fraction by proximal tubular cells. 
It was postulated that this was the consequence of a specific receptor-mediated 
reabsorption mechanism.
Specific activating responses by renal proximal tubular cells following stimulation by 
proteins present in the glomerular filtrate have been described. Production of the 
chemokine RANTES (regulated upon activation, normal T cell expressed and
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secreted) was induced by cultured tubular cells in response to albumin and to IgG 
(Zoja et al, 1998). Release of RANTES from the cells was predominantly basolateral. 
Therefore it was concluded that release of this chemokine into the renal interstitium 
might contribute to the inflammatory cell infiltrate seen in chronic renal damage. 
Exposure of cultured proximal tubular cells to albumin also led to cellular activation 
via the Janus kinase (JAK) and the signal transducer and activator of transcription 
(STAT) signalling pathway (Nakajima et al, 2004). Activation of the JAK/STAT 
pathway appeared to be mediated by production of reactive oxygen species by the cells 
in response to albumin overload. Activation of proximal tubular cells has also been 
demonstrated following exposure to transferrin (Tang et al, 2002). In this study, 
increased production of several chemokines including monocyte chemoattractant 
peptide-1, interleukin-8, macrophage migration inhibitory factor but not RANTES was 
observed when tubular cells were stimulated with transferrin. This evidence supports 
the hypothesis that proximal tubular cells respond to the presence of excess or 
abnormal protein in glomerular filtrate by activating specific cellular signal 
transduction pathways that in turn lead to the local production of inflammatory 
mediators.
The neonatal Fc receptor (FcRn) was cloned from a placental cDNA library and is 
believed to mediate transplacental transfer of IgG from mother to foetus and the 
systemic absorption across the intestinal epithelium of maternal IgG from breast milk 
(Story et al, 1994). FcRn is structurally homologous to the MHC class I molecule and 
is associated with p2-microglobulin. Receptor binding to IgG is pH-dependent with 
higher affinity binding at an acidic pH. Preliminary data had shown that mRNA for 
FcRn was detectable in human kidney and more precise localisation to glomerular 
epithelial cells and the brush border of proximal tubular cells was subsequently 
confirmed (Haymann et al, 2000). A functional role for FcRn was demonstrated in 
human renal tubular cells where the receptor mediated transcytosis of IgG (Kobayashi 
et al, 2002). This suggested that FcRn played a role in the reabsorption of IgG from 
the glomerular filtrate by cells of the proximal tubule.
137
Chapter 5
As renal tubular cells can be exposed to immunoglobulins and immune complexes in 
proteinuric glomerulopathies such as IgA nephropathy we investigated whether these 
cells expressed any of the known immunoglobulin receptors. Signal transduction via 
such receptors could subsequently lead to cell activation, production of inflammatory 
mediators and initiation of processes leading to tubulointerstitial fibrosis.
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5.2. Results 
5.2. 1. Human PTCs express mRNA for PIGR and FcRn
In order to examine expression of immunoglobulin receptors by renal tubular cells, 
primary human proximal tubular cells (PTCs) in culture were stimulated for 24 hours 
with 50ng/ml IL-la, 50ng/ml IL-6, 50ng/ml TNF-a, 10'7M phorbol 12-myristate 13- 
acetate (PMA) or ImM dibutyryl cyclic AMP (dbcAMP). RNA was extracted from 
these cells along with RNA from unstimulated PTCs. cDNA was generated by reverse 
transcription and PCR performed using specific primers. PCR demonstrated equal 
expression of (3 actin for all samples (data not shown).
PCR for the polymeric immunoglobulin receptor (PIGR) was performed using the 
primers “PIGR-for” and “PIGR-rev” (table 2.2.). Primers “FcRn-for” and “FcRn-rev” 
were used to detect FcRn. It was anticipated that in common with other epithelial 
cells PTCs would express the PIGR. Similarly, immunohistochemistry demonstrating 
expression of the neonatal Fc receptor (FcRn) at the brush border of human PTCs had 
been previously reported (Haymann et al, 2000).
Expression of the PIGR and FcRn by unstimulated PTCs was confirmed by the 
presence of bands corresponding to predicted sizes of 694 and 359 base pairs for each 
receptor respectively (figure 5.1.). Stimulation of PTCs with the panel of biological 
mediators did not significantly affect expression of FcRn in this system. However, 
both PMA and dbcAMP appeared to reduce expression of the PIGR transcript.
5.2.2. Human PTCs do not express mRNA for FcyRs
To determine whether human PTCs expressed Fc gamma receptors, PCRs for FcyRI, 
FcyRIIb and FcyRIII were performed using cDNA from stimulated and unstimulated 
PTCs as described in section 5.2.1. The primer combinations used were “I-for” and 
“I-rev” for FcyRI, “II-for” and “Ilb-rev” for FcyRIIb and “III-for” and “III-rev” for
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FcyRIII. Primer sequences are shown in table 2.2. U937 cells are known to express 
FcyRI and FcyRIIb so cDNA from these cells was used as a positive control. 
Neutrophil cDNA was used as a positive control for FcyRIII expression and this 
cDNA was a generous gift from Dr Loma Murray (MRC Centre for Inflammation 
Research, University of Edinburgh, UK). As RT-PCR for FcyRIIa yielded technically 
unclear results (data not shown), lysates from unstimulated PTCs and cells stimulated 
with 50ng/ml IL -la or 50ng/ml TNF-a were immunoblotted with an antibody specific 
for this receptor. The anti-FcyRII antibody (IV3 clone) used (Medarex, Princeton, NJ, 
USA) has been reported to recognise only the FcyRIIa isoform of the receptor 
(Maresco et al, 1999). A lysate prepared from a culture of U937 cells was used as a 
positive control for FcyRIIa expression.
The results of these assays for FcyR expression by PTCs are shown in figure 5.2. In 
each case expression of the appropriate receptor with a band of expected size was 
confirmed for the positive control sample. Multiple transcripts of FcyRI have been 
reported for cells expressing this receptor and these can be seen in the appropriate 
positive control lane (Ernst et al, 1992). The predicted size of the band representing 
wildtype FcyRI is 876 base pairs. No transcripts for FcyRI, FcyRIIb or FcyRIII were 
detected in either stimulated or unstimulated PTCs. Similarly, no expression of 
FcyRIIa protein was found in these cells.
5.2.3. Human PTCs express mRNA for Fca/pR but not for FcaRI or 
ASGPR
PCR for three IgA receptors was performed using cDNA prepared from unstimulated 
PTCs together with cells that had been stimulated with mediators as described in 
section 5.2.1. The primer combinations used were “89-F2” and “89-R2” for FcaRI, 
“H2-for” and “H2-rev” for the H2 subunit of the asialoglycoprotein receptor (ASGPR) 
and “amr-forl” and “amr-rev” for the Fca/pR. These primer sequences are shown in 
table 2.2. cDNA derived from a culture of U937 cells was used as a positive control
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for FcaRI expression and cDNA from HepG2 cells provided the positive control for 
ASGPR expression.
The results of these experiments are shown in figure 5.3. No expression of either 
FcaRI or ASGPR was detected in these primary PTCs. Each positive control cDNA 
yielded a band of the appropriate size for FcaRI and ASGPR. Expression of Fca/pR 
transcript was demonstrated in PTCs. This result was confirmed using a separate 
primary PTC culture and with the immortalised human PTC line, HK-2 (Ryan et al, 
1994)(data not shown). Stimulation of PTCs with IL -la  for 24 hours was associated 
with enhanced Fca/pR mRNA expression. Incubation of PTCs with IL-6 and with 
TNF-a did not significantly alter Fca/pR expression in this system. In contrast, both 
PMA and dbcAMP treatment of cells appeared to reduce levels of Fca/pR transcript 
in PTCs.
5.2.4. Fca/juR protein is expressed by renal tubular cells
In order to establish whether Fca/pR protein was present on renal tubular cells, 
immunohistochemistry using a specific antibody was performed. The murine 
monoclonal IgG antibody was a generous gift from Dr Wei Zhang (Institute of Basic 
Medical Sciences, Beijing, China). This antibody was generated from recombinant 
human Fca/pR protein encoded by our receptor clone described in section 4.2.3. 
Immunohistochemical staining of normal human tonsillar and renal sections was 
performed by Dr Barbara Young (Department of Pathology, Western Infirmary, 
Glasgow) and is shown in figure 5.4. Staining of lymphoid tissue was undertaken in 
order to test antibody reactivity with B lymphocytes. Expression of Fca/pR by these 
cells was predicted based on the reported cellular distribution of the receptor by 
murine B lymphocytes (Shibuya et al, 2000).
Figure 5.4.A shows predominant staining of the mantle zone of a secondary tonsillar 
lymphoid follicle. This region contains B lymphocytes and the staining pattern would 
be consistent with expression of Fca/pR by human B lymphocytes. Figure 5.4.B
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confirms expression of Fca/pR protein by human renal proximal tubular cells. 
Staining of glomerular podocytes was also observed but no other glomerular structures 
including mesangial areas were positive for Fca/pR expression.
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5.3. Discussion
These data describe expression and regulation of the Fca/pR by human proximal 
tubular cells. Confirmation of neonatal Fc receptor expression was also documented 
but no evidence of the classical Fc receptors for IgG and IgA was found in these cells.
In these experiments we used primary cultures of proximal renal tubular cells derived 
form normal renal tissue. In order to induce expression of potential immunoglobulin 
receptors the cells were stimulated with a variety of biological mediators. Exposure of 
tubular cells to these mediators was an attempt to mimic the local microenvironment 
found in the inflamed and activated tubulointerstitium in vivo. These cultured primary 
PTCs expressed mRNA for the PIGR as anticipated by virtue of their epithelial origin 
(Abramowsky & Swinehart, 1986). Whether binding of ligand to this receptor has any 
pro-inflammatory consequences or whether the PIGR fulfils a simple transporting 
function at this site is not clear. None of the biological mediators tested appeared to 
increase expression of the PIGR in these cells. In contrast, both PMA and dbcAMP 
led to reduced expression of PIGR transcript in PTCs whereas each of these mediators 
can induce expression of other immunoglobulin receptors in other cell types. These 
observations would favour a non-inflammatory function of the PIGR in these cells.
The FcRn is responsible for the transplacental transfer of IgG in addition to mediating 
transport of IgG present in breast milk to the circulation across the infant gut. 
Receptor affinity for IgG is enhanced under acidic conditions and this property may 
underlie the relatively long half-life of IgG in the circulation by promoting ligand 
dissociation from receptor within neutral intracellular compartments and subsequent 
recycling of IgG to the bloodstream (Ghetie & Ward, 2000). The presence of FcRn on 
renal tubular epithelial cells has recently been described and a functional role for the 
receptor in the reabsorption of IgG from tubular filtrate has been suggested (Kobayashi 
et al, 2002). FcRn expression by our primary PTCs was confirmed but the 
inflammatory mediators examined did not enhance levels of receptor transcript. Once
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again, this suggests a non-inflammatory transport and recycling function for FcRn in 
the proximal tubule.
No evidence for expression by PTCs of the classical Fc receptors for IgG was found 
using both stimulated and unstimulated cells. These cells did not express the 
activating receptors FcyRI, FcyRIIa and FcyRIII or the inhibitory FcyRIIb receptor. 
This is consistent with the reported distribution of these receptors on cells of 
haemopoietic origin only. Similarly, PTCs did not express either the classical IgA 
receptor, FcaRI or the H2 subunit of the ASGPR. However, these human renal 
proximal tubular cells did express transcript for the Fca/pR and this expression was 
upregulated by treatment with IL -la  in a manner analogous to that observed in HMCs 
(see section 4.2.2.). Enhanced Fca/pR expression in the renal tubule in response to 
IL -la or other inflammatory mediators may be of significance in the pathogenesis of 
proteinuric IgA nephropathy where these cells are also exposed to filtered IgA. PMA 
and dbcAMP appeared to reduce Fca/pR transcript levels in PTCs. Fca/pR 
expression in the human renal proximal tubule was confirmed using 
immunohistochemistiy with a specific monoclonal antibody.
A recent study by other investigators also examined expression of IgA receptors by 
primary human PTCs (Chan et al, 2005). In common with our results, these authors 
did not detect expression of FcaRI or the H2 subunit of ASGPR by PTCs. However, 
they also reported that PTCs did not express the PIGR or the Fca/pR which is in 
contrast to our data. This difference is most likely explained by variations in cell 
harvesting or cell culture conditions. The most apparent differences are that these 
other cells were cultured in the presence of hydrocortisone and were “growth arrested” 
in medium containing 0.5% serum for 48 hours before use in experiments. The 
absence of PIGR expression by these epithelial cells is unexpected and may represent 
de-differentiation induced by culture conditions. Similarly, the failure to detect 
Fca/pR expression by these cells may be due to altered cell phenotype. Our PTCs 
expressed the PIGR and therefore may represent the phenotype of PTCs in vivo more
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closely. In addition, we documented expression of Fca/pR protein by renal tubular 
cells in normal kidney sections by immunohistochemistry.
Therefore, we have demonstrated expression by human PTCs of the FcRn, the PIGR 
and the Fca/pR. The most likely function of the FcRn at this site is the recycling of 
filtered IgG either across the epithelium to the circulation or back via the apical aspect 
of the cell to the tubular fluid. Based on the known functional characteristics of the 
PIGR it is likely that this receptor is expressed only at the basolateral surface of the 
tubular epithelium where it mediates transfer of dimeric IgA and IgM from the 
circulation to the tubular fluid. An integral part of this process involves proteolytic 
cleavage of the receptor so it is unlikely that intact PIGR is present on the apical 
cellular surface to permit interaction with immunoglobulins in the tubular fluid. The 
function of Fca/pR expressed by renal proximal tubular cells is unknown. However, 
it is possible that this receptor is available to interact with filtered IgA and IgM in 
proteinuric glomerulopathies and receptor levels may be increased in the presence of 
inflammatory mediators. Under certain conditions this interaction may be a 
component of a clearance or recycling pathway for immunoglobulin but internalisation 
of excess ligand may induce cellular activation and production of cytokines or 
extracellular matrix contributing to the process of tubulointerstitial damage. Evidence 
of such a tubulopathic effect of IgG has been demonstrated in cultured rabbit renal 
tubular cells where production of the mediator endothelin-1 was induced in a dose- 
dependent fashion (Zoja et al, 1995).
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Figure 5.1. RT-PCR for PIGR and FcRn in human proximal tubular cells
RT-PCRs for the polymeric immunoglobulin receptor (PIGR) and the neonatal Fc 
receptor (FcRn) were performed using cDNA from a primary human proximal tubular 
cell culture. Cells were either unstimulated (0) or had been stimulated for 24 hours 
with 50ng/ml IL -la , 50ng/ml IL-6, 50ng/ml TN F-a, 10"7M phorbol 12-myristate 13- 
acetate (PMA) or ImM  dibutyryl cyclic AMP (dbcAMP). The figures to the left 
represent molecular size in base pairs.
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Figure 5.2. Human proximal tubular cells do not express FcyRs
RT-PCRs for FcyRI, FcyRIIb and FcyRIII were performed using cDNA from a primary 
human proximal tubular cell culture (A). Lysates from the same cells were also 
immunoblotted for FcyRIIa (B). Cells were either unstimulated (0) or had been 
stimulated for 24 hours with 50ng/ml IL -la , 50ng/ml IL-6, 50ng/ml TN F-a, 10'7M 
phorbol 12-myristate 13-acetate (PMA) or ImM  dibutyryl cyclic AMP (dbcAMP). 
Material from U937 cells was used as positive controls (+) when assessing expression 
o f  FcyRI, FcyRIIa and FcyRIIb. Neutrophil cDNA was used as the positive control for 
the FcyRIII PCR. The figures to the left represent molecular size in base pairs for the 
PCR images and molecular weight in kDa for the FcyRIIa immunoblot.
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Figure 5.3. RT-PCR for IgA receptors in human proximal tubular cells
RT-PCRs for FcaRI, the asialoglycoprotein receptor (ASGPR) and the F ca/pR  were 
performed using cDNA from a primary human proximal tubular cell culture. Cells 
were either unstimulated (0) or had been stimulated for 24 hours with 50ng/ml IL -la , 
50ng/ml IL-6, 50ng/ml TN F-a, 10‘7M phorbol 12-myristate 13-acetate (PMA) or ImM 
dibutyryl cyclic AMP (dbcAMP). The figures to the left represent molecular size in 
base pairs.
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Figure 5.4. Immunohistochemical staining of tonsil and kidney for Fca/^R
Immunohistochemistry o f human tonsillar (A; xlOO magnification) and renal (B; x l5 0  
magnification) tissues using a murine monoclonal antibody specific for human 
Fca/pR . Positive staining is shown in brown.
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General discussion
In the four decades since IgA nephropathy was first described many clinical and 
epidemiological characteristics of the condition have been documented. Valuable data 
have emerged relating to aspects such as geographical distribution, clinical features, 
determinants of progression and the phenomenon of recurrent disease in renal 
allografts. In contrast, relatively little progress has been made toward an 
understanding of the molecular pathogenesis of IgA nephropathy. This difficulty 
reflects the complexity of what is undoubtedly a multifactorial and heterogeneous 
disease process.
There are several fundamental aspects of disease pathogenesis that remain unclear. 
IgA nephropathy is defined by the presence of IgA deposits in the glomerular 
mesangium and these deposits are associated with mesangial expansion and 
progressive tubulointerstitial damage leading to end stage renal disease in some 
patients but not in others. Although a causal relationship between glomerular IgA 
deposition and subsequent renal damage is widely assumed, the evidence for even this 
basic tenet of disease pathophysiology is at best circumstantial. Another significant 
area of uncertainty lies in the origin of mesangial IgA. Evidence of altered regulation 
of elements within the systemic immune system has been interpreted as supporting 
this limb of the immune response as the source of mesangial IgA. However, whether 
this association is causal or is alternatively a consequence of abnormalities in, or 
responses by, the mucosal immune system is debatable. The classical association of 
macroscopic haematuria with upper respiratory tract infection in IgA nephropathy 
intuitively implicates the mucosal immune system and the recent observation of 
cultured mesangial cell responses to secretory IgA and the detection of secretory IgA
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in a transplanted kidney with recurrent disease should lead to close re-examination of 
the origins of mesangial IgA (Oortwijn et al, 2006).
Most progress in unravelling the pathogenesis of IgA nephropathy in recent years has 
been made in characterising the associated glycosylation abnormalities of the IgAl 
molecule. Hypo-galactosylation of the O-linked glycans at the IgAl hinge region 
promotes formation of multimeric IgA immune complexes, increases IgA binding to 
mesangial cells and mesangial matrix and induces production of biological mediators 
by mesangial cells. Patients with IgA nephropathy have higher proportions of serum 
IgA with reduced O-linked glycosylation and the same glycosylation abnormality has 
been described in IgA recovered from nephrectomy specimens. However, abnormal 
IgA glycosylation alone is unlikely to be sufficient to explain disease pathogenesis but 
may be necessary in combination with other factors for IgA nephropathy to emerge. 
The abnormality is not absolute and a fraction of IgA in normal individuals will be 
relatively under-glycosylated, although a critical threshold may exist at which point 
the amount or proportion of the abnormally glycosylated species exerts a pathological 
action. Another piece of evidence against abnormal IgA glycosylation being an 
independent determining factor for disease is the absence of recurrent IgA deposition 
in approximately half of transplanted kidneys of patients with IgA nephropathy. In 
this situation mesangial IgA deposition does not occur despite the persistent 
abnormality in circulating IgA glycosylation suggesting that some other factor or 
factors are required to permit expression of the disease phenotype.
Ultimately the clinical definition of IgA nephropathy is dictated by a combination of 
diagnostic convenience and limited understanding of the pathophysiology. It would 
not be unreasonable to propose that the condition represented a common channel for 
several discrete pathological processes each with a distinct array of initiating, 
susceptibility and response characteristics. The presence of mesangial IgA deposits 
would then represent a common pathway of expression for several molecularly distinct 
renal pathologies in a manner analogous to tubulointerstitial fibrosis. Although this 
scenario would be likely to further complicate the process of understanding and
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investigating disease pathology, such a concept may help explain for instance, why the 
presence of glomerular IgA deposits is associated with renal damage only in certain 
patients.
An aspect of disease pathophysiology that has received more recent attention is that of 
putative receptors for IgA in the glomerular mesangium. Such receptors could be of 
central importance to the pathological mechanism of IgA nephropathy, as they would 
facilitate a link between mesangial IgA deposits and activation and proliferation of 
mesangial cells leading thereafter to renal damage. Antagonism of a receptor 
operating in this way would be a potential strategy for therapeutic intervention. It is 
also possible that IgA immune complexes are localised to the mesangium by non­
receptor mediated mechanisms such as interaction with components of the 
extracellular matrix or by an electrostatic interaction with cells. Such associations 
could be promoted by the abnormal glycosylation profile of circulating IgAl. 
However, the interaction reported between IgA and cultured human mesangial cells 
suggests that these cells express a population of specific receptors for IgA as opposed 
to IgA association by a purely non-receptor mediated mechanism (Diven et al, 1998; 
Barratt et al, 2000). Initial reports suggested that human mesangial cells in culture 
expressed the classical IgA receptor, FcaRI. However later studies contradicted this 
finding and our results confirmed and extended these reports using a variety of 
approaches.
We demonstrated mRNA expression of the novel Fca/pR by cultured human 
mesangial cells. This finding is of significance as any IgA receptor expressed by 
mesangial cells would be a candidate for mediating the deposition of IgA in IgA 
nephropathy and could potentially underlie mesangial cell activation by IgA immune 
complexes. Fca/pR transcript expression was enhanced by the inflammatory cytokine 
IL -la and this finding could be of relevance when considering the array of 
inflammatory mediators present within the kidney in IgA nephropathy (Yoshioka et al, 
1993; Yano et al, 1997). We also showed that human Fca/pR was able to bind IgA 
and IgM in a similar manner to that reported for the mouse receptor and identified two
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variant transcripts of the Fca/pR gene. Differential expression of an Fca/pR splice 
variant by mesangial cells may be a basis for diversification of receptor function due 
to distinct properties of the variant form. Such a mechanism may have implications 
for mesangial cell responses to IgA. The function of the AEC3 transcript was not 
determined but it is possible that it represents a component part of a larger multimeric 
complex with a function distinct from, but related to, that of the wildtype receptor. 
Such a distinct function could be variable affinity for different species or molecular 
forms of IgA or specificity for either IgA or IgM alone. Based on differences between 
cytoplasmic sequences, it is possible that these receptors could be components of 
different multimeric complexes and would activate distinct signal transduction 
pathways. We hypothesised that the di-arginine motif in the cytoplasmic tail of the 
Fca/pR AEC3 variant acted as a retention/retrieval motif that confined the protein to 
the endoplasmic reticulum in the absence of an additional specific signal or 
association with another molecule. The nature of this signal was undetermined but 
association with an additional molecule may only occur in a specific native cell type or 
in response to a particular intracellular signalling event.
A limitation to these studies was the absence of a specific antibody for the human 
Fca/pR that meant we were unable to determine whether the receptor was expressed at 
the cell surface in cultured mesangial cells. However, such an antibody became 
available more recently and immunohistochemistry of normal kidney showed Fca/pR 
expression by renal tubular cells but not by mesangial cells. Receptor expression by 
tubular cells has important implications for the pathogenesis of IgA nephropathy as 
IgA present in the glomerular filtrate could then interact with and activate tubular cells 
contributing to the development of renal injury. The failure to confirm Fca/pR 
protein expression by mesangial cells can be interpreted in different ways. Firstly, 
mesangial cells may not actually express Fca/pR transcript at all and the expression 
detected in primary cultures may be due to contamination by surviving tubular or 
glomerular epithelial cells. Secondly, mesangial cells may express only Fca/pR 
mRNA and not protein under normal circumstances. However, Fca/pR expression 
could then be induced in IgA nephropathy either directly by abnormally glycosylated
153
Chapter 6
IgA-containing immune complexes or by components of the general inflammatory 
environment. It could be hypothesised that functional receptor expression occurs in 
only a subset of patients determined by genetic or other factors and that this may 
define disease susceptibility or determine those who subsequently develop progressive 
disease. Alternatively, cell surface expression of a splice variant protein may occur or 
be induced under certain conditions and this protein may not be detected by the 
monoclonal antibody.
There is strong evidence to support a role for the transferrin receptor (TfR) in binding 
of polymeric IgAl to mesangial cells. TfR binding of IgAl was modulated by IgAl 
glycosylation, IgA immune complexes from IgA nephropathy patients were bound 
more avidly and the receptor mediated IgAl-induced cytokine production by 
mesangial cells (Moura et al, 2004; Moura et al, 2005). Furthermore, mesangial TfR 
expression was enhanced in renal biopsies from patients with IgA nephropathy and 
receptor distribution was coincident with that of mesangial IgA deposits (Haddad et al, 
2003). However, other data suggest that IgA binding to mesangial cells is probably 
not exclusively via the TfR and that alternative receptor mechanisms are likely to be 
involved. Use of exogenous transferrin as a competitive inhibitor reduced IgAl 
binding to HMCs by a maximum of only 50%, implying the existence of other IgA 
receptors on these cells (Moura et al, 2004). Additionally, binding of monomeric 
IgAl and IgA2 to HMCs has been reported (Diven et al, 1998; Barratt et al, 2000) but 
TfR has no affinity for these molecular forms of IgA. Similarly, TfR does not bind 
secretory IgA (Moura et al, 2004) so presumably an alternative mechanism must be 
responsible for the secretory IgA deposition described recently in a transplanted 
kidney with recurrent IgA nephropathy (Oortwijn et al, 2006). Other reports have also 
documented binding of secretory IgA by cultured HMCs (Barratt et al, 2000; Leung et 
al, 2000).
It has been reported that HMCs in culture do not bind IgM and that IgM does not 
inhibit binding of IgA to these cells (Barratt et al, 2000; Leung et al, 2000). This 
would not be consistent with a significant contribution to IgA binding by wildtype
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Fca/pR in quiescent, cultured HMCs. However, this does not exclude the possibility 
of Fca/pR-mediated binding of IgA by activated mesangial cells in vivo. It is possible 
that restricted expression of such a receptor under specific conditions is associated 
with a specific cellular response, perhaps underlying signalling pathways leading to 
renal damage or disease progression. Alternatively, expression of a variant form of 
Fca/pR by HMCs may permit IgA binding while precluding binding of IgM.
Any current model of the molecular pathogenesis of IgA nephropathy is complicated 
by significant knowledge gaps in several areas and must therefore be speculative. An 
overview of such a model is illustrated in figure 6.1. One constant feature of the 
disease phenotype is the presence of increased levels of circulating immune complexes 
containing IgAl with reduced O-linked glycosylation in the hinge region. Whether 
these complexes develop spontaneously in genetically susceptible subjects or whether 
they are produced in response to an environmental antigen encountered by either the 
systemic or mucosal immune system in susceptible individuals is unknown. It is 
possible that a range of different stimuli or initiating factors lead to the development 
of IgAl-containing immune complexes thus contributing to the heterogeneity of the 
condition. Other components of these immune complexes such as soluble FcaRI, 
anti-glycan IgG, or fibronectin may also be variables in the manifestation of IgA 
nephropathy.
The interaction between circulating IgA and the renal mesangium must be central to 
the development of IgA nephropathy as the condition is defined by the presence of IgA 
at this site. Good evidence exists to support the notion of an interaction based on 
specific IgA receptors although this does not preclude non-receptor mediated 
mechanisms operating in parallel and contributing to IgA deposition. The factors 
determining whether IgA becomes deposited within the mesangium at this point are 
unclear but most attention has been traditionally focussed on characteristics of 
circulating IgA such as molecular form and glycosylation profile. Consequently, the 
model of the kidney as an “innocent bystander” has arisen whereby the crucial 
determinants of mesangial IgA deposition reside with the IgA molecule. However it is
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equally feasible that mesangial factors and characteristics also influence whether or 
not IgA becomes deposited. Evidence to support this concept comes from the 
observation that only around half of allograft kidneys transplanted into patients with 
IgA nephropathy as their primary cause of renal failure subsequently succumb to 
recurrent deposition of mesangial IgA. Thus, variability at the level of mesangial cell 
receptors or of mesangial cell responses may facilitate or prevent IgA deposition in the 
setting of abnormal IgA immune complexes. Therefore for mesangial IgA deposition 
to occur, and for IgA nephropathy to develop, two conditions must be fulfilled -  the 
presence of appropriately abnormal IgA-containing immune complexes and a 
permissive array or state of mesangial receptors. A variety of mesangial cell IgA 
receptors could potentially be involved. Some, such as the TfR, may be constitutively 
expressed by all cells whereas others such as Fca/pR or a variant form may only be 
expressed in particular inflammatory environments or by genetically defined 
modulators. This variability could determine either a harmful or protective mesangial 
cell response depending on whether an activating signal transduction pathway was 
initiated or immune complexes were effectively processed and cleared by the cell.
In the proportion of patients destined to have progressive IgA nephropathy, large 
proteins including immunoglobulins will eventually breach the glomerular filtration 
barrier. Consequently, both normal and abnormally glycosylated species of circulating 
IgA will emerge in the tubular filtrate and be available to interact directly with renal 
tubular cells via both non-selective and specific receptor-mediated mechanisms. 
Fca/pR expressed at this site could mediate the response of tubular cells to IgA. 
Tubular cell activation may occur leading to local cytokine production and 
tubulointerstitial fibrosis or alternatively renal damage may be determined instead by 
failure of a receptor-mediated clearance mechanism for IgA.
The molecular pathogenesis of IgA nephropathy remains incompletely defined. 
Identification of Fca/pR expression by mesangial cells and renal tubular cells should 
contribute to new hypotheses in relation to physiological and pathological renal 
responses to IgA in IgA nephropathy.
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Figure 6.1. Model for the pathogenesis of IgA nephropathy
The cardinal features and possible outcomes o f  IgA nephropathy are shown in 
rectangular boxes. Potential determining and modifying factors are shown at various 
points.
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Figure A.I. pCR4 vector map
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Figure A.2. pcDNA3.1/V5/His/TOPO vector map
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Figure A.3. pcDNA3.1/CT-GFP-TOPO vector map
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